var title_f21_15_21744="Auditory pathways";
var content_f21_15_21744=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 592px\">",
"   <div class=\"ttl\">",
"    Current concept of the auditory pathways",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 572px; height: 441px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Elizabeth Dinces, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_15_21744=[""].join("\n");
var outline_f21_15_21744=null;
var title_f21_15_21745="Diphtheria antitoxin: Drug information";
var content_f21_15_21745=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diphtheria antitoxin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F161343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antitoxin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F161340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diphtheria treatment: I.M. or slow I.V. infusion: Dosage varies; range: 20,000-120,000 units",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F161342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F161341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F161330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11218433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Diphtheria antitoxin is not currently licensed by the Food and Drug Administration (FDA) and is only available in the U.S. under an investigational new drug (IND) protocol through the Centers for Disease Control and Prevention (CDC). Physicians may contact the CDC Drug Service at 404-639-3670 (Monday-Friday 8:00 a.m. to 4:30 p.m. eastern/standard time) or by contacting the CDC Emergency Operations Center at 770-488-7100. Additional information may be found at",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/diphtheria/dat/dat-main.htm\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/diphtheria/dat/dat-main.htm",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F161337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of diphtheria (neutralizes unbound toxin, available from CDC)",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8900 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-210.101.131.231-93E8FEEFE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_15_21745=[""].join("\n");
var outline_f21_15_21745=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161343\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161340\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161342\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161341\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161330\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11218433\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161337\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299220\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219916\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8900\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8900|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_15_21746="RA hand 1";
var content_f21_15_21746=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F57439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F57439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Synovial thickening of the metacarpophalangeal joint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral swelling of the MCP joints is evident in this patient with rheumatoid arthritis. Note also the mild swan neck deformities present in several fingers, particularly the left middle and fifth fingers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Patrick J Venables, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_15_21746=[""].join("\n");
var outline_f21_15_21746=null;
var title_f21_15_21747="Warfarin (Coumadin)";
var content_f21_15_21747=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Warfarin (Coumadin) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/15/21747/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/15/21747/contributors\" id=\"au690\">",
"       Karen A Valentine, MD, PhD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/15/21747/contributors\" id=\"au701\">",
"       Russell D Hull, MBBS, MSc",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/15/21747/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/15/21747/contributors\" id=\"se1211\">",
"       Lawrence LK Leung, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/15/21747/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/15/21747/contributors\" id=\"de8736\">",
"       Jennifer S Tirnauer, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?21/15/21747?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      WHAT IS WARFARIN?",
"     </span>",
"    </p>",
"    <p>",
"     Warfarin (brand name Coumadin, Warfilone) is a prescription medication that interferes with normal blood clotting (coagulation). It is also called an anticoagulant. Many people refer to these medicines as blood thinners, although they do not actually cause the blood to become less thick, only less likely to clot.",
"    </p>",
"    <p>",
"     The normal clotting mechanism is a complex process that involves multiple substances (clotting factors). These factors are produced by the liver and act in sequence to form a blood clot. In order for the liver to produce some of the clotting factors, adequate amounts of vitamin K must be available. Warfarin blocks the availability of vitamin K and limits the production of these clotting factors. As a result, the clotting mechanism is disrupted and it takes longer for the blood to clot.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H1823582\">",
"     <span class=\"h1\">",
"      WHY DO I NEED WARFARIN?",
"     </span>",
"    </p>",
"    <p>",
"     Warfarin is prescribed for patients who are at increased risk for developing harmful blood clots. This includes people with a mechanical heart valve, an irregular heart rhythm called atrial fibrillation, and people with certain clotting disorders. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"      \"Patient information: Atrial fibrillation (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16642?source=see_link\">",
"      \"Patient information: The antiphospholipid syndrome (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Warfarin is also used in people who have previously developed harmful clots, including patients who have had a stroke, heart attack, a clot which has traveled to the lung (pulmonary embolism), or a blood clot in the leg (deep venous thrombosis or DVT). In addition, warfarin may be used to prevent an existing clot from growing larger. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"      \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/53/19286?source=see_link\">",
"      \"Patient information: Ischemic stroke treatment (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2517?source=see_link\">",
"      \"Patient information: Pulmonary embolism (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      WARFARIN MONITORING",
"     </span>",
"    </p>",
"    <p>",
"     The goal of warfarin therapy is to decrease the clotting tendency of blood, but not to prevent clotting completely. Therefore, the blood's ability to clot must be carefully monitored while a person takes warfarin. The dose of warfarin is adjusted, based on the results of periodic blood tests, to maintain the clotting time within a target range.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Prothrombin time (PT)",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most commonly used test to measure the effect of warfarin is the prothrombin time (called pro time, or PT). The PT is a laboratory test that measures the time it takes for the clotting mechanism to progress. It is particularly sensitive to the clotting factors affected by warfarin. The PT is also used to compute a value known as the INR (or International Normalized Ratio).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      International Normalized Ratio (INR)",
"     </span>",
"     &nbsp;&mdash;&nbsp;The INR is a way of expressing the PT in a standardized way; this ensures that results obtained by different laboratories can be reliably compared.",
"    </p>",
"    <p>",
"     The longer it takes the blood to clot, the higher the PT and INR. The target INR range depends upon the clinical situation. In most cases the target INR range will be 2 to 3, although other ranges may be chosen if there are special circumstances.",
"    </p>",
"    <p>",
"     If the INR is below the target range (ie, under-anticoagulated), there is a risk of clotting. If, on the other hand, the INR is above the target range (ie, over-anticoagulated), there is an increased risk of bleeding.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Dosing",
"     </span>",
"     &nbsp;&mdash;&nbsp;When warfarin is first prescribed, a higher initial \"loading\" dose may be given. The dose is then adjusted downward until the INR is within the desired range. The PT and INR are monitored frequently until the appropriate dose is determined. Once the patient is on a stable dose, the PT and INR are monitored less frequently, generally once every two to four weeks.",
"    </p>",
"    <p>",
"     The warfarin dose may be adjusted periodically in response to changes in the INR or other conditions. For example, having surgery may require a change in a patient's warfarin regimen. The dose of warfarin may also be changed if new medicines are added.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      WARFARIN SIDE EFFECTS",
"     </span>",
"    </p>",
"    <p>",
"     The major complication associated with warfarin is bleeding due to excessive anticoagulation. Excessive bleeding, or hemorrhage, can occur from any area of the body, and patients on warfarin should report any falls or accidents, as well as signs or symptoms of bleeding or unusual bruising. Signs of unusual bleeding include bleeding from the gums, blood in the urine, bloody or dark stool, a nosebleed, or vomiting blood.",
"    </p>",
"    <p>",
"     Because the risk of bleeding increases as the INR rises, the INR is closely monitored and adjustments are made as needed to maintain the INR within the target range. (See",
"     <a class=\"local\" href=\"#H5\">",
"      'International Normalized Ratio (INR)'",
"     </a>",
"     above.)",
"    </p>",
"    <p>",
"     Warfarin can also cause skin necrosis or gangrene, which can cause dark red or black areas on the skin. This is a rare complication that may occur during the first several days of warfarin therapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      When to seek help",
"     </span>",
"     &nbsp;&mdash;&nbsp;If there are obvious or subtle signs of bleeding, including the following, patients should call their healthcare provider",
"     <strong>",
"      immediately",
"     </strong>",
"     .",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Persistent nausea, stomach upset, or vomiting blood or other material that looks like coffee grounds",
"      </li>",
"      <li>",
"       Headaches, dizziness, or weakness",
"      </li>",
"      <li>",
"       Nosebleeds",
"      </li>",
"      <li>",
"       Dark red or brown urine",
"      </li>",
"      <li>",
"       Blood in the bowel movement or dark-colored stool",
"      </li>",
"      <li>",
"       Pain, discomfort, or swelling, especially after an injury",
"      </li>",
"      <li>",
"       After a serious fall or head injury, even if there are no other symptoms",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The patient should also call if any of the following occurs:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Bleeding from the gums after brushing the teeth",
"      </li>",
"      <li>",
"       Swelling or pain at an injection site",
"      </li>",
"      <li>",
"       Excessive menstrual bleeding or bleeding between menstrual periods",
"      </li>",
"      <li>",
"       Diarrhea, vomiting, or inability to eat for more than 24 hours",
"      </li>",
"      <li>",
"       Fever (temperature greater than 100.4&ordm; F or 38&ordm; C)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     It is important to remember that warfarin is taken to reduce the risk of a clotting condition(s), such as a deep vein thrombosis or pulmonary embolism. If one or more of these symptoms develops, the patient should seek immediate medical attention. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"      \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2517?source=see_link\">",
"      \"Patient information: Pulmonary embolism (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      PREGNANCY AND WARFARIN",
"     </span>",
"    </p>",
"    <p>",
"     Warfarin passes from mother to baby across the placenta and can interfere with normal blood clotting in the baby. This can lead to birth defects and other problems. A woman who becomes pregnant or plans to become pregnant while on warfarin therapy should notify her healthcare provider immediately.",
"    </p>",
"    <p>",
"     Heparin, another anticoagulant, does not cross the placenta from mother to baby and is usually used instead of warfarin during pregnancy. Warfarin can be restarted after delivery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Breastfeeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although warfarin does not pass into breast milk, a woman who wishes to breastfeed while taking warfarin should consult her healthcare provider. Warfarin is considered safe for use in women who breastfeed.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      OTHER RECOMMENDATIONS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Take warfarin on a schedule",
"     </span>",
"     &nbsp;&mdash;&nbsp;Warfarin should be taken",
"     <strong>",
"      exactly",
"     </strong>",
"     as directed. Do not increase, decrease, or change the dose unless told to do so by a healthcare provider. If a dose is missed or forgotten, call the prescribing clinician for advice.",
"    </p>",
"    <p>",
"     Warfarin tablets come in different strengths; each is usually a different color, with the amount of warfarin (in milligrams) clearly printed on the tablet. If the color or dose of the tablet appears different than those taken previously, the patient should immediately notify their pharmacist or healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Reduce the risk of bleeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;There is a tendency to bleed more easily than usual while taking warfarin. Some simple changes can decrease this risk:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Use a soft bristle toothbrush",
"      </li>",
"      <li>",
"       Floss with waxed floss rather than unwaxed floss",
"      </li>",
"      <li>",
"       Shave with an electric razor rather than a blade",
"      </li>",
"      <li>",
"       Take care when using sharp objects, such as knives and scissors",
"      </li>",
"      <li>",
"       Avoid activities that have a risk of falling or injury (eg, contact sports)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Prevent falls",
"     </span>",
"     &nbsp;&mdash;&nbsp;Falling may significantly increase the risk of bleeding. Taking measures to prevent falls is recommended, and could include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Remove loose rugs and electrical cords or any other loose items in the home that could lead to tripping, slipping, and falling.",
"      </li>",
"      <li>",
"       Ensure that there is adequate lighting in all areas inside and around the home, including stairwells and entrance ways.",
"      </li>",
"      <li>",
"       Avoid walking on ice, wet or polished floors, or other potentially slippery surfaces.",
"      </li>",
"      <li>",
"       Avoid walking on unfamiliar areas outside.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Warfarin and food",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some foods and supplements can interfere with warfarin's effectiveness. After being stabilized on a particular warfarin dose, consult a healthcare provider before making major dietary changes (eg, starting a diet to lose weight, starting a nutritional supplement or vitamin).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Vitamin K &mdash; Eating an increased amount of foods rich in vitamin K can lower the prothrombin time and INR, making warfarin less effective, and potentially increasing the risk of blood clots. Patients who take warfarin should aim to eat a relatively similar amount of vitamin K each week. Some foods have a high level of vitamin K, including: kale, broccoli, spinach, collard or turnip greens, lettuce, Brussels sprouts, and cabbage (",
"       <a class=\"graphic graphic_table graphicRef65279 \" href=\"UTD.htm?37/44/38605\">",
"        table 1",
"       </a>",
"       ). It is not necessary to avoid these foods. However, the patient should eat a relatively similar amount on a regular basis rather than eating a large serving occasionally.",
"      </li>",
"      <li>",
"       Cranberry juice &mdash; There have been mixed reports on the effect of cranberry juice in people who use warfarin to prevent blood clots. Some experts have reported that drinking cranberry juice while on warfarin can cause significant over-anticoagulation and bleeding [",
"       <a class=\"abstract\" href=\"UTD.htm?21/15/21747/abstract/1\">",
"        1",
"       </a>",
"       ]. However, a small study found that drinking one eight ounce (237 mL) serving of cranberry juice per day for seven days had no effect on the INR of seven men taking warfarin for atrial fibrillation [",
"       <a class=\"abstract\" href=\"UTD.htm?21/15/21747/abstract/2\">",
"        2",
"       </a>",
"       ]. It is possible that larger amounts could have a more significant effect.",
"       <br/>",
"       <br/>",
"       The best advice is probably to avoid consuming large amounts of cranberry juice, and to speak with a healthcare provider regarding any concerns about a possible interaction.",
"      </li>",
"      <li>",
"       Alcohol &mdash; Chronic abuse of alcohol affects the body's ability to handle warfarin. Patients on warfarin therapy should avoid drinking alcohol on a daily basis. Alcohol should be limited to no more than one to two servings of alcohol occasionally. In addition, drinking excessive amounts of alcohol can increase the risk of injury, and therefore bleeding.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Warfarin and medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of medications, herbs, and vitamins can interact with warfarin&nbsp;(",
"     <a class=\"graphic graphic_table graphicRef54061 \" href=\"UTD.htm?41/0/41996\">",
"      table 2",
"     </a>",
"     and",
"     <a class=\"graphic graphic_table graphicRef55639 \" href=\"UTD.htm?33/31/34299\">",
"      table 3",
"     </a>",
"     ). This interaction may affect the action of warfarin or the other medication. If warfarin is affected, the dose may need to be adjusted (up or down) to maintain an optimal coagulation effect.",
"    </p>",
"    <p>",
"     Patients who take warfarin should consult with their clinician",
"     <strong>",
"      before taking any new medication",
"     </strong>",
"     , including over-the-counter (non-prescription) drugs, herbal medicines, vitamins, or any other products. Some of the most common over-the-counter pain relievers, including acetaminophen (Tylenol), aspirin, and nonsteroidal antiinflammatory drugs (such as ibuprofen [Advil]) and naproxen (Aleve), enhance the anticoagulant effects of warfarin. Vitamin E may increase the anticoagulant effects of warfarin. Consult a healthcare provider before adding or changing a dose of vitamin E or any other vitamin.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Wear medical identification",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who require long-term warfarin should wear a bracelet, necklace, or similar alert tag at all times. If an accident occurs and the person is too ill to explain their condition, this will help responders provide appropriate care.",
"    </p>",
"    <p>",
"     The alert tag should include a list of major medical conditions and the reason warfarin is needed (eg, atrial fibrillation), as well as the name and phone number of an emergency contact. One device, Medic Alert, provides a toll-free number that emergency medical workers can call to find out a person's medical history, list of medications, family emergency contact numbers, and healthcare provider names and numbers.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our website (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498711850\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11568765\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1075?source=see_link\">",
"      Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/10/42145?source=see_link\">",
"      Patient information: Taking care of bruises (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/32/24067?source=see_link\">",
"      Patient information: Pulmonary embolism (blood clot in the lungs) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/23/11635?source=see_link\">",
"      Patient information: Prosthetic valves (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/44/2755?source=see_link\">",
"      Patient information: Warfarin (Coumadin) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24514?source=see_link\">",
"      Patient information: Factor V Leiden (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/43/28337?source=see_link\">",
"      Patient information: Prothrombin time (PT) test and International Normalized Ratio (INR) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/11/14515?source=see_link\">",
"      Patient information: Latest medicines to prevent blood clots (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11568799\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16642?source=see_link\">",
"      Patient information: The antiphospholipid syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/53/19286?source=see_link\">",
"      Patient information: Ischemic stroke treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2517?source=see_link\">",
"      Patient information: Pulmonary embolism (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1258?source=see_link\">",
"      Anticoagulation in older adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35880?source=see_link\">",
"      Outpatient management of oral anticoagulation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15960?source=see_link\">",
"      Overview of vitamin K",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/index.htm\">",
"      www.nhlbi.nih.gov/index.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Neurological Disorders and Stroke",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ninds.nih.gov/\">",
"      www.ninds.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       United States Food and Drug Administration",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088578.pdf\">",
"      www.fda.gov/downloads/Drugs/DrugSafety/ucm088578.pdf",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?21/15/21747/abstract/1-7\">",
"      1-7",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 15, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?21/15/21747?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21747/abstract/1\">",
"      Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006; 26:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21747/abstract/2\">",
"      Li Z, Seeram NP, Carpenter CL, et al. Cranberry does not affect prothrombin time in male subjects on warfarin. J Am Diet Assoc 2006; 106:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21747/abstract/3\">",
"      Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998; 114:445S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21747/abstract/4\">",
"      Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am J Med 2000; 109:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21747/abstract/5\">",
"      Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med 1994; 121:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21747/abstract/6\">",
"      Franco V, Polanczyk CA, Clausell N, Rohde LE. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med 2004; 116:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21747/abstract/7\">",
"      Ansell J, Jacobson A, Levy J, et al. Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation. Int J Cardiol 2005; 99:37.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f21_15_21747=[""].join("\n");
var outline_f21_15_21747=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           WHAT IS WARFARIN?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1823582\">",
"           WHY DO I NEED WARFARIN?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           WARFARIN MONITORING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           WARFARIN SIDE EFFECTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           PREGNANCY AND WARFARIN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           OTHER RECOMMENDATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?37/44/38605\" title=\"table 1\">",
"           Vitamin K foods PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?41/0/41996\" title=\"table 2\">",
"           Warfarin interactions PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?33/31/34299\" title=\"table 3\">",
"           Anticoagulant herbs PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f21_15_21748="Adolescent polycystic ovary";
var content_f21_15_21748=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasonographic appearance of a polycystic ovary in a 15-year-old with PCOS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 265px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEJAYEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5lOevQ9z6U0cfQetKeCB82fejtx3OOfpj8KgkMY69uM+/9aQDkBcZ6DHb/PrS9wT1Ix74+vrRzjaece2OfcUAHGO+OMc/Xv60HOeOTn8zQe5yD+P+eaCPcEkZ5PT2pgJ0IyMkcYHX6D3qRox9njlV9wd2QqPvZHQ00nj7wwB2Pb/Pel6LjjPHU8evPtQn3ExNvJ5UYzlvU/8A1qvWemXF22y2Csc5yzhce/P+RVAei59s/TpTlbDfLkEnrnp+P+TTTXYCe70+4spVju0EYJHzK4Ix7H6VpT+H3/s8XFjIbhlTe4EqnI9lxngdRVCK9kVdkixyIM48xORn0PoKTzVKAcocfw9c+wp77C1IIVjaTErOi4/gxwce9BRduY2Y47MMYNPhikuZB5bKCxGGY4GfXP8AOtpfDDNamT+2dJQjPyPJg4A9SKHoMxEijaM7XfzhwEK9fx/yadFaE3UUMp8vc3JwMqvqK1LnSra1sHuJLiSXnAaEZTrwR7Z4q/omlT3UEsuliBInyp+0EbuBngntnv7U242uI6K8+HNq+lR3WkzahcylQfKkuol8zuQpxxxzzWE9h4btMjU7PxVBLFhZRHcwuCcdjs47Hmtbw9qGlRR3Fr4g0+8tZXcl2XJDE9geg78/hWzoWtafodjPZ6BquitbXMjNPBqpYcMPmwfcAAVz3kt/6+Y7F1PA/g3+yYLrT7HxzfzTAFI4b+2U9OCP3f1q83w38D22npNq58YWV46CUWcWo2txIM9M7Y+vtXovha+8F2eh2On2eveHozIrMUkvAuyTgtuBP3SMgHsemea848YWreGdS1PWvDGsJZ3l88caR25Ei8nGfy7isFUlJuOqH8jzvxN4Ph069mNreXyaeX3QPeQfMAeocjv2yBg1yFzA9s+yXY2CQWU5BHqMV9B+LfDHhq60G3n1C8lu/Ek0eImFwwd3HXK/dwOnIyenauWn+D3jGa2jiXQNLs0WMM00lzvx/Fxg++K3hWjb3mSeQdOpGc9/X/PejpjO7AHbr7iuk8T+D9Z8N3BS8tzNGc/vrbLKMdQQBlcVzfBC9MDk+mPStE7q6KE4A6jg4yB0+lBPQfkB/SnDPHc+xP0/Ad6Qd6AAYP0x60c7cYHQEjjr2owR7HOD6H6e9HYHtng/j/n60AB+8ccHJ68/mKTA6Y4yePX3pTnJ4HU/TP8AhRjjgdOAT/npQAE55yc4/wA4/wAKME46jPbvQcDI7HnjuP8AGjsTxxwcdzRYAHOCPmH5/lQBj6+wzn/PNHy5YsQ2OM4xnil54Axu6cnp7cdqAGjggj9P8/WlHoD344/T+dHXpnHGM/55oBz06kc46f8A6qYAMfhgd8DHp7f/AFqB+o/If/X96ON3sDSYOOPTuP0P+NACgfNyOo/i5GMUDkA8dP8A9WKUDPTBB447n/OaQnd03EeuaQAOgIHvz/8AW6UDHXI9fb64oPT3+nFB5z19cH+voKADoMnoOuOT+dJ/CT83Tt/nilPrnJyPx/GjjqR1OP8A61ABzn6jGM4zjrRxx90fVeP/ANVLk9ST2Oe+f/1UgPTk4PI9v/r0wAHj1Pr+Hp60o5zjIHB4/T/CkAyo6+vX6dfyo469jxwO1IBdv+0tFNyf70f/AHzRRYfLIDgZ7EevGPr60pHT69MdfoKD7H6DHT/H6UZ6HOR+dAgHGOT16Z/kO9IMjAPzEcZHb+v4UoOAQSBxtI7UE+pwRyc80AGMjgj0JHI//VQOD1A6dR/Sgjkgjnj8OvFGSy8EH3HOaAFGRyMA579f/wBXakOQOgA9/ag/Xpnn+nvQR/Dk5PHX9aEAuee5IJB7k+x9aOnDY46+/PrSZPXvjPXHFKM5POfUg4oEKgJcKoYHpkA9++PWrz2otY4ZYWBLdFkX5Tjnj1+nSqyTTRriNyinoQev41dheO+Xyb6UREnKNj3/AJe1aJpCZs6ZrslwTbXlvByuxJVCjHpj3+lTWtzZ2uoz2mt2FlJPgPDJuBDAnPbg85zVyy8GQXcP2jTLq0FzE42LdyfLK3Xbit6/uYrTRp7TxTonhZ2gljhjtofMW7ufMHMsDDgBRjO7gkEZB4OMmr+6MgTXNLhgkhvbG4RpM8JFnceBge2B/WuN1Pw5f291b3MGi6pbaXfwm4sGvDt3wZHzKTjcBuH4Mp7jOnHqWkJp2jQWcMFncWC3Bu74zbn1ESPujDpjI2Lxk9T0qDxNrltdWkVva3dxO6QC2V2mZ4reEMCIo1I+VcgdM5+lOC5Xov6/r8BsdcTTyeHbGW4vLSO11RZmVLWfzJbfy3Ct56HlM8FfXOakuNQXT/DulXFhd6bdXFw86SWj2oM1iqEKrSSdW8wEnHQYGO9ckjhVkQoCzcl1IJz2+tRFjgA4yBwM9Og/Lr+dU0krC6np914zubTwtp18JfDOpXd20kcumS6YrTWaocLK8gAzu6gdMEY74yNfv21Hwza64/iDTk1eO98tNEgtiksCjP7zzPQ8cdMHrniuKDybcbnCABSCc/h701Q+AqDHcc8D/wDVUqCvdId0eoW+ranrVn9ui8RWVnHpiRzTNKyR3L7vuiCM8ysOfxx3r16yvPDvh3SVl8W+MtWuZo8xiO4LGRJAcbFRQSxz+VfPuhJfl1N+ogt413RXK2wllQ9tpHI+tdJ8PLrUtN1a8v8ASNZmtLrY9vBe3Nn5sgRsbsI3Gc/xDn6jIrKtTT0vYN9ztvGeneKNRu49T0rw94jbS48OruyIxGOX25zj0zXhOoafdGS5vYrS5ezaRm84xEBfUH0IOc19A6R8SNa0GzTT/GtpDe6bDC1vbyicI12wUCISy5/d5IyzN0z7Yrl/GNjNfXthc+FNan1W91OWG2l05E32yyyHARZiApVT8vmH7wAJNKk5R0aQHibgYBXOMBRn0+vbvTcdlySecH07DFbt/okWmXl/aatew22o20rRCxt/9IYyA4K+YuUA+hPpWdqGn3Wn4S9t2tyTwGOQe/BHGBnpXTo9hX7lMAHHfnsRn/8AXQM8E43dCf8AP17Up9u3v2/wpAADjHI9RyDmp3GHUnvye/TnrRnPqD+eTQ3X6Z69u9B/i29uRk/lQAdiAO3r2oI5OQARxjNB4yATtBOPahgcEdAo79MnrQIBjOTjHTBGc+9J+P14604n5yefX1J4pOnXoCD8vH+RQMP4ifm6jPPT6fSjqOSBxnH8z/KjHAJAwD0P54pSGJA7njnjOev49aAE6EE9R3IzQRg/pwevFJ06depxxkf570vbJAA68DP0oAPXgk9wP88UAdAeTjHPNIwxkHggdM8//rpeNx5GOvHPamITPfjkYBbn60oPI5GBxjp0oHb369+PSjPHU+9IYg4IOfQfWlxgAZwOnXH+TRjHUle27pR0+YYH19+tMAHYAHA9PX/H2pRwCccY7ev+HtSAYx1P4dv6ZowB3yQOSaADryQD3xjk0o+oz24/X/6/tSEjJBPfjPWjkA8HA557Y9KQCbj/ALP50U/eP76flRSFp2Gn8QeTnI/MUYO4dfb2oPU9+frQMcZAPJzk9f8ACmMToBkg8dT35pfTGPoP880djk9uc/zo9Bxk9s0AJx3xzzweMetKTnknnj/JNIenJxjrx9aXBB9COe3H1oAAB0445xn9B+VLgHIJIDDr7Z6+2KmmtZ4BGtxFJCJkEsRkQoHU8hlyOV9xTSrYY7ByQobHyg9dpPb1p2ExhOWyVBOcjB4NAXdtwyhifvOcY96UjJOcBhySRwfelk3JEnmBgh5XI3A9uKpLyA2IvDGtyRx3ENgJo2G9WhnRs+nGaseGIfI1ZrS+t7eC5u5YrWP7a3lxRl2xvkfHyoOrEc/nV3wV4cGsa9baVquqHRUnhmnild1+Zlj3KgO4AFiBySOmBzVTXIrCfw7olxpttqzai1vI2pS3kiPHK275GhAJYDhs5x2+pLPVBurm7eXdnoD6/YNpOkazKsEmnLNHO0kFpNuB+0W5IyeOOxyo5IyDhPq1xdaNtnuRNIwCEKhLjH8RJ55xkjjmsGKVkYBCfTb0z9ff/wCtTYZmhferZYZ3bumf60cumoNt6D7S1uJtvl200gBAOOMZ9+g+tdDpGiXH2djNa2R3JgBnywHf6Z557fjVKxvriSZIpZS6udm8Hbtzzz7A+2KfqunXukzpdySwzWzMGDJLnjPGR/Wh322FvuZOpQx295IkBIjGCB1Ke2f696rZA3Z4XuB39v1/Wrc7LLeOxIHmZf5hzznHT3qtgKMHII4O3+f6ik11GhO5IA3YwcZHX+VBO3l1OBx6cf55pz/QD/Yz7+venO5LPng4OTj/ADn3p2QXOr0XwlrF/ZRXOnahaxo/37ZrkxsPbPuO9adnqlhp6ywXUMaXcWeIbkzbiOMH096f4U1nQ7LTBbarLcxzLHg7BneD82Mjt6GuN1a5trzVZJ7Ay+U7DG9QjMfVj/WsrOTaewdD0TTfG6JY7LzwxDdxHrKlypZj23KeoHFUIvG7ahcfYN+oaXop+WY2MG6Zo+65H3R6muHtpkDb5i4VvlbZxz7jtir2lzaeL7a+papa2kjAAw4Xb67jmm6UVcVz34x6Z4i8PQWvw78BLf2wMIkMkqWqm3WQGRA0h3AyAMpbJPOa8517wleaTq2oHW/D0OiaRLM9wlsbsXa2qAcpuXnHcY54x6Vc8HazZ+Gb+L7FrM91ZyMrNBchkY9ipIyCMdOnNe9NfeGfE2lSpeLHc20kTKEmQ+b0wRx94gcY71xzqSpPRXXzv/X/AARt20PlD4k6A3hrWIbC70ibSrloxOI7jYN8TEhWwrEdVPBORjBFcifl5ycY79u4r23xN4bubfz7nTNJsbfT5QEjTxDf+bd3ZTO0xqfuAcgKT+NcnqvgB2W+l0jxBo97FZRx/agI5IIkmctmGJmH7zaVOWHtnFdcaia1f9f1/XQDz5gd7Ag43Hvz9M0h5HfB5HH+cVLPC0M0kUy7JFYqwJzgj3qMg7CcYB59AR2H9aoEIeC2M59DRwOnQEn/AAzS9GJyfr6fn2pBnPHXH/1qBigHfjLE9Of8/rSZACkYAAHXsKAecBvTBx3o6e2OenINAgGMjtRnaoxwcY5/z/k0YOCTgDrnNKQM5XIz0zj9KYxBx0JxnPIzQuP8T1/L+VHTt+AHP0+tL0xz3OMdvYUgEIwMAgZGfYf/AFqOgBwOOQPQ0be2M55Ge/vn0pVPOVOOnOaAEwRnI6gj1/8A10dCCcHHH6Uo6KRgrn5f/wBfrSAHaB3HUDnof8aADtzz2bPcUc55ySRz3zihhktnJHftSHpyF9cYOD9aYC5Ckjk8/njPX+lAHUDueg/z+FKOWwc5PbPX2FNz8nsRjj69KAF/h44LZ5GcY/wFLxnK4BBzxwQaDkMcjPqPcUmMDnpkexP+FIQbh/eX/vkUUnmD1X9KKfKVqOOeuTnnkd/X/wCvSfdPcHPSgHvkc88elAHXHH0/h9etIQDAAHb1z1o9sDkjj3/wpeRnj0yDSccjqOnTIH9fegAB2jjgA4HPSlxngcA54xyM0HI44zxkY/T/AD60YySByB79R9aANPUdZ1DVbawh1C6nuo7K1Fpa+cwPkwglgqn0GeM5wAB0AFUo32bmdA0D5yp6Y6Z+vp9KkS1WeFPs4zcKhLx9C3unrxTFMm7cGBcZG0jDKc9MHjPvWkU1sS33E2Ro4ydyc43cFT2B9fpWhpct1ZC5giZfKuIQC20HZuPBwehPIIHODWdMcy4dTGV4Yfz9+auaXbS6jqljY25Rbi6njgiZ28sJI7bVLnsASCTTdtmGp61pCSeJbUW/hTwLoOgWmqWl1C+pXhluYLpYowzCHeuVkUgsCO699hrz6fW9Efwhp2mw+FIbHWYwksmtJdyNJKoZtx8ojAyDjqen5bn9o6j4O1QaLq+uazZz6I9xZxC2lSa2hZxiQJkHIZW6EZBPqK4+6sUEkcX9oQtbgMLaY7mDAcgEYyOp5rGMV/TZblpYgnks5bUHyp4rwEszpjy3Unv6VWkIYBo0cHy+QMN17+3APNORBbylLm3E4xyob5W5+8CPb0robHXNIt4E8jRBBcqcCeN9zA9uc8/561o24kJdijb+VqNm6WloglhUEMXAKH19SPamy6drNtaPm0mltScF4/3kZ9MHtmjU72TWZI5Us4rd487bhWIO3OfmIxn61NpC3lj50tnqS2rhcvE4LIQCOCf89OaHewaEUJtJoI7WXTLma5iBUiJSkkZz1Pr24qa28Naj/wAt9OlhgfIV52wQM9h65p7azeXMrm98RTCYDG2CPeGB7A8dh3qWx1PUvPaWQ6reWxI8zfGMcYwQc4Hak3JaoLEWv+F5tFeMzCT7PKVRWIzsPocdic4xWZcQwCD7PFGVudxyzNgE+gz/ADruodXubySOfSVs7eVGzt1DO1T0xg5znik8Q6bPBdJrPi06fqKhMTWdlCylAeAS2B7HgmojVaspDsVtE1S0GkR2s5sZGgGcJGAf90k+9cpqlrcS3lzNBbs0JcuCnAPPUe9X7678OSWrNYaVNC7AYUucr2yCSc9PXrVe31KeSQQ2lvGWY7QZm/VuwPvTSadwehjB1K/Mu5uB9fatPSxb6hdLFLCm4Dl1GBgdAfb9e1S3umXUMyzStYoHOP3c2cknk46ir+ianbK/2e+iYygZU28IY9cZI9fc1XNpoLfQ7rw1p8GlLNc6pIk6MpfEUQdY1HH1yCRV6406/wBY1ixuvBk9zFJFL811MuyILnlQOck/yHWsfOg20bynWZbNmUMscuVJwDge457fjUHhP+3ZNReWx8QGSzXrDECCBnpt7HJ/HmuV3d5FbHo0OoavbaoLLXjot6zk5uJIC5x6g/lg0/xl8M7a80vzDfXG6GJhB5s7bVAG4JGp45POPTiuLu/CF7PqsmpSapeeey4iWHgQjPO05/8A1c0ad4rv9IvYrXXtVu9WiRgMKoVTg9OvTnr71nyvRwYWOe17SfDGrpE+hRDQ4NLt0t7iZpDLLeyKB5kjRE/uznOBnn26DzydFj3vEzSW+8ok/llQ49x2PtX1hrOl+EfGWhSw6h9nhl8hljFmm0q/Zh64Pr17155438SvFNdpqWv6XG1zEsaadZ6KYrYKvBbDZJY9zz1wDjAGtOs5aNO/n/X/AAAvfU8QbjIUjB5BznHoTSdsHJAH/wCvNdFc+E9Sha7QW7w3FtJtms7tTbzxFhuAKN6rhgaxbi3ls5/JulaCZcHa579iO1dC8mIrjqSSSM84/T8qaF447LjPp/k1IBwAc8A8g5/z/WjGcYwXIx/+r/PagLjCACeoOckeh7gf40uMEZzwctkZOfWnopDHDKgxwTzx04p4iJVlXAC4BUHpz0Pc0JXC5DwByQRnODzyeM/pS7XHYhs7QccHHepTlWyxIOcgkAAdsGgxH5lAyAeh4wD0/A+tU0FyFQCcADGMZ6AjsaWMgbejY6gj0OeQe2RT9owNxG09j1P9c/4V0vhnwJ4m8TzLFpOjXEu4DMszCFBzwdzYqG0ldhcyPEmrS6/rl3qk1pZWst0wdoLKLyoUIAHyLk4HGT6kmswfNjHI9u1dd4/8Cap4GutPttde1Nzd25uQls7EJhyhUnGC3HbpXIsD7HHvQnfVD3E64wMtx7d+tC4zuXHB6gf40vT7wA9McYOP0ozzzyB3xjH0pgJ0OOFPfn8OtGcA89R34P8A+ugZGOdvqT6d6X2Axntnn86AA8Z44A4yOgoGMnBHr+HfigAn73Tp14+v04pCSwJbJz94+vNLcBu8ep/M0VJ+9/vP+VFMNOw09DwO5x1/L/GgjnBHf+lC9RtPX06tQOnXjof5jNIBOvGSfanE/N2B6A5pO/Oemfz7UL1A/Lnt/SgBQSM4yP8AJ71JDA91IkMKhpZGCRgEDLMQB+prt/CXgSbxd4K1HUNAg1WfW9NkYzW/k74LyLg4t5AvEyAkmIkl1IK5wRXOeEbeO78S6RC5vPLkuY2/0KHzpuOf3aZGWyMYzx1oYnsa/iPwjqem3Fx9n028U2rm3mWMiZVlTCvjocbg2Paq+n2cFzcsbu4aCV12y217A23px8wIPXp34r04+K/CWta5c3H2LXluLmeWae3BIK7jkjODkjp711Om6H8PfF9tLZ21xf3k8RXzbZmw6n0yR2HHHTBrOVdxV5r+vxBpI8VPgu5u38vTL60bc5McErncnHOG/TnnpTbfwaLdLp/E99b6Nbx2ss0MvlNcC5nTGy3wpG0uCSD/ALJr1W8+GPgR7p7LT9R1HTL9XKCG4d0DZHBDHj2ridf8J67osF3FZarq8kyzRpbwi3JEluUJkkadTtTaw27Tycg4xRGs5aX+9WGkedC5Bto7ZooxEnzBVz8rHr16npz26VCwKh0k+63PBzz1zipJy7SuLqGRLjnJI2tn3/vVW2tIRtRn9APmP4V0ehKFIJyMhunAb/PXP0p6heC0pG3IGBhvTt0pDBMoVpAME4ByOfb9aCWChTkOOQTwT6j2zRZj3JbYssbMpcR7hlugJ+nr6Vf0uCe7ulWxuLRpCefNbZnOOo7j19aoW6pIvMrRjBACAHjvketbDXsNha/ZmtEuYRwsrHaR7cd+uPrSb7C3Z0994J1m505XF7oiyIoYRwjynfPZXxgnnHOKwYPEeraGFtzbRLIq7dty2/PPJA6Vh3N/O+VWeeOIDmPeSO3B9aqPIzgBySR6noPrWaTtaWpXodLqfildZi231lHDcYG25hIXB57Y/CsuLW7+3jEK3jXECjAEqbsA5OOfzrLJ3HJ5z/n/AApCScZBPGBn1/zxTSS0QE0s7OQSwCjnHHGe9IsmzaAiDB75/n6frURyvPIwc5xn6/hQOvYkc4Hb8KdxFmJ4XdftYlKDP3OGwPc//rrvvCd3aWi+foUNvaA5Ba4lBcn0J/yK85UgNzjGM885HrWg93C9uUTT4F+XaWJYZ9CT0OOlKS5lZga/jPUr3UZzFefYLpIySJ4IxkAY446D2rPtNUfT5xPpMs9jccbyZA+885/P+lZcLGJj5asoOODxkY5pgOBnjueRx7/5PvTSSVrAdXceO/EF3GUlvQd3JG3HP4dvb3plh4razDNJp8EpZWBydoYfQjpx+lcyM4C9z6nn6Z9KcAQodctnuO/OMc0lTjtYdz0HwnrF/ve8+yTPb78IlsfljA6A5/nxXo9gY9etsT6tpsTkgK80YLQuCGG115BBAIx6V4Ja6tf2aSR2d1LChQqYs7lIz0x/npWzomqrpkiXV7D5jAjLLJtAz3Zcc+n0rOdK+sRX7nu2hRpaeJrm38aaZf8AiHUL+6yut2yGUXcqocRiIAbUVN2AvA5qXxSnw31W0NpZLDd3D5RIvLLOGBxgE/MrDkGovhpdan44hnS71QWUEYJibSJWWeEDglG/hfbnnB61ov8ADtNGv7CTT9PWWCNR9rkswT9kUklWYSHe+7OWJyeScAdOOXLzWk7Pt0Gjyu7+C3iC9eefQ7Ux2WcCGTJZSBzgkfd5rDvPhR4ttoZJX0tXiXIYq5xgdTnoAPXpzXr3jy3U3cdhLrOoXrRdNGs5/szTkj5TuGTtGfSsIWFlp+mRN4p8OfFJrWYfNaG8860bGflZlw2OOhrohWnJX3+QkmzyXw34O1/xDO6aRo8lyFLF5PMVUyOCQx6j2FdlB8DvHEiAzaXp9rGowJZbgnJJxxt56nvXp9n4mvdOs1Gg+AZrKxVCYmMhQhOPQdueB161FpF74i8bvL5Wu3um2i/I0SuNpHPG7qMc8+1KWIqK9kkvP/gXFbqeNXfgyLSrySxu/FWjveAFJobe3muPL9iVXAPWobfwZFd38Mdnrvm2UgO25TTJsFwOVC9z65+tfSPhjVLLRjJ4c8KS2Os3sLf6SlrEvBOSfNlAwzZBzznmjRopNF1a8uXg1jSLm7PmSLcss1sD0JjA5H4VDxTV1/lr8twsrnjGl/C+SEwixmvrm6l5S9e28iOHpnhsk5OBx616RdeCPCelaKk/jrxVe4jAYsl09upPcIg5Yg+1bHiDU/FWpTPp/hrRhq85BjF7MTBbRYOVYDoec9CM4xTPDml2sGox6L4t8Nx/260S3Ec9y6XMTLk52g/dAP49OaznWnJczdvSzdvnt9wa7nkfxZ0myj8BaHqXh7Tb620M6vdEz3Eryu5eKHZI24krv2Me3T1rxwgg443jjb3z3/8Ar19KfHHQ9P0XwNqi3Wqy6dJeXVveWmnMDIlxJGGRkReqDBB3nAOAOetfN0nDHK4HUhhkD6+/vXXQkpQuiiLjsBjPXrj8aOecjvnP88UD7uc5xjGT6+1AHynGcngc1ruADI+7jI6Y9aXHIA69APXmg88dQRwRxzjrQfmJHABGSP7ozTAQAdQBgfkAaDjqevAyfT2ozznv15+lAztbZkg4HFIQv/AaKMr/AH0/75NFK5XM/wCv+GDPPXkenb2pOM+uB6YpR1PbHqMY9qTkHHPyj8qYgI55zkYBJ9euBQenIITOCe49qAOoA6ds9KM4YbeDxjHQ0AacmuatIlvG2p3wjtSrW8cdwUSEqDhkA4BHqOeTS+HriW01i0mtGdJ4lkkieJypSQKdrK2fvA9/pWXgAEAcdR9P881o6bpl1fQXkltGzeUIwWxhdzNwm7oGIGR7A00lfUT0PSv7X8Q3GlBL69v76G2UlYAgWVcdQJB8xPv3FbPhB9Rt7ldV8P6hObxwWe01q2CybiMNtdccY7e1cNpWuXWgSiz15I5g4yrSMSeOjBx37V22k3/h7UJeLmW3u3I+VpdwYDoTg8+g6VzzjyrYZ6ZZ+NLySFofF+l2TRx7WLQYYxnqpAPQHnp0PpVnW9S0bV9MFvpN9i5uZXgtLaFW3TlUBcu44QAHGW4JH5eQ+IvGcOjXS2c9uL4jcvmw9eT8wB/izj2qCDx1Z2+latcabeTQSPBD9nsvsxeO+l8z54pMD5Qg+YYK5POT0OCw6unFf5BYxPFWi6kz3kz3I1CK15RbtlSUoRxjH3u/5VwHmW7HcqSQkkZVCMA/410Gua5fa9J5k0Edrh8gI5RhgHjn8eK52RzuKty6A5BAB/z3ruppxj7wnZvQsW4WYukl5DHzgmVTnj3qYAQxvBOBKAMhxwMD1PXFVbeaMHbOqvGucY6+xBrb0fT9Hu4HFxe3cV0P9W3mqid8DkHNW5WV/wCv1Fa5nW2lS3MEr6f+8aJSZIZGCyY9VHcY7dahe4VYNn2dhCw7k4PNaraTDG++K7laSJuTB+8PTggjvnnHPBqrK88k0n2Gee5hY/OssOxgR1BAyM/Q0J32/r9AZknA4BIIA69cf/qpuP4enPAPrVtoLlnVym0D5QN2Np9MHt7Gq7qUfDxgZ59jz2NDiNMZg8HknGev8qU9MA8MPXqP60Z5JBJ6YwP84pG6NzyemT096kYADK4/AZ/DH1oJPIJOAM8+v0/rQe+e/cnp9aOO+AP0FAhynnjac/3v1+tW7uJgIzC8TJgfKDznHf6CqhBPOM9cYGf8/SpoLS7ugZLe0nmVT8zomeev41SelhMgY8tuO4470u0gEkNj1xn/ACetKjhV2tGMjhgR0/z6fSnnyvmVmcMMc5yPxoshkTABTgEg5zkZ/wDr0pJbPPI6AfrTlbZhgckH7xOP8/8A16axLMGCjPTjjNIC03lKrALgg8lcnn0+v1q1YRS3BS4SHcsWCWkQlMD+Eqeo9O3riqdq4jmVgxVs4UlQcZPXHcVstrN4ZBDFOp8xgA0i/c5xzjjnqapttaEs6fwv4q1m2mEnhzVLTTSjFmjcKFbjB4HI/qa7zQ/Gunx3lpHrNnfahqUd2moee7Ss0cyKQkowQH2rkBWyB6V5vZaFdGE3S6hYJE2XleGxDbQTgdf0ArSgEttLts9fkbZyEnRVQe/HvXLOMW7r+vmUvM9Uu/EK6fq+k6vovgk3Op6zuuLK+1W9Rmmi43uAp+QLuHBwfm4Hp0dv4o8Q23+l+ONOUWZ5jGkuGRDj5S5JJPfketeZ+BrHwz4g1Sa31XRpDqtwsjzX9xdmK3CRpvZy4yFTA4wBz16V13xB0/QtC8JR3VlLqctqSjxwQXHmrOmPlKsCdy+hzjjPOK5akIcyi1r8/wAGN6sz9Z8Zah4m8SxafdLPo+hEF4tzeUJiOpeU+g6KO/Fei3T6bp3hgw2Gkrq0SRnclkBiRsnBMmcnr0968r1C71/XPDcFj4hg02y05GDwiyQm4QD5l5bgHHU10XgLxbY2ck6T66otFQZt5SAwJwd35Y+lTUp+6lDp0XUTRPoGkatY+EpNRl8UWHhHSxmb+zNEsIp5IR12vIcsznjPWrPg5ta1V/7T1m5vzoj5NgdTkT7Vebv4igGEXGCAB71V8H+JfCVx4v1aTQrJdMtN2Jrlo+LmXk7ghOMj1qp4q8SR6/r8On+DLn7ZfRR5nuZoyILVCcLx3Y8n8KHzSk1bfr2/r1B3Z1/j/WNM0/QwdZvtRigZQILbT2xczg4wOeOTzXmllq13oKXt74e8JT/2/PGVMutX/wBpkt4s53Y42j+LHc+tYvi608WyanB/xPb28ixmW4ngCCFgOPLAHXGee1UfAelaTqd3d6br2o3d5piOrvDaybTMx/56v1JyOmeM1pTpKENX/X4B0OptdS8P6n4P8R2yS3uq39/pNxLqWqXFxumzAUdUVjlEj3tjaByCPQV87lsojsAMqCeuDx/nPvX1XqXirwJ4MvdOtdB01bi+LMqaZYRmWSXdGybG55BLD5T1xXyvc+YLiTzohbzCRw8W0oI2LHKbf4QOmO2K3oS5ruzt5j6EQ4Ybif58f1po5OTnJxuJ5496XtweODnGM+9HHQnbnnpx/wDX+lbgIM4z3A6H6d6GwAepHbPB60L1Ax83oeQfrR6jPHbPGe3T86YAM7j0JH6+lHPXBBGNvbqf50ck85zn7ueelB4BPbgHuPfH6UgHbP8Aaf8A75FFN20UDuHf5R0yAfbHv60HHGAAAcjP+elBALdOOw/D170Bj1BGe3H8qBAANox+Ax+dDYHY/TPTikOfm6E8Hr+tL2OBwMZ7igAwWG05A7Z7Dnmux0y7bT/h5dD7Y6warqapLDHb52i3j4+Y9C3ndum33rjztAJOAB1J4yfXH+etd8svhubwx4e0dmuxfSwSXjXMcm5o7p5Nu3b93YUjQ465zmlL+vz/AEDqYYewXSZX0/UpWBZTPbXUQkQ8nGM8/j9ahOlWs0kSQTW0DyE+SzsyxS+6OSdpz2Pc1dFnp/2p4b4aha3aE4ubdd0cg7sFxz74/wDrVHqOjm000xi/8yAsJdjRgqM9M46E5qk+lyTOurWaCQw6pIfMX7rq4cbPQMOo61d8PQ2b3d6b3xF/ZCxWUs8Ez2rTG5lXASHAPylgSd3bFZCzXMyKifNtUkLgY/AVJaXMauUmQRRPhHKx+Y6AkZcKSAxAzgZHbpV20DqTvbPdWyXNxcRSRFcu0A3PCSB99OOO2RUV1ABCo+0W93Eo+V4iQyexz/8AXrU8W2uh6d4gvIfCGsTX+lIqJDczxmJ5wRllIwMqG43ED0wepwHJjDebAFcrwy8D6+h+lJPS4EbZyQ3PJGe1LguMhN4zhiOhH1pVRwoO3gcKOuf89akja4EDAI3lNyzL0PPX0696FHyG2S2E7rIFFxNbqSCxiIBOB/Pj8a7nw+bGUIsOsalaXG4MZLlxJHnH93HH3j+dcJbrB8rSCTJJOVHK/wCf5ValmkgRQmZIh07nHofrjH4Upx5lYS0Z7JbfDfTPEdr5hu3e8ZgDPDKEZucjCDIJ6+lcb4g+E3iHTN7LcWM0JAaMPIVdic8AYxnt1xmuW0/xPrGlNnR9QmtQw3ttbO49j/jWxc+O/EtzH+91iZspk8B0J6EYxx1rBQqp6PQq5yF1DLBM0U8MkMyD/VuvPXGfce4qJcAc8gEfKODn2HtXYSXmqawyW2u2QnHl7UnWPawGMgFgOgrL1LQruC4YRhJAwGGY7WPsP85NbJ9Jbi9DDZeQAcgdCabz2HA5wSOO1TSpJGzRyxlJFP3D/CcdzUQHTbgsD6c/gP8AGhrUEBHDKcH1A/KtvQL3VTMtrptxFH0YeaBhccjB9eOlYu3P8PA6KPmxjsaVGZD8hYHOCc+3+fpRvow9DU1tZUdZJ9QW8lcjzB5WADyefXvzis0lShCxhTjAKg9evP4e9SwYmuIRNK6oxAkfOML3P0716Xp2jeAbiBYZAsl0Fz+6nfdk+vODilOfIl1BI8sJ3SENw5P3ehPv9eaMfLu65HYYzz0r0rXvB00EMi2K3F5Z8FozApkAHQbvve49K4O6t3hZiIL2FP4kni28fUduaqMoz2FtuUmyT8zcYK5Ix7f5AqxYypDco5+dY+gz09/f15oEaPIS/lqoblc9vb2p3mRORHDEkRbHzseD9RTSC50Om6jr2q3T2uku6RhSxIQbgvcZOef/ANdXLjQbuwJkXSLm4uyF3SX771APfAx8o6+tXvB3h7TGuAzavqlpdg8NazKpGR16c8V6vZeDn1RFtdY8Y6vf6RICWspUCF1HXdIME/pXNUqRg9Ngt3MHwT4Z1GLTpLmyl07xCJVO+wWNY7d1OMoQcZHGfwqx4l8W3z+FrSXVfD9totveRsmkNBIj+akOFKog+4q5yAR3Prz0+qaHoeiaZ9n0ewhiVRhHjmbJP8OCT165zXiniTQbq61bVJIpLFYdNsBqdyRcNuWMyKmxCxIEhLg7RgH64BypuNV6lLbYt29vq99ZifU7ZW2HzDfXF8fMPXBEY4+gxxVjSJrog6fbJa30qkt9paAIuT0xz+HPpXHX1vZ2cjR3Wvy3MkXWK0JYKejfN6AVFbX00xVdEXUdqcySM4ORz19/pXRyNrQm520mqSademC4+ypdOBiFQXIHBzjpgcnFaWgeNdH0e7nS7tNXa6usgudih+MdiOcZrhvD2iT6hOL59Kj1VWIDW816YmweFLYwcZHrXT3kUtw6Wel2Ol6IV++RD55znAAZs7RnvUSilp/X+Y1qez6H4w0nxFp7xRW15aweXgm4K4bgjjrySc8/jXmnxF8FJDA134c+2xT3LjzjDLthAGBuZQM9DXIw6Vr9rctLZ6tJMVO5hINiZz3Hf0/GuvsfG+r6UFOrbAQRkkfKx9/fHGKxVP2bvTBeR03g/wABaP4S0yLVoNRF3Ok0N1PuXbJIsciOdhPI+6eOpPrXhfxJt7uD4g+JBqVr9ju5dRmneLcH8sSt5i4IOCcMPz59K7rxh4xsda00TaiG7rG8AKFmPOFxzzjGfavN/FNpc22oRT3n2hjf28d7Gbpt0rIwIGT/AMBP4VrSUrtyYeRjZ+b5h+vv/OjPGTjkjJ68/wCeaM8feBPrQeTg5GTz6/lW4wwcEcYHr0o7DJ7d+eP880g5wcDjpjt7j2pQMBsdepUd8evtigBR93B+VehHv7+vakzwSeOp49fWj7uQp5XoQc/lSjg5A6e/b60IQmB/db86Kbti9f0oouh2QvsRjuM8cUvQ4bIJOcf1/CkHDc8Y7D+dA47cZ5x2PvQAvPy525HT/wCt/WjIGCOnOM9fegcYH4Ht3/SgZAHUnHPv/wDroAuaRqF1pGo2+o6cypd2sgmhZkWQK46ZVgQfoRXZ69BoWpazIUW8s7vZFJdxGHy3EzopmcIeFHmFsKoAUY4rjtDt/tWr2MK3FtbtJMi+fcNtjjG7O5j2HHJr2HXL+TxhJcXUOl2EGpXFw11aX7TBmj3Sbvmb+7zjafWplJppoBqadHqWmRRx6u93HCgWCWZFMkR6A5AGACehrJ1HQ9T+wzxQCKG6UMYwGBWYZx8ynuQa7Kz0ySDSPtN+LaKRSA81qB5ZboeByM88mub8QeN4tLvFtL+zjus4ZZ4ARux3Ujrjp9Kwi29I6/1/X6AeRtbTxyTDyTBLbn54iSGXPHGfemmUsytIN4PBzx+Xv9a2PE+oQalcQ3lnIrckb9pEig9Fb1A7GsQEysd7hd2CSx+X0rrTbVxM6VptEbwvCbZrp9ca6cT2U0am0S22/KyMfn8wtjv3PAxzzeC+EUbAT0JJAP41t+D7DTL7xJYWPibUjp2jyOwuLxACYhsYg4weSQBnB61lXEMakm1laePcwVmXbvUNhWAzkEjnHamt7AVhkNtQnO7op4q3bz3IQ+UxIBz7fXH9KqkZICBstzt/qD61NbySxpuT5wQeR2HXn0/nQkDGvM24llAfGcr/AENNkcliQQOMjHYH26UjMGfftGCMkZ6jPP0q3cWDwwpOB+4KbzIPmAbPTjp2os31EVOu5gOByOOv+HarWmQx3M6xzSbICSHyeOmfqO3P0p9ho9/qMMsljAJo4mCN8wBJPAx6/X3q1pWizzyPHcwPGynbtYn73uew4PPTpSul1HZnVaUmhvaQwnxZqttGvW3XDHkc4z/WqviOLw1EdljquoXl2SuVkbgn3boDxVXdHFm2j8KC9mVfvSKw/H5e3481jX+nSpcsrWQ02N8YgMpdlyeAM8/gecYrOMfe1dvuKb0NyK28I3liwZ10++6ETTSb1b1JPyke1c9eaW0MrJBcQ3A/hZG4kHUH8+K6SFNUSzSGO60howBzcwIxUdCdxBOBWx4W0uWB2l/tLS5LhuV+0KqR4HB49vajm5b63JPMzmJ9hVkkHUEdB6n1/lQo5Bxwehxnvz7cfrXtWveFfEeq26/aJPD1tCBhJLN0JUdQM54GOCfeuT0XwXHqE8tvfw3KzRlt1xakYk9CB0A/WhVYtb/qBwYYLg7QxIB+o9PqMVsWPiC7sJIzpwsrALj95Dbqzj6ls5NbmreA7ixjM1uJig3BhMRjj3HUYx+lSaB8OPEWpWyXJW1tY3GY/MXzHYeuADjtjp1p+0g1qwsaEfjzxZDZ+dbSw39ui+Y7yQBH25x8wHT0yOTWZN4l1nxan2Z4YYIX+SSQgkEHkjnt/Ktm68K6PooD+I/ENy0rnakMb7TJjnhR7nr0Ga5yFrS48SxWmnxXtv8AP+8S7mPpwfb/AOtURUHqkPUs6z4chSwYWX2KGRdz7tpLOAegJPH865OC4toYjGLFJLgcF3kwV9cAHn/Ir0/xfDNpmhvNbLDcrwuwjcwbsxHXB56elcNaS3CgXD6dpd5EGwwCBXyfVRzxV05tq71FZFnwXq0uhX5vBFbhm4WPJ5GMjA/Wu6u/jPJKqQW+neVjAkdQOV9h9f8A69cFquo2c9kywxrDKBu2xoF69fp6cVzkbgMnQ4xzyN3b/wDXUulGo+aSBHtZ+Kxv4/LeSO3dhsCtGGMjds+gPrXPrNb67q+nwXdhY3bXFwkECzubeEuxIBkkHOxep7nIFcAty9vIsqiBQU2gqgIPqcent+NPN7NPKPMDyB2CldwGc4GDnjn1PFCoKL0C9z2XUPE1j4dtbu2fw3ou+zn+yyDSAJIbiZQCSjkZ2YIznJzkckVneH/C8Hi9JdR1W8tdCtX+eHTtLG1+pyZGPRunH6CqR8NnQtZu9E1PSpodatY0DxxziWGNXG5ShHAzznI6jrWLeaLqX/CS29t576RHcqzBzLkMwPKnt7/5FZKK+y9QZ1Go+D/D2ls7aTfzC4IDF5bgFn4Of8RXE3tzeaPfLDcTMLdmO2dGDK/OcEdjjtXW3Xg7TNDRry+gXW5ZAMtcT7cnuQPQYwfrXnniS+sZrlUsbO2ghiYhtrEoScfdHcCrpe897h6Gm/iN4rhFS8bj+Lb8oPbd/wDW9faunGl6Zr+nf8TTVZIzkt5MLBn6+/XmuE0sPfSN9n0uwYEgAyRnJzxgA9e3TpW3ZLDoVwy3cFqkkvzMyN8oC8kIPTH+eaqUUrW3DUbI3h/TtZjhvbu+vooAAgnG1R7rj6Vm+KbyO8tdIcQIZBbyiS9WRme8AkOxnU/cKjC/QDpnFegQW2lahbK01xbyK4BAVQ/Hv6Dpx3Nch4+trLTLGxsLaSZ5FuppnRlGFVkQAg++DwOOKmMk2u4ziyc84J4BOP6fWk56jA5HtzSkFW+Ynd3JpGwcenvWoBwc84H0P+f/ANdJnCnooA6e9Kc5OfvY6Dv/APWoGQADnPbb3Pf/AD7UwA89c46YHWkycHPOOTz3pcHt6cHrnt+FHfIJwBx2zSAXzD/tUUbT6rRRZdgsJjHc8e3X1pB9CSCehzg0duPx9vr/AJ4owD0HP16UALwPqDxk/wA6OBjbu57gYz3/ADozwMDtn3oOB1ye3XGaALWlpbPqNut8ZxaZLSGFNzhVBJx3xxyfTJrtLiw8MJo+dPup5IPvP5cuXBxnkdumMY5rF8ETtbXOrSxSW0NyNP2wTTISodpYwRn+Esm9c+hPar13rFml2YPEmhIJSAyyxKFcE87g6/eXpgfWk7t6AR6fZppsBvbLWP8ARCcPd2UjGWDIOBNCTyp6Ej/61ZOrQ3MckEs22e3uCWjmgb9zIB1wP4WHdePpTtQnsSz/AGYvPbnJjkePE8BP95h94ZJ4PasuBmjjfB+Rvvc8D3x685zVxXURM0qyxKMZcDPmHhyemGPQj39qrkjapUEsc9RkE+34U3lk+YAgdz+n+fejqzbsksOc9R9abdwsWbeJpnCWsX71c4Ctz+ddDd6Vp1r4ZSa8XVrbxI1580IhH2RLQKPnLAEly3Gc/gOCedhnWNFIQ7uodGwVP9a0otdvILeZI33MQQnONjZ4Powxnj15oldgYpXAycknn5RgZ/rTw7YBUDPPz5wfqa2fFk2hz3dofDFtqdtaiziWdb9w0klxz5jrgnCHj8c8DoMbadpJU4PGQMYz6j+VF7g0SLKodTJEsh9xgH0/z9a2JrC9sIvtmmrLHCUDSJE+VORycH37fSsaDfIWWPALYUnODkkYznpjnmut0iTVrW0dYtRglAOfJYeg6c9Rg/5xSk2kgW5teGdWs4rMSK2Ax+eLbtAPcYHGe+OnFb2jvYyyyzwWLROcK2w8Yweq9P8AIrjb+6BHlalAsDMSTJGeBkHOD6HJx36VT8NXtnotyNl5cTE/MYkXPX/9Q/OsHC6bGdX4t8P+dILq3ubrT5UUbokOUbryB69M1zNlBcWs81xpNq+oyBv3u87iSByFB/OtK+uoPEFyy6dq0mnXAIH2e6Q7cdeD7k/54q5NpmoX+kJFdW1gt0n3bu0ugjfjg+vrSi+VWY9zMudC1TXZEmu44LS1RsvbKuxl44B+tbFsmieHJ0l1nS7a+iRQHSZN2znB4PUil0+z8UoEjn8Tw28IGFVcSPgnuSOuaxNR0a40ydtR1e6tNWtAWJSckMCTjLL3IovfS4HqPmfDDV9MNzYeG7FXYHMkQdNme+M4BHoeKy9N0f4fuHf7Ne2823CNFfSBiFXBLc/eJ5xXH3fhrTb22ju9Be5tTLkyW0c37tsnqO+O2O1bGneGDqdulu2qW+mxx4BSJQxA/qfWs2kl8TEZHjuK2SeGHR9R1C+mLZS2WckKOxbHQV3Gla1qsem7LW6t7a7aEYMg+VSOAzAdun414xexT+HdaEUV3byOFBM0C8OCecg+4FdE2vXu+Ka2vZbq3UBnkMW0pwQCPQg5rWVO8UlqD8zpb220ewS4bUvGMt3r95Hsylj58h/2Yxj5BnPTHIx2rmrTUvEWlWzaPcRWGmKU8wS6jBtlkUgdCcncepHqa2U8ZeLFsHm0pNSNrGfmkFmFzjvnH5j3qzbxa/4w0lJtRjtbyBPmUyx5KuecY6r35qVePxbf1/VgOGsp9a1C8ubOx1IMEJV2dxCWzwVUnnt0qS5sZ9Mt57a80w2cufnu0k86Qe59seldkXsorhFvBExhceW0afLwcbWI6f8A1qfJ41Vl+yaDo3265QEGeZ9qRnPcev1qudv4UFu55IJTvISV3IPUDBPP+eKcZS6KGCAckbFxgjsOxFdH4ltdaYLf6u9n5SAI32Zl3RZPAIHv9arnRVu7NJ9OmknHGC4259fwH51upK17ksxl8oZJjJOAxO7gccmmxKzMPLjLkIWKAZJAHP1GPxrWi0iLAFxfIH3bdqDAJ5wearSi40xvOjibyQABP5WVY/8A16ej2Fc7LT9Kl8H6ppH9rG3xf6eupQQ6dMZHZJPurIP72OR29K0/GGqWWv20em2Wly2UKvl9TvwYguB0TPc9ST1FR+GrWXw/eW8PiK6GkG8sYtQikshHIJYZT8rPIuSrHpg/4V6Fe+EPC2q2v2tNXXWtQQgRtdXpeNDzyVHHB4IrlqSUZe8UzxQ6QpvCBqc19CqZ3hmA3Hoc+natLwadN07V7xYbCDWLsKQr3W3yoew2g/xe/bFe1eGPC/g4afbpr+uafNexkCZFlEQ3g5HB/gBHTvgZrjfHmmaFokdveeHtU0OG8BYLBJIro5zkg+3A+Y1PtlK8f6/IaOR+IF3q2oLHI1zY28CDKwWb4PPUs/p/hXN2uj6ojfa5NOiubbau6XO8Kp6YzzXTTW9z4hlFxrN7pIRM4trIYDHruYj2HA6HFWLLRtH0eOS71jVVdFXcEefjB52pGOSRxWqnyRshWOatrK2lvfNaa40yErmSOz64Bxkema3tak8Ey+EdWs7K1vLLUlWK7t72/R5ZHkUlWtsgfKGB3g9OoPauw0Q6jq1jFdeEbWw0+POXuNTjAXkY+UHtUuvxeG59NuYPFN9JqU0VnM4jtH2BJFGUdSOOpPB6g9xWcp63YHgLAZJVcDHGOcj0/wA+lNBAxkjA64yOKXJYIzkF2AyfXj+fakHQgcjGM+tdAxec9FJ64xgHvSDgZHQDOT/X/CjI54yPQf0/zxQckkkZY+nf1+tAARgkDGemMfrnpRkc9+/1+vrS8cDIwe+P896TPBHTODx+vNACbm9F/Wil2f8ATNv0op3/AK/phYM5PPqccfpR355789/woJzkg8nq3r7mjAyMAZPP/wCv6UhB3J5POc0nOMnOSOmOOvQf4UAc8gZ6c9v/AK9AI25BxxjH9aBmvoetXukQXa28aS2dw6efFKu5JCgO38RuJqW5v7e9t/LgRrJWwTbOfNtye7KeqH8/es20n8hcEMMszbgenHcd6WRkkbIhO8sSHiPX3x6+1Woq9xDXMsRwQCBgq4YEfmO5pryuxG4s2BwAOfz703IZmBHzN1/rx6//AFqbkE/ODjIyD1/yaGxAGZTyefpxz9fWkAwcbT9Aef8AIpxyVGFGTnqc4FNK7S27I9eOn0FJoZc0e3tLi8VNReVLccFoQAwbsMd66e48I2Ets0mmXsrsATmfDL/unHIyeh6+1cnEWjc7GGD8pC/yHrWnZz36Ju052YDOI4iCVHbC+g5zmlJS0af9fcK5e0KHTtC8SWsvjfQri90UbjNDZS7BISp2/MCOhwSuR/Q5gg02dGMLS2kjsxjDSeYifMSqFgOSBjnHqaWS91RxulvJFVsLifjPbHTn/CtPR7mztbDWE1Dw3a39zeW3kW1w1yYVsJcnMwA4Y8qcZGMY6Egu3V7jvfQxUf8As64V0MNzheGVsg56/mf51PNdW1ypbeLaQjG09PUH3GfxqO5tLIuWt7gxEnKRyAgsB3H15qO1uY4lZJLaF487i0inIOcfjT03Eje0q7u7klbuS0u7Zm3NuwHXHOfYdj3/ACqe5aCxcNp2o29qCceTKA2D68fzrnrCLT7i6kOpO0Nvn5TGML7DIzj/AOvW9aajoensfslrDJECQHk/eMxz948Z9f0rOSs9BouaLo0F7O13JqS3lw+SQrhQDwBgN1HJz6YqLUdBstDvzc3A1J7ZnDN5K5jJzySR0B7DrxUqWqardG703VrCOMfPJAAoLYOeVPQEfzrctozqkDwW95IZ0GJI4pRkjHHHsOBWbk073KsY7eEbjUZ1mj0/XGspDmMRgBSO5OeR+VQReDNcsr8+Tpt62kg/MbnaoTPTP8+K2dG1TXdHupNPfUL42kYAhjuIvmIx0J68GtWz0CXVZmuPHM1xqUTMfIgF0YliXr90dT60nOURGbq3hmS00+O4t5JI4j1Fsd5U4+YKOv41i3mjabq9gk1nfXKXKjBEkZUcdAw+vXGa0td0DTROj6JrV7brEuGgaUN5a5zgHOc//qq3J4S0W8tHew13U5r1l5lnuVClj/s9cZ60lPbUNTzZbG6nR3Ec00g4byreRifq2Ohp2nX0lvFNblHkjlBVk5Uk98dx2/KvRYfF2rWcMei6nqs6SogTZuwsidsEdz2rJ102fkhNNSzeZyBJPLJiRG9fcnr9a1VTWzQWYzT/ABSukKkc+jajaW2cHLPtK+uG74q/qD+DtUQy6RNrWl3JTcJkUqkmT0YZx16kHt3qa38P6Vc2K51XW7yRV/eRtcAxEg+46Zyc+9U92kRh7LXCLfcjIGZyCff6YPFZe69VuCKMpliLOvixfIX5N8cYyAPUfrVPTrHTXLSW+sSi7f5jM6YAPbA7/U06Hw8Bct/ZOpWl1boQ6EkEqT0yPWqd+s0F9FZal5dvFJx51uuRyeoxznJ5Faqz2Yi9eafbRME1XWVuyDyHbYvqPc1djlso7ci014M/VIbe3MjEnoOB1yPwqAaHYWtqs2mWVxfXLsqi4u02wRk8biem3vz3r03w/wCA9TELSpr5vWaMHy4ikEW7uvHPHbOKzlNJasGYHgrR11XT0TxJoE19cSSBtoiKnaT3YYIx3r0q3TR/C2nRR2eki3ErrDH9rn228SsSBJOeSsa4OX9K4aaHxb4UnkuotOg1Ox++sVpIzSg+vHUHuOT3rc0Lxf4s16wuVu/DWq6ZY+RLJDLZaU9811OMbYGUrgKw3ZJwOByKxmnLVbeozz7xT4gksdau5fCUOmaZCkjxXf2FgbO7KtjejHh0yflHHfitTwn4pK6eLOFdLt9uP+PXax3E5/rxU2valLe3FtDqmi6jbXGyMylbMJDC235lXA2jDcdKz9f0fwqthLNaTyRahgGJ412k8cqwHYevetNGrNAN8TN4auvNle11LUNSJ48uyJUZB6t3+nrXJC10qC3Dz2heWQ4ESoGkD4+7ge/GO1dB4cvrvV9Me2lvrhgMklgVQ4O3Pb2qHw9oVh/aE9vrl5ZQWEPzx3c1wsbZJ5U85Jq0+S6uJjLWXVbG28rSvDLWiOGAmk+dx2yV749+9b/gvwtqr38mqWE+npqK/el1SISRxqTg7EAPOT6etdN4Yihv7y6g0CJLzRI4gDqDB4wz9CiFgMgdS3StrULmDQ5ZYontDFIQ58ydQzN05I7/AOFZSqdAtfQqa18PopYY73xv4zTV7iJi0UCFIbVfqAcsc/TgfhXNWraBD4m0W4vtVtpobS5VvsMZTyXHP31HJycLzxzWla6PYajcPdyabBdSBiWaSVjEvPU+1dH4d0Xwbp1nqOpaxdaRPqKoXcQDiER4faPrgfzrPn5V7z+4LHzPrUFxbavew3dnJY3K3Ega3dCrQtuJCbexGao55wOBkcEZx/8AXrt/jJ5MvxG1e8tfJ+y6gYdQi8liyhJYlfGfXnt36VxHUkfd+vbmuyGsUMTGBgnIA9cUYHTgA8DHal5xwO/AC9/Skx2zkHgY/T/PvVgKD7EADpjB/wA/4UA9DnIyOR7/AOelJwBxx/MdutBJweDu7Y4//V9aQDNh/vD8qKm8uP2/79mincd1/X/DEeeMnJGeh7UEZwOCM847/wCNL0bHOSCCMf09aQ9cNyTkDJ5pCFGD1JbAA4pO+STkc4pW5HbPXp0+lAB5wOAc8YAGfSgB24bVAwjgEbu5PrTi+HU8o2Mgg85/zxTDjBA49B2pc5G3dgE8jsfc1V+4hXIY5bBc8kgY5/rTOAOwA5HGD9f/AK1KD8oJAI68jpzSLjjpnPB/+tSeoDwQMgjGeDim5BPJOP4sc0nTkZ6Z5OcClB3Hjk9h1ouBYtrWW7kCRyQLuON0jYH0rr9D8FWV4N17rKw3J5XySu3HoMnJP+ea42IklgxCnpljnn3/AM9q0NPhWScx3dwVOcK4Oc//AFx6U5J293QL2On8Q+ELy3iBt9Xt9ShLEYb7w/HNYcen3llBlbpUyWGH7dicfTrWzbeHoNrO+rXbbjnH3RjrnPf8OlVtQs9CXC3c94TtxHJG2Dn0bORj9azjJ7PX5BYrJ4n1CLw/rei+XZzWuqvCbiVosyp5JygjbOFUnrwe+OprHh067msnvza3H2FZRAboRN5SStyELgY3Y5xVm8GkSmGLS7S9llGAGB+Zu+D7jtgdKuyaxfWejyaO/wDaVvp88iXE9gs+yCaRcYZk57BfrtU9ga022X9fj8heRWs7C/UxmFbN4JByJCBtHfI7Z/Ok1bR2t40uLRI5ME+YkWSQP7309h6UtppxuNH1PVo9R0y2+xNEpsp7nbd3JkIGYkxhwucseOAaggu7i2QoxfA3EFG4/wAnH4Ua30HtuR3UlrOtvLGEguBkv8nDj1+v09KXS5rmK932F8lrNncCxIDfjUdtcW+T9ptEuUfkckMOexHXFNedfOP2OFYlblU+8R2655FN2eglc6G2vNVmuvLl1qOebG3yoEDs348c/nUt34g1DTruKEys0mcKJCCQOnP41zcF+0UvmCOMNnO4AA/Un/Cm3l5PecytvCjKhuqj0B9ajkTY7stalqGozyL9r3QrxgxLtVx2y3emf2pNFAqQttIGd/cHPU/5xVNLmZU2M5MY42sScfjUOSRxkkd+/wBP607K1rBqSSSSTOZbiRnZs5d2zn8fX+VXoNVmT/lnE+BwXX5sY5B/L9KzMgc7Rzwc+n1/OjjOHAJ7/Njqf16YoWugHZ23i2D7MyyxvFI3/PMDjA4APYe3rXN3d9JNcO0sguo+pLpg7c/l700/2e+NqXaybsEh8jBHv3qKVP3mWV9gOCAMYPp7GnGCTuhXvoWbe0iuZSttc/YwBlix4A9eOcYq1JFZ2bqU1Z7ucHcqhCBn3z3qqJreNSIIBG2MFmJyCTnH0psYSQYnUEEDkH5voPanuK50Vr4kvbyGS31e4RdPIBaBFGXwcDp055961LXU9M1DUYYZbrVFsIzmWG3kwr46EsP1rg0heaVYrMPI7nCjjnt+eK7Tw74c1MRiWTSdSvEZt22yjVw3bpnn17ispwiirnoN14xt7DRZU0F5IBCnnTSXEbMdg5KjtvPQc9TWprfjzUPCWmWMOrWX2rV7iyW9nvobgmOaCYMbeNYuCDlcMwGAU6ndXEQ6NA3gzVdav7DxTDPa6jJbQh/JGmIY8OEuYSfMPAbcQCCeBk8VJqHl6h4t1G++KNn4otry9gtZrKPw08SwJAytsGJC21MLlRnIIcEA1k6Mevz/AK6/8Ao53xH8QNd16URpDBaOxPywvmQ55PXj9OKfpS6o8A8y60i3kKgZuZxK7A4546Y5/wDrcVuSaLoCWedO8ew32qyKS9pJYuB9A+zqOAW7ms/S/Der3jBoPCMc0kakuWuliUnjmMFuTx61XuJWSt/XyJu+pJ5OrJbbLzWtGW1b/WNaxSSyqMnIUBeTz+Vd94D8KaPbwi5sfDhuZDgmfVYPvnru2v159q5/wvayaRfTTWvhrxhDqbrtC2nlTQAZzkPwF+YDJ54roNV8ReONKtpbzUx4c0mFRhlvr7zZ8AZQfJkFh149aym5bLT+v66g+xq+NJ9RWyRtbElyuxxHZ6bmRhjooI4wf0NeRaf4asL9bl9Rktba8kzILeW4aSaEHoWP9MfWtex8T3GtarJc3mp67P8AKDvtIlito046A8nn1qfQ9Hsbl7y60O/WKYv5c8t+2Zc/3Tu749BRG9Na6P8Ar+uo+hJ8P5dVuIbyyl1GNraxkaFHC7W5XuP7vb3zVf8Asq2vNX1Szl1K3srG4ISdgQCu5cNyeCB1x+FKnhrVdKeZrK+TdOxL3Eg4TIwccnI6fWpbDS9Siskt9SuILsM37xxGGB7c+oPH5U9L3TA5r4xPosutaRPol7b3TyaTB9sa1lWSNJIyYUwB91vLRSV98968+zjrlQP4RjIGMV6T8ULCOPQ/D1xaWCxwCW9tpLlLcIrvvDIpKjGdvzAHnBrzY8884reDvFAAH8JOOgz6Ug6Z9MHrwPfNLwAMYx1Hv+PegdO3rx6H+tUAZx0xxyDnkf8A66Q42kcAcDHUZ+n+e1LnPJxx2/D/AD+NJnnOTwOT14oEOw3/AE0/7+f/AFqKZtX/AGvyop38xi464HTp6UDjgc845PX/AOvR+n4Zo9uxPT2pAA+X14xj/P51f0nUI7Fb5ZrCxvRdWj2y/akYmBmIImjKkYkGOM8ckEGqAOeDn0IB/wA89qVASCMN3yB69OfxoSAGY5JIHPLDp/8AqzzTgOQATnqB3/KkMThQwGV9VOce/wBKTsc8D/63Bp2a3EJwe557jn8hQw5569/f1pSThvTvQMH2HXK/4UAJkMefqcHpinYLckHr3Hemk7uvK9f8frmnK2GJyMnjOM/pRp1GORgvEm7K9sH16VZt4Y5pVCXRgK8jdk8+gPbiiK8wm2eNZUPOSozxwCD7ZpLaSNLsOwEijgEjB+p+lWvIk3pf7as7bFpqguIQp42kMB6DI6egFZJeedpGvnvJFxz+5J5I4Oe3auhGvvAM2eo2UDDg/aIyScYweBnj2H4Vcs/EOsFg0l1pVypPDRtjJz16D9axTa6Depz2nW2qxlmsbOYxMu3zJ1CB+ferZ0y3vmkbUbmZGjBwU/g9AT9eK76KHWtVhlktZtJBJKNmT16n6+p6dxXM+LNCvAif2hGYJ0XIa0O5XHrtOPzqVU5mCRyuo6faWLr9m1GO6UIDxwyevP49PSprS30hNF1YXk+q/wBphYDpiRbVt2O4mbzwecYwVxjOfwrX0vQtKmt1uI3kinHzb7r5UcjsMj5c89foKpa7oUcEmIrgp2Ckh1Pv7H2rVSV7MNTB+ztNM62SvMAhk2pGzYA5LYAyAPWq5IALAjB9uDz1z3/Suh0C813w7Lc3mh3JtzdWrWc0kYVw8Mn3lKsDgkgH8Kg8J22iz6zFF4ovb2w0wROzz2luJnVgD5Yweik9Tg56cZyBtrX+vwBGYkDz5xJGqrwd3p/hVv8As2z436zGAcEhYmLb/THoB3qpBbSXV3Fb2cUtzPLII4oY4yzyMTgKqLk7jx8o70t1A8Ez21wksU0bmOSKZPLeNl4YMD0IPBB6U731CxBIqh2VHEg7N2OTyaYRyPfoSP5+9SlV2Dj5uv1z6Y6UwKecAZxk5+vb/GhoAAJIwCeM47j6+2KRW+XIZe43Yz+Pvx6+tLxjru7nkH8f85qRSm1txIbqSoBx+FJAWYbs8K7gIx6bA3bjHr3pjsjZVDI+QAwIyR9PXrSRG0LkTsfvZJBySCeR/wDXHatOXTIXCPZN9nkwMn7ynOcc+vXkVd7bk6GfcW4iYqEki+bBjdSCfQH3pgNqIsTglSc5XPIrUNssshXUtadEB2xoi5z259OnXmp18PTKkc2nTC5ikJjhe4gcRTSquTFHIBtaQDA257ilzLr/AF+gamdpLqLvKtDDsXJnkJ2x4HX1J7Y79q9G0XWNY02xF9deIdJGjfZZHt3+yvMsk4Py2uFG6Nm67iOOtZ2leD003X7eWPXLK5vrW3g1B5bPkWNwXG2J1YbSyt1B9CCAa7O9tBfPKbfWp31XUrgz32qrGkUspIAZVRSVRQBjj15rGrKL03KWjsdPat4X8R6L5Ouw+TK1uyB0uthtWmjxKVUfujIVO3ewJ4rko77VNc1K+h0iXTdS1COK3tYprRD5aRQKViDBhzIQ7FzkjOAMAVveH/BXw+jk8mN57zUyoDebcEhyMklsng9sVW8b2ekWptdG03VXe8mkCjTtGcK6qeWLsowAB1JPIrmUo3cV+QI1Ytdto9Pa11uwtZ9QRQsogiDMW9cr0xj+VV9F0HTpmm1HTvEl3aahIwfbOQUBH+yRzgY4FQaBax+FhCmnrawq7bWhAJl78sTyT7+mKpeP7+3uNKH2WK/juQu4NZxDOc9Tx1xkf5zU9bIaT6Gpofi4Wqyad4nlS5vYmPlNZ2+1pIwx2nAHBIxnPsKztdgu7hjPovhmF2Bz5+r3ChVbqWEYPPP5DFedza1caZaW1tawXWl3MhG6eeIzuBjLYGM5PfPatzw5q9950x1e91nUoIkBDGw8lB+fLd/yFaez5feC2p0fh62stFs5W1G6iluXkbzPLUbWY/e2jHCjpj6Vt6V4e8N64zXsiWUV8qn947NCV92HBP8AntXG6Vq9+vixr6z0WfUbVlRUEoWMIwPJIPGCP8a6fxV4vvrbT/tGqeHrKMuCSlod8suTgZPoP5etTLmvpv8A10FZ9CKSyv8AS9TaKS9stRssq0SxcbQM7g3r17iqXiHW/wCzIfMNlGiA7VlZssD9eh44we1c9FqGiz3hmbxDc2uoSAAW2lQtcLGOpBZgBk9D16Vnarq97BqMbRzPq8cybVi1GJYdvpjnHT1qlBtq4yTxZrUXiH4eXslsrxLp+sR3ro42RvE8QiTywSCzhlbdxjBBzXlrDBOS3BHUg5Oeea9Ovro69oPiC2NjZRTpYrdiW1y/lfZ3+YH/AHt/Jzxgcc15o/zMWK8NhvYZ5/rW8NhdRn+7jOfwB/z60mTtGD0zyexPcCnMG5B6kDOe5/pQo+cDHOcjB6//AFqsBOpwB0zjnke3P5/nSY47+mc4znvSqPlGS2AOo/h+n6UnILDADZ5CjkcUDDA/vUUbR/zyX9P8aKBXXcTnAI68jIz196Oe3POQB0x/hR6c5I7jtQQMjJzz1oGGMhsZI6cDJpRgEkY3cYI5A9qaMEA9Ppng049PujA4wD0Ht70wHgjABBJJ4IbqPpTW2McqMZyTkf5NIc4IPQ9SB09s9vpSc4x37f59KdxWFII5bIPQ+3bH1oxk8rnPHHGaCTk4I3dc4zx60mBjAXsKTGGc5Y4OfQfrS5JDEgnnHXj1wc0h4wcH8Rj8DTgccdeqgnv6D+uaAHKQhJO0kcfMP0/wq5ai1klEbhodxxuQ559Pr+g5qvZwz3twsFtEZZX+6uQM/n0rUbQtWsJoJLnSJwXOUxhh6dBziqT0tcnc1xpFxpsLyRpbXtttIaPaCyA/wqT/AE+vesi5FrqLhYRc2JxtWFoMoPqR64rotKuvtjCz1HVtL075htt7m3ljZuefnI2gZHJJ7U/xTpPiHTkiljh22bkgXUEiyKwyfcjHfrWalrqMoaHo1/bxSi3kUBjj58ge+f059KdZ6rd6LfyrqFzM1zIP3dum6SN17c9+ayVuL+OZRaXF/cuDmRJbfCEHnJOen/1q9B8O+J9RgiMKaUb+QMFO1wDnH0pTv11BNF3T7ueeEz6uLGGJkUpFIRgr6E9OuMVYtdU8IFzDc+XHKzbVldsoSc8c8L6Z96oza/o+q3wsNb8N3GnGZQubl8ow56HHX0rSsvhro7uJtNhnmDMT9jaTemcce3JPAJ61zuy309BnPeLfDuiXOLmyunhJwvlQz7gx9Pcj8q4e8h0rTSI59OupXJH76eUhT+K//rr0TVPD8tv4jES6JBYQRxqfNlu9qyHPT16k/jVnxIJdNsojcabFDaKRtkt5A4Qnr8uO/b6VpGfLpe4bnnNtp95ps8Wp6ZfQ2rwnzoZre4ZZUI5ypwPmx+lZ5vZJ9T/tG5L6lKbkXU32zLi5IO5hIQckHoeea7yDwfY6zcJc2/iT7JDMqkBYQ4UHqWG4fStqP4Q6VCBNPq9xqYccRxKItx7jjNX7aK1luKx5prCya3q1/e2mn2ln5zvOljYRkRxZA+RABwPYfpVfVrLTrS9ht7LVEvkeKN2l+xvCUmYfPEUPLbT8u4deDXXaj4ZbS9WaLTbvU9GsFiaWW6ugXU47KF5Jxz9PevQ/hF4Tvru2Oo3fkebKhIuZB+9kT+Hr9wkc/jzRKtGEb9P6/r/hw9Tx5fDM1xaaTNbXOiXR1GJ5Wgtblmms1RlX/SFx8hJYYx15q9p/hzS0ttMuL+WxcX4l220V4xubPym2k3SYwgb+HB5z35x7J4ls9WtZTHp9rYXUMhBcOFh3kDu+MkgYGDxzXCaJoreIrCbUJ9V8OQLcHzJbTZtkPUYL9T0Pr0qVXck30H5kOiaHBPDpj6K2gxvqUkscdskjS30Kxlw0k6YwkXybhg55XrzitrXga7S3tku9agTUpJWMmnpZSJHHbjfmZpwNgJ2ZCZz84FbHgHwtPLp8uo6ZLqGmQ3S5a0UqTgMVAZjhsHGcdMGtWzvLDQZWtvGgkljkmbyo7a7L+aARhmXHbgZ6d6lzs9P6/r+mgPNYhoFramyh0SS/1ptSjkgnNzx9mxzAYc5LEgndjuDkdD0OqSXun+HtPtLu61W102C4aaC2KLJb2krg7pAg+YkFmIHQFuOpr2fRbLw7dH7X4Y8mG7b5c3Dqzc9OvbHWuNv7TxHp3im1uLq3i1O3I/dbW8slwcbg3RuKn23M7MLnGaWuo3luBps15c2kZP8Ap2uP9nhUn+5GuWOfXmneHYXs/FRivL3SnYoTLDZo7bjngg4xXa3fh7UNGuLzxN4ol054GUf6IJjugX0Gf4iOSAM1Rs9YsEtZNXs7AWrPly833U/3RjJHQ4OOaOe+wLY2tT8EWmpK0+lJqGn3e3C3MKh1xjo+Tz/Tiue12/uvDHh+KCG51Kw1O0try6v7jSLn7G1832iCKEyuAd2wSPxjvx1NdVpuuPr+lZ0rXrTzSo/dAnJOeQR61w/xHupH8KPZXSx/aLXT7uR51OfO8y+tAPy21NOUlJJsFfqZb+Ob3zTuv/GDzIcCf/hJ5CyAjt8mP0po8c3kjBm1Hxu7nCq//CTncpPYfJg544rjp9zSyj72HI4P9fQUwnc24HO8BdwXcMHjH+fWurkTI3O2HjecypN9p8YicjBn/wCEobdg8nBKdM8mul8M3HivxJBcXGmav40WKK4W0X7T4tigaadl3rDHvjwz7eccdfrXk8Y5RVXb6KvAXJzwe3pxXpOieFdV8YfBzUrHRFiaaHxPDPcTzSrDHbxLZ7Wmck8KCwJxk47GlyLoVHc1PDsfi7xfqOo2llc/EF2053hunn8RJbx28iBsxu3lY3ZXtnqM4HI5pPHd4bUyxa94+EOzzA7+I4woUHaefL9RwBXfaDqo8RftSX17osss2mtbzxHy5QI7qSG18rfjO2Rcv8pJ6HPAFeHaDMLePQpjPFCLe5gnM8kRkSALKcyPGAS6r3A60kvefy/X/IbSWqPQbX4qam7xwWfiLxdIuPuf2laO+Mepi9K1LLTdd8a2Vlqd1o3ijxJY3Dv9lt9W8R28EVyVByVi2qzAdivcelVviP4ns/ENhZ2tp4w0XXrg6qlz9nsdBeymHytufzGJBHTI6txzWt8D/DeuvqOha5/Y9rq2gTIVtb06gHbQcM+8rG/yq+SH2hWHTvmk4abf1+AW6HO+DdOn1i31az8K6N4y/s6CJo9QtG12CCBEJIeOUyxqAx2nI6gc+9NPgnS/+Ejk0I+BPEK6pFai9kVfEVv5aQ44kMxTYB+PtVfw54M8R6vPeJpkTa1aTOL+eyl1JrZ/EVqt1IomKg44cZJZgw3AjO4V6guj2d/d+LPC9zpixXh0/R7+Pw1azoryrBEWay8zONokwS/3sSE4PBJyq17/ANfeOx41rGn+E9G1C9stV8KeItOubOXyJoZNchUo+Mg8x/NleQwyCDkZFUWHgUHy/wCyfESnAOP7ete/TH7uvaxfX+p+NfEWoWekaFr3xH0/TdLtVsbiVNsDsh+2bF3bXZHIUkN8oON3VWteHtPsTq/hjw9d+GdJWLVdW1+xY+UzpZWyA+bFA42ly5UgTEAqAyBQARRbXr94cp4QI/BLKWGmeKjg7S41m1IB54P7rjpTJE8DpG7Sab4wVUU5B1S2I9B/yy9fSun+Ih0zUvBvw01rTtHtdK/tGDUbVoYCSDDBNthV2P32A5LnliST6Dze5/49LhiRhosdOD82f8n2qlC5NrOxjbJP738qKfuX3/SirvIf9dBQOmAeOQMf5xTTxwcenryRQBnAOTxwCeaUHjPAAyeB/KgAyOOe2OeuP6UuCQoPI7A8H60n5ZFH0Awe3b/9VACDgrhufY9/8ad0PfnvikyWBPzdAMkj8qMdfpn0oBBn5cc8DK+g5owM45P40cDoQD9fbr/n2pewHX2Pp/nj8KQCY+XJ7dc/yqe2tpblmWJRnBJ3HHQc81EFLHJHTr/TH+FX7C8mtHCr5ZyuGVwOmeOe3rVpCL8NhpZQCaS/u5yMr9jT7vuM8/gcV2nw7/4SWWZ/sU1qxTPlQ6ophZ89gfXisvRNUtoyZbrzbN/vMYMD8vUYyav2Mvhq91j7Svia6a7AUKLglEft1x6dfasZu+6HY9Ws/iFoGp2zaJ8QNHttPnTA8q9VZYmB4Lq+MkYHUHI9+tZj+BPAWpxTXXhm4vtOZmx5ImaS3kz3wew+tcb4k0fQR9mN9r08M8rMYfs8K3KMx7bSeB79qraVrUXhQ2tre2dxqkTDMcUcpiEmOfu4I5yDjvWHI94Nhaxt6V4K09hfR3csN5a+YRusrx9wUdsN/kemKqW95YeGJzZ+HbXWtVgZg5jkssOoyesnofpXXaF4w8OanaeXH4TubOQHeVZhuLDnf05XHGO9a154401bVrQ6LqO6Qbdw+VscYwp7Gk5SvZp/1/X/AAAPOvEfiOa+Q2Vx4O1qSU7Qsb/Mq57AgHFYcOlq9tJcapL4l01zylvb8ogHQZ6nFd3pGvR6Ff3L2Vve6k13KZEgklxKeAAF7Y4q34o8a+NX0yWeHwt9h0xdplmvJULbR1+VRkZAxkZ7VV2tEvx/zDY8y0/RRqxX7Hb6hr6ZLQK0ximj9dzHjPFbjeFNVMsi3lpqGgvsK+UblbhiOy47d+2RnNdN4P0DUdUf+0dLkXSL2RdzJJyB3BKfT+neuhj0HxHo+vzav4j8Mz62riIJe6dqEaomz7uYSMjJJ3c84odXWy/r9APMpbLSPC13bpNZCaxmJEmovKzPExHG8DovpivVPD2neHrbTkvtJ1aIFk3LMJjKoyM8jGR9Pxqlreqahreq40Pwri2U4muJp4lHuAoHzHPJPQdKQ2HinSpg3hy00KE4KzSyxFhGp+9hRw1ZybktXZ+ovmYN5441m+1mfTLexsNVs7YbvPnDQRJnjbnHU9fevUPDtxFNp8HnWECTlBkR3IeM+2e2D2+leaajrOr+HGe51u6v9VllI8zy7ZBAg7bUUdB780eGtc8M3+of8Su4nkvWXfLFDE8caH/gQ4OfrSnT5o2SBq5Y8Y2Fxoeuyapq0c97p5+4ojLouSOSAck1Wnsx4ks7bULjTLPR9QhBaA2lmWUEdQc46jGa9M0fTrW2KtJf+a7DO12wGIGRkHoOgznk4rK8XeL7+0nhs9CWzmlkkeMy3MoRFz1y3boOB1xUqo27Ja/cFzkrpo4LKOXxtbG2dR5ZmspGVVPYkY/P61gwzeG9N14TeI7WEWcgHlagtx5zA44yqjjt7VY8V23i/VLT7Ldanai2fKvHaxYDLjlNxPT+pqHwZ4b0nQ7RZ9R+1C4Ee+aQRBkPcrzxx6/jWySSu2PyOiudZ8CID/Zf2kSLllaOFgoOeTk4wP6cVgxHVPEUpGnakbHTY3+aQjfNcHP3QT91fyrcv4rXxVZtYWBdLVxseQTLGcZxzgfhVu80qWy0kxxaxZW2zhW+zbmBHrkjkelQrLr94eRStJ7OGU22o6YmpXcZ3I1xcfLzxux0FQarF4tkne7stNsDZoN7RMvz4yACvYHOOvHeuc06ySCZ7zTr6fWL11Jd2YfQjb0wegFXTqHjS8l+zSRfZoSxSSIuqMiY4w5yPboce9VazBjtF1nRZ/Eska6TdR67nLwldgLY4O4e/fFRfFi2lXw2b6SKKE3Wl3CGNMZXZf2ud3vk1fe00jSI2vtTn8i+ZV86a3dpCPRNzDJXHfAya5bxfqem6l4VujpuoXV68GmSrKLmIoYwb+22EA9Swzn6etVFe+rB2ONmX95IvXaSODjB9d3rj2qNG34ZWGGHRhxg8ZI68+vbipJgvnMSygh8Eg4P+ff60x2BUtK43Dgnu3PH19q6kQKFyp4O3GeuOM/pjnHqcV2XhzwUmt6Ndarc65pmlR/2gmlQpe+cEu52j8xUZkICKQcZYHoc9hXIYG/DMFbcDnscg4Offnj8a9G0LQI/Fnwg1TTDq2naYYPEsd/dSXswUx24tMO4Tq2N3AHXB5oHFXZmWfgMeXe/8JFrGleGodP1UaTuvPMZmmK5fZsKkIFZSGOFYNkkAVheINIu/D/iC+0bVFiivrCdbeRYGLIzEAoYhjLBgRhcA88167GNL8a+K/FPjHSLTw3qV6t5Hp2nrrd4IYIkhiTF15eMy7yBhTjAHU848u8S3Gp2vju9udd1OCbWYdUhu7rUtLZZ1Rl2tugHyhjGuBsPfqeOJ62/rp/X+ZTikkZU9tdROkN9aXlnvYxj7TavCCw5IGQPm9gc+3NdP4f+Ht3rmmaXdx6roemya4Zf7PsLq8lSe825UNtj+UbiCvOPxNW/G3jKPxHY2trH4u8S62sd+ly9vqOnRW8aABh5gdDkEE8L0yeldN8NtCuNP8J6Rr3hMeFX8T6ijzPqetXir/Z4LsvlQQDOG/i3n1YEc4BqgUVexwHhvwbd65aaxdrLpmjWmhgpfXOpXjxLayFmXyE8vLYLbugwSeMnitOP4fz/AG+8tpfEXhSymt4Yb6G9u9RmhF1DMhxNDKRuKjBQg9x2yMnhbwldareRXbap4bOuRf8AEygtNUkMsOoItzIk3my5Cn94pbbg5DAgjmt7xLoth4t+OOm6FrGo6aIZ9MtJNUa3ZWhtpIIS0ltasSBGjYB4PG4n1FJNtf8AD/5lOJw/iXw5caHrNppcs9rc3ElpHfWMukNNIZYpVJzGdu88BmJIOQe3SsSFhGLSW3lvUVFeS1liaYBAoy7REDgjGXYdOc4r2fwN4xn8TXXibVvDs2j6N8QNRniax/tLHkxaWgVRFCx4DDad4x8wBIHHy9H4Y1lX1jwXo5uNKk0zXtT1+O7aKKJontldiIYQclLeVlDFSSzMODjAp311JUex82uB5KR+ZIUjT90jFtsasfvRg9FYjkjg1Tu+bS6bjJjGfQksP1r0r4i6ydf8C/DLVp1soNQuLfU4JVtUWIJAk+2GEAdI1HyqD798mvNLwqLS4BHPl5AxjgsOPqP61cSWrMofP/eX/vmim4f/AJ6j9aKzC0e5H1Bx1xkgUcdu3f0H+NJ1AIOSBkYpfT88596soOvJz/P/AD9aVMlTgcdyOn/6qaBkA4IUc+nWlJ9c56deOv60AJgHoCen9ePrTlJ4K84IJPXtwaaw55BycnB5pxxuyx4Hf/CgLiZxjtjkCggjgD25P60Hjknb/SgcHgcg9B3oAkRizDnaCQc9O4IP/wBerUctwyhEiVtzZGV3ENnoPfvg8VFZIxbctuJ1ByU5O714/nWnFqAt2IuLB4kPDqqn5sdeD7fyrRbEiTW088ap9phBUArGxwobPIB9fWtRdWu9JsttzpOl3lsOGlRfyyfWr+m/2ZqEDRWjQSzHGItwUn356nnqK0tC8HXUrSXAnlhjb7sSwAZAODwehzWTmrahaxV0WwtLy9TULeI6eyufuSbk5x1B5z9OldxqNlb3mnKJdweMZjkgkXcD7A9/8KqL4BuGned7wtG33kS1EZz3Ofpxx9a5jxD4RsdIvYXa21jUIpJCjKjk7foQM/nWLak9GUh2iw3uqebFeWMsyRSELdWtx5D/AIjkDB/WtG1m0uJYrWfU9YXU1YkJcSiWQ89eBk9sfjW3ofgjRoI/ttuNW01ynzETGRDzwGGMjjH14p2o6JpcVzDf6Pqsc+rqMCMEGVl917k/pzUuSvYW5neIbTTf7Bmn1afULcwv5glt2AbOe349veqNjceML7TWgt9P1fUfDkvCyu0UN2UIxhXwcfkeorrb06drGji21+TUoQz5ZoYVByGGDjHBB/Srf/CwtM8P6CJ7U2us26HaHZCkxPTAX2NTey0V2PXoVtA1sabp0cdja6hbzQnaLXUD5kgPYFwB1xVFrh/F2ovP4q0Wy2Kdq2z6q9uCpOCWRSCQcdAa2dD1vxP4hK3SXng3SGf5YbW7jeaZiezMDgE/pkVR8XXs+h3OPiD4J0TUkypGpaU5BB/3Cc8Z5PtStrtr66/mBuaJYanoRuB4Ls9Ne2mIMNkJGdUP+yxJLZ5yD05rH1jWfHcm2S9tLMFSW+y6dbsqhRxjzGJ4+nWtHQvG2h2tqE0zSZ7RcnaBJszuHOCe5HrWLr3xAuo3BVjLuZUjghB3MR0Uds479KhJuTbQralq0+JN/oV/BYReHZJ750JCNMBgDqx/Pis3VPiDqvifVBFJp8GmxW3DqSolbPAX09smsvUNH1jWiNR1vTLSyt8ExxWkrfa8dcM44x+HNa3gTQ31y8aK1trPRNPQlF+2AzXMzZ5Y5OOe3atOWC94NB/hC38Si9uJ7qxjlsZP3cUMkpZtpJ53dAufxqxrF3rWqCW3m+HSXEIH+uhvFUKucd/u+vrnFd+fCj2VkzWviCW4hjjYgOoKMoyDwOwPGOua8x8X2ljqEzbI9VcQTn7S8cjbHZfvK2OvBBwPX61nCUZu8f1/4AJ3Ldjc+HtKtg2tzyWcqrj7IblZyMHtjqf55qG3iPiTVluNaGpLoEJBhhb/AEdZWxyzjrg8DHvzWK19osstlB/wjej6RGsm43jRTBgQRjY2Tz069813UPizTSiWkt5ahSOEuWxnPXcT15zVv3dUPU0b6Tw6lmsei2lvDMgJRkYksOg47jvWeLNNTt2g1R4FkdQvmTtwM8BivHU8fSoY9LuL+4CafqujWB4OGjLZB/iXB59TinX9jeiVLLVLSHXBLlX+zxlNvbB59OQKladRHM30Ft4X1e0tPPtrjT5HMTzW0gzDIBwu3uO2TWleNZwRJKNe0wMAHWKe8QsQf9kc4ro/+EI8N6Vps09voR3PHumVMsWYH7vzE4OOfbmvPrTV7AazLY+H/CejWnkufP1G/wBP87Z/uD16DmnFqewJ31Lk2p3W5Z7UG5C/cFpH57ye5zxwPyrO8e3N3qPhCO+v1vUuJ9KmjEd1bLDsRdQtdpGOuS3Ppj3rvtB8RaPpgVNJvDPelQ0rW9uIoVJz0GOAPSuW+Luo3eoeE9OfVJoppl0+6IWMcpm/tO/Q8dB2qoP30rdQOd0TwxpEmg2ut+KvED6DYarczWOmtHbCZ5ihXNw5J/1IYsDjByRzik1rwc1pp7Np017q15bS3Ju3060DWQgiwWmgmzl9hdA4OeZCBjbk6Og3Wg+IPCHh3QdZ8Q23h278NTXpjnuYvMiurKYqzkA8NNk4CdMA5Haug8KeMNG0LwxH/ZmvW1q+maZ4iGkLPKFukMkkDW4lThRIxDsFA2kAEDOcdXox2R5qfDWutqmoaQuiam2qWMBuLyzSFWeCMhTvwDzkMpCgk5+lRnQtRlVZ5dDvJFGnnVY5XgUn7Ep/14yfug9jkkEdq7b4a+IIzoUtjq3jCbw9rI1O31ybXZnLyXkEcIQ2hLcu6MciNtwOT8vrd0XXfDtr8M31OXXLSG8XwfeeHf7GLlrr7TLOSJApP3GyDj+EewwCTsgUVucHd+FdZfUI7a98L6q99NN9jRXs+WmKh1jDA4B8sh/Zc+lZdvA7TRW1tbSi4MyW620ceJRMW2+Ts6hyRj14zXt/irx5a3up+LrWHxpbxaYLjQYLXyL3Gbcg/afJZTlSCxLsvIA2n0rzX4hapbX/AMVPEGo2V415aHV451n02dUeSFAATBIARvA4DD365pJ3uuwOKSuUNa8NeINHSNtd0bVdMhkmMEct7GREz9dm8HnIzj1wcVr+HvAVhrun6c8l7Z2mva+ss+i2D2pkiuUQkETSj/VsxDYA+7t+bkio/E/iPT9Uhs49Obxuskd2tyf7a1MXMOxQ2XCEf6wE/L+Ndj8NvFdhoPg+wWTxDZ6Rptgk/wDbuiSRLLcaw8gO2S3bIY712JwV2FTnjknR2BJXsjz/AMP+F7G/ttSvtZ8jR/D+lSbdSvDEJnWflRbQAHEkhIzkfKq/MffWi+HqTeIJNGN/pyeH7ayTWZdYkjKxLZOoKTCLO7zTnGwnHHoaueBEttN1X7PB4r8IWekahpa3lxY6oftluVMzeXbTA7Q88Q5yNrZ4xjk9Vp3j/TNQ1nxba+GNUt/Cn9orZw6JqWpQoLQ29omwxNuB2bhvK7gQRxwerf8AX9eX4j5VY8uvtFg1XXptH8LyTeKYM+bZtbWRjaaIICzmPgptbKdgxXgc1npoNxPZ/bItDvJbOa3luPOSzOxoICBK5wwKrG2ASMc4HNetad4k0vUdc8YWGieKtN8LajqE9jcR679nFvBetCoW58t+NitIN4XJ3fNkkOcbnhnxnYR+IfAMD+KLSXSr3VdfuNTka4EaSkvJ5LSoT+6V9wYR8KSQcEmpUrLXT+v6/EOTQ+fbmyexlhaSwltHuYEuY/MhMZlgfGyVM8FDjGR9etZt2ALG5wAMxqCRzk5H9Pz/AAr0bxt4gl8T+BvhxcXmoR6hrapq0l8A6+ZFuuPk3gY2LjhRwABgACvO7vi0usAhgisSRg/eAz784/M1pF3/AK8yGrOxmb/9qGinbf8AZT/viis7FXIjk5z8x757e/vQOoPfPI44NA+8AD06Dpj86QcgccemO3aqA7HXLDwnF8PfDl5pOp3U/imeaRNStJFASJB0wP4cfLtxnduY8YxXHqM4wDz6Dj/PtRvJXBJ29Tg9+nSj04xzz/n+vvRr1AQHjA+XnGPTrx/n1pcgHtj+Y9P5GkHQDkDHelB55/HnoKbAUcdDyO/070nUdPb/APVS8HjOTxz3+h/xpfpz0B4x9KLCL2mTRRSEyA9MAglSPfPpXSWUl3cSqUm85GY5iDAb8jA6898YrjgAQC2OmevGPSt7SdImu4lDxOSynbJC21wfQjv2+tVJXV2BvvaxXCNbnwzK7LggoCrI3fDL1/8Ar1veEbHxB9pu0tNUvtMjeQGNLqNZsDH8RPTB9O1cloOra9YytZea5TO0pMwzkHr78dq2NQGqXUMlxPb35LYbdDIQpUeqjqtYzT2/r8Ro7i78R+JvD08Met6potzYykol7Guwx47MnTHXH0qTVdO0/VIhfT+KbuZgpcNY3ioh/wBsjvjpXm9ne644e1Fk17LJz5d1g5+obtjoMe9UL+xX962q6DPpW/Ck2JO0g9DtJOc4PTj0qPZ66AjvtP1bULW2mmto9burIHLPEBIduMHcQOSAM59KqNr3hLU7pJF0vVdS1DGN1paFJVPTGQRz/jVHwfqt5DbvZ+FNZlcIoxBqUZVN3Q8jp9PXiumgh+IlzM1zBJ4cR2XD+XIwLj/PGR61LSTf/DAUzc63I8Q0/wAOXWmWeBifUJiZAB32emPbBPetqDwvfyxx3MetwLdbt3lXVnFJG4PTcccdh+Jq6t545ybbVdNtbKRgFDLKJNy8d8556nsKzr1PFNlFcTyeItGjhJ3C3u7LHBOOo55OAfpU37CuULq1s7yNodR0iLzkH3rYtFvHYjHTnqawreysry+nsdOvL+GaJtssVxOJDg9hu/DnHvW9pPiTXrqbz100zxqxWQrCRGwHRlzyV6jAroJ9G0nWHN7d6GUv8ZDiPaybemD7Hjmn8O43ocmtiLOxCWun6jeQOmCJHDM4U4Ht1BA9hVHStQYauJI/BeoTzohG+W4KbM9SoPAPtXaR6Vrb3Mq/2umnWJQKY5bTLp7q3oev51h69byWmoCPV/GVvcWbuS1vaRKr5H+1/LHNCdwOigOpTRCZrC0tZNuUjS56DqNxzzg8nFYGl6w2sX720jaNa3cDOsg1KVoSoB/hwefXjrmrln4O8P8AiKLy9MhieULmQrM3mn1ZTnBOe1ak/wAKX8iJrmTSpkiT920sW/gcnnrwP1qOaEd2K5i+JPEsrH+ztPiF3ekcDR5Hl+YDJyx/h6e9df4fvfG91awRatqGg6BAMdbDz7heP9rg9cZPHNYcviDxl4UWS3tfCNo9rGARLp7AHb64GT/+usmKXXfFRtbnUPEvhzQzu3x2atvmA7q2/p9B3FDV1t+v9fiB2usWki6bJbW2oXGqlsvkxRosiZ5IAGFx6VhaN4Qg1qA2+qXmotb7jmBo4vmP90ZG7rnBB7Guoj0TX5NN2Jcabe8fLJGB82MDoOvB4PvXDx6V4Tsrw/8ACwbXxIf+WauJJPsqcnIynIxznJ9aUX2YlqQ65oGn+HfEUVvYXipcmT5FnnRsD+JYxnpnH0PtWnquq65pciyLdyhNgQeSivnPq2M5GOvY1D4h0zwpa2rjwH4Y0e+jfbia6naTZnp87NuHfjIrA0XT9WSW6ke8EUDE7LaJCIo/9kM3JB/Sq+Ja/iUa0PxR1Jrj7Fr1za2UUh3AeUy7uMH5uhyKz/E/ivS9IniuLJitwzZKhuM44bB6dauX9zrL2jf6bpFmIVG6aWISlfRhnvnp71yPhu01rUry5m0Pw9b6vMWZH1XVYBsVuc7QeOn1NVGEd7W/r+u4HRaXJeay0Nxq8Mlpbu+6BIpcGXHJZsdvSq3xIitoPB0Qs7a6gRtNuGHn9JFOoWuMfrk1z8UniHTtejt9ZkIeIFY47RVkCevT8sdqs+Jtdutf0LVo57i7uo9O0lFVbiARi3L38JJGPvbsLknjoBVKPvRa2uJnLSM3nOCF4PAJBGTwAAf/AEKr+g6XfeIdbsdM0tEl1G/uY4Yi4D7SOWkY4J2ooJJ5xjNZMgIlk2R7vmIX5c9T0Pf8K7f4c+JtI8LL4gv9QtZL7WWtI7HS7LMkQlWRyLorKgzG4QDD5B2nvmuliSuGu+CtUj8a6pomg2c2sxxxtqtiYWEi3GnFd0cqsR+8fkJlRlm4BNN0/wAAeMb/AFmbTrPw5ctq9vbxXbrLPFGYo5BmPfI+Nrk5HlnB+VuwNdbpfxC8MpceGrict4WvNHW+00RWplvpEsZbUtDIJ2BJ2zkKi5IG49BXOeCfEOjHw1e6H45vre3W7vU1X+09Q0+bUPMmEXlvDIqur7vm3K+ccsO4qVe9v6/yK5YmDpPh7WdWl1BNG0G+vJ9KGby2htx5tqWfYY9mMlywbKjsGPbiCfw/qsGvf8I5NpzDV0u0sBZRyIcTPyihx8uCMknoAOa9ETxzpV1qGtXmteKNcHl6vbataX+m2Ytn1VEjWB0WInCBAARubJQsSpPFcR401nTNT+I2t61ZINV0ibVlvEGXtVuIhyV3nDR88buDQr9f1FyxHeIPAvifw3bQXPiLw/NptpNc/Zo5ZJo5A0wyVB2nIU84bpxxWj4e0DRE8IS+JfFWpapptrcPNBpH2KxErSNEo3TO5UhULsFABXJB54JrM8R6/o2p28KaZ4ObQZlu/tMl0dZmvNyFSrKUkJG5uPn7bRXYeDfH+n6b4b0eLV9a1G3k0S2lsm8NRQGe31+OTcUJJBRM7yrbgxwvy4JxS1a7f1/XQfKr2MXwJoXh7xXrMek6lNB4bupxZLAqSm4S6kLbbjBlDYmfKFcZVffOaZYeDZta8Ya/pUd19n0XR9Rnhv8AVtRRBDZ28chRS2cI0zYwB+OByRU0O60XQ/HHg/UbbVIp9MiuoNR1DybSSNdMcyMWtwGyzqmevJwM96tXXjf7Dd+MLK3s9H1bQ9Y16S/LX0MzqqLMSsoWNlypBBwfToaI3v8A1/X9fMEl1JfEngq/HxF1zwp4XsdS1xtPkGIZVjyI/LRleRseWOWIXgE4GQDxWG3hTxC1jNdyeHL9rM209zK7pErCO2fy5i6nkMjjG0/NxxxXqeq+OfCuseIvGdhL4nvvDun6hqdrfWevaXG+y4MMaI8TADeDkFgwwpZd3bDr4a+IGg2fiT4ezf8ACQTJpkGo65d6mbklH3StJ9nluFUAF2Vxg4wMnGOamMnZX7foHKjhfBvhmS+8QyaVrHg6a/1W+sYr7T0vpjb2sMDH57q5aMhim08c5BBXBJFcl47fQW1vXB4Q83/hHlmVbITht4T5SwG75gu4sRu52kZ5rsLzx9qMXg/wKdK8RXyeIorXUotWnWQtOiS3W+MO7A/M2wHrnGOma4DxHq+oa3c3+qarcy3V/dFGmuJAAzkYAJxgKAAAAOABVxbbu/Pr5idkrGHuHrH+tFN59F/75oqbBYQ5xnO769c+n1pMY4Ge9Nk+5/wAU+T/AFj/AFH8xVoEJ3z1B/iGef8AJo6YxwQeP8KD9+X/AHqIvup+H9KQMOCDjHHQdzQcZyGPTg4x/nFB+5/wH+opy9JP94UN2AQ9CDx3IPAP19qTOOTnP5EUn8C/9dTSt938D/OnsAo6npnNIyhsgglif4uD/wDrofp/n1p0n3m/H+lA+g9ppWk3+bKHxgEuSQPTPp/OrlrrOp2m02mpXkJGSFEpYduMd/pWaO/1pR0H+9RYdjal8RajcOv22eO9i67JYQuT2yyYYEdRg/4VSGo3gfc11MzEEEySM27j3+nT0qkvVvp/WnDofp/7MaLCOt0bxm9jCY7jSbW6DELlJTACuM4IHc8HPpxV2T4hTmRDZ6UbfZjK/bmYEj2I4rg2/wBT+FK/Q/Vv6VPIm0wTPbdD+J/hu7tJI/E2na1ayAgqlpsvBLnOXJkKlMYAwM9aoah4q8Krex3Gl634mNqp5sL/AEqGUdOCrCTj8q8mT7j/APXIfzWkT7i/9dB/Ws+SPQfQ+gdI+MHhi3SJZI/EKRJn5YrCApnjtv8ApVu7+Juja0syaZ4lTTGTAaTWrJk8zfn7ixbsgY53YxnjNfOUfX/gH/s1St93/gL/AM6Tw8b3JdlrY9/1TUbK/syg+JvhtvkI3SrPuDew29O30rF03xH4a0qEIupeH7i6C7Wla3lcOemSxTPP5AV4mev/AAE1K33T+P8AOr9h5hzJnvEdz4Y1pI5tQ8VeGNOnC5T7J50TIe2SE61qWmv4k8mDx/4Plt4hlZbmaZJMnp/CM4/Ovm+Tv9HqGf8A5Zfj/Ol7C+l/6+8XMnbQ+jJLawu59+q+O/CdszNxJpetzIx/AL8ozg0yw0nwfp96Zrn4geHNVYElmv18+QjPI8zZk9z/APrr5wHf6in/AMI+gqlh3bf8P+CU2j6M1vUvBGmI91pniC1tp43X99pdzI7N23CE4DH8uKmuvjBp76abQ+LftTMm1t+kuFbj07nnvXzpp/8Ax8R/WrJ/1TfRf51m8OvtO/8AXzFdM9U8O+IPBoMsuqa7PZzg7tsenOyHPVQB90Gmaz460gOw0zVZ54UwAotCsk2W5C7vlXaOcnrXl6/6xf8AcH9aif8A1Y/D+VV7JbjbOy8ReJNJ1C0VLQ65HMihC0scW1fXAB61QvfFNxHYi30vV9bWNQP3c+xFA9tp45rmD1T/AHjTn/rJ/KrUUtA62Oo0bxjPoX/IP0rSY3IIkkcO7SHPLbienb0pnifxld+IoLRL2ztLdrcSRvJaMYzOjOrqsnXcqsuVz0JzXMQdD9B/KiP/AFqfQf8AstHKua4myzLcRNGV8u48wrncbktz64wO/vUYmlBxvk5BXBkP+cVAv/Ht+f8AOpV/5Zf71U2xaIeLiVFIE8oQ4yQxxz689KVLq4jJaOeZDjGRIeR2zz+FQ9/wb+tB6p+P/oZoKWpKLqVdxE0gDHkbySe2OtBupSdxnl3ZzkOfSoo/vR/7p/lS9j/uJ/OlfUS1Hi5lAx5svHUCQjn1/D/GnC6nAKi4lAznAcgfU81Gv+r/ABX+Zpsv3T9KE9bATrcz53CWUEd/MPA9c0i3Vx1WWbPqXPPPb39qqS/w/wC+f51NJ1f/AH/8ae4EwvLgPxczE+znP885o+1z4ObiTg54c49fy/8A1VEnVf8AeP8AOli6wfU0r6gO+0zMMNLKx6/M55P9f8Ka0ruHVmkcHA56N9c1EOn4H+RpF6/jTBK5Nvf1j/z+NFJRUczM/aH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasonographic appearance of a polycystic ovary in a 15-year-old with polycystic ovary syndrome (PCOS). Note that in the maximal diameter the ovary is enlarged due to excessive central stroma. In addition, it is polycystic, containing over 10 follicles that are approximately 3 to 8 mm in diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L. Rosenfield, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_15_21748=[""].join("\n");
var outline_f21_15_21748=null;
var title_f21_15_21749="Valsartan: Patient drug information";
var content_f21_15_21749=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Valsartan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     see \"Valsartan: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/1/22550?source=see_link\">",
"     see \"Valsartan: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F233186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Diovan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CO Valsartan;",
"     </li>",
"     <li>",
"      Diovan&reg;;",
"     </li>",
"     <li>",
"      Ran-Valsartan;",
"     </li>",
"     <li>",
"      Sandoz-Valsartan;",
"     </li>",
"     <li>",
"      Teva-Valsartan",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help a weak heart.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to valsartan or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High potassium level. Signs include feeling weak, lightheaded, dizzy, feel like passing out, or have numbness or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11137 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-FC5DC09734-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_15_21749=[""].join("\n");
var outline_f21_15_21749=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233186\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233187\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022776\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022778\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022777\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022782\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022783\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022785\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022780\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022781\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022786\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022787\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=related_link\">",
"      Valsartan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/1/22550?source=related_link\">",
"      Valsartan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_15_21750="EB nevi dermoscopy";
var content_f21_15_21750=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 606px\">",
"   <div class=\"ttl\">",
"    Dermoscopic image of an epidermolysis bullosa nevus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 586px; height: 465px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dermoscopic image of an EB nevus on the thumb of a five-year-old boy with recessive EB simplex with muscular dystrophy showing an atypical pigment network, irregular dots and globules, and homogeneous white and reddish areas (multicomponent pattern).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_15_21750=[""].join("\n");
var outline_f21_15_21750=null;
var title_f21_15_21751="Prevention of genital herpes virus infections";
var content_f21_15_21751=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of genital herpes virus infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/15/21751/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/15/21751/contributors\">",
"     Anna Wald, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/15/21751/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/15/21751/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/15/21751/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/15/21751/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/15/21751/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of genital herpes simplex virus (HSV) infections can avert significant morbidity associated with primary infection and the ongoing discomfort and psychological distress that may occur with recurrences. Preventive measures include patient education, use of barrier protection, and chronic suppressive therapy.",
"   </p>",
"   <p>",
"    This topic will address measures that are available to prevent HSV transmission. The epidemiology, clinical manifestations, diagnosis, and treatment of HSV infection are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=see_link\">",
"     \"Treatment of genital herpes simplex virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COUNSELING AND EDUCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Counseling is important for the effective management of the patient with genital HSV, particularly in the setting of a primary or first recognized clinical episode. Many questions invariably arise at the time of diagnosis as to the expected frequency and severity of recurrences and the potential for transmission to others.",
"   </p>",
"   <p>",
"    There are also psychological aspects of HSV infection that can be distressing for patients, which may be under-appreciated by the clinician. A diagnosis of HSV may evoke anger, disbelief, low self-esteem, and fear of rejection by present and future sexual partners [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/1\">",
"     1",
"    </a>",
"    ]. It is important for the clinician to openly address all of these issues.",
"   </p>",
"   <p>",
"    Anger is often directed at the current partner and questions regarding partner infidelity may arise at the time of diagnosis. However, the first diagnosed outbreak does not necessarily imply new acquisition [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients should be counseled that this may be the first recognized outbreak; only serologic testing in concert with virologic testing of the lesions can determine if their current episode represents newly acquired infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients need to be reassured that recurrences are generally less severe and shorter than the first episode; episodic treatment of recurrences, or chronic suppression with antiviral therapy, is available therapeutic options. They should be educated about the probability of recurrence, which is much higher with HSV-2 (&gt;90 percent) than HSV-1 infections [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The natural history of genital HSV is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\", section on 'Recurrent infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Reducing risk of transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a patient is diagnosed with genital HSV infection, counseling should also include prevention of transmission to the partner(s). Patients need to be educated that HSV can be transmitted even when symptoms or genital lesions are absent, due to viral shedding. Direct contact with mucous membranes or skin can lead to viral transmission, even in the absence of sexual intercourse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Determining partner susceptibility to infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of genital herpes can only occur in the context of accurate, laboratory diagnosis. Up to 20 percent of persons clinically diagnosed with genital herpes do not have genital HSV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/4\">",
"     4",
"    </a>",
"    ], and thus remain susceptible when exposed to infected partners. In addition, persons with genital HSV-1 infection remain susceptible to HSV-2 infection, and thus counseling associated with diagnosis of genital HSV-1 infection should include discussion of the risk of HSV-2 acquisition.",
"   </p>",
"   <p>",
"    Sex partners should be included within counseling and education sessions regarding HSV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Serologic testing should be considered for partners without a clear diagnosis of genital herpes to determine the risk of HSV acquisition. Couples who are serologically discordant should be advised to abstain from intercourse when active lesions or prodromal symptoms are present [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of barrier methods and antiviral prophylaxis in discordant couples is discussed elsewhere (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Condom use'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=see_link\">",
"     \"Treatment of genital herpes simplex virus infection\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Educational resources",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many educational resources are available for patients including the CDC National",
"    <span class=\"nowrap\">",
"     STD/HIV",
"    </span>",
"    Hotline (telephone 800-227-8922) where patients can obtain additional counseling, and order educational brochures. There is also a nationwide list of HSV support groups available to patients. The Herpes Resource Center (HRC) has an affiliated network of local support (HELP) groups for people concerned about herpes simplex virus. The groups provide a confidential environment where participants can get information and share concerns with others (",
"    <a class=\"external\" href=\"file://www.ashastd.org/std-sti-works/Herpes/emotional-issues.html\">",
"     file://www.ashastd.org/std-sti-works/Herpes/emotional-issues.html",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It is best to give patients written information that they can review at home, because the initial diagnosis can be overwhelming. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?36/3/36916?source=see_link\">",
"     \"Patient information: Genital herpes (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DISCLOSURE OF HSV STATUS TO SEXUAL PARTNERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All persons with genital HSV-2 infection should be encouraged to inform their current and future sex partners that they have genital herpes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retrospective studies evaluating source partners of individuals with newly acquired genital herpes have demonstrated a short interval between initiation of sexual activity and the onset of genital herpes infection.",
"   </p>",
"   <p>",
"    A clinical study was undertaken to determine whether persons who were aware of their HSV-2 status and disclosed this information to their sexual partners were less likely to transmit HSV-2 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/9\">",
"     9",
"    </a>",
"    ]. Based upon the short incubation period of HSV infection, a time-to-event design was utilized to assess the risk of HSV acquisition among these newly infected patients with the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most individuals who acquired genital herpes were in new sexual relationships (median duration 3.5 months).",
"     </li>",
"     <li>",
"      The median number of sex acts prior to HSV transmission was 40 (interquartile range, 15-75).",
"     </li>",
"     <li>",
"      The median time to HSV-2 acquisition was longer in participants whose partners informed them that they had genital herpes than in those who were not informed (270 days versus 60 days, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this study, the risk of HSV-2 transmission was approximately halved when the source partner knew their status and informed their partner. The changes in sexual behavior that accompanied the disclosure, which protected against HSV-2 transmission, were not clear.",
"   </p>",
"   <p>",
"    Since nearly all infected individuals regularly shed HSV on genital mucosa while remaining asymptomatic, sexual transmission of genital herpes continues [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The study findings support the use of type-specific serologic assays that can reliably distinguish between HSV-1 and HSV-2 infections to identify individuals with HSV-2 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. Serologic testing coupled with efforts to encourage disclosure of genital herpes infection to sexual partners, may provide a pivotal advance in public health strategies adapted to control transmission of genital herpes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Avoidance of sexual activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral shedding is more likely to occur during prodromal symptoms (those that precede the appearance of lesions), or during the lesional stage. Thus patients should be encouraged to recognize the symptoms specific to their prodrome (eg, localized genital pain or itching, or neuropathic pain in the buttocks or leg) and avoid exposure of susceptible partners to the genital area at that time. Sexual activity during lesions should also be discouraged, even if condoms are used. While viral shedding may also occur during asymptomatic periods, the frequency of viral shedding is higher during lesional episodes, and the amount of virus present may be higher.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CONDOM USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Condom use has been associated with an approximately 50 percent decline in transmission of genital HSV-2 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one analysis of 528 monogamous couples with discordant HSV-2 serostatus (261 susceptible men and 267 susceptible women), condom use during more than 25 percent of sex acts was associated with a lower likelihood of HSV-2 acquisition in susceptible women (adjusted hazard ratio 0.085) but not in men [",
"      <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study of 1843 participants, 118 (6 percent) became infected with HSV-2 [",
"      <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/15\">",
"       15",
"      </a>",
"      ]. Men and women reporting more frequent use of condoms (&gt;75 percent of sex acts) were at lower risk for acquisition of HSV-2 than those who used condoms less frequently (hazard ratio, 0.74; 95% CI 0.59-0.95).",
"     </li>",
"     <li>",
"      In a risk-reduction counseling study of 1766 patients, overall seroincidence rates were high at 11.7",
"      <span class=\"nowrap\">",
"       cases/100",
"      </span>",
"      person-years [",
"      <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/6\">",
"       6",
"      </a>",
"      ]. Participants who used condoms less than 50 percent of the time with occasional partners were twice as likely to acquire HSV-2 infection compared with those with more consistent condom use. No additional factors predicted incidence of HSV-2 infection, including circumcision status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk factors for HSV-2 acquisition in these studies included younger age [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/14\">",
"     14",
"    </a>",
"    ], increased sexual activity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/14\">",
"     14",
"    </a>",
"    ], and female gender [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data suggest that consistent condom use can decrease the risk for acquisition of HSV-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The use of condoms remains a pivotal strategy for the prevention of genital HSV-2 infection and other sexually transmitted diseases. However, patients should be counseled that transmission of HSV-2 still remains a possibility even with consistent condom use due to shedding of virus from mucosa not shielded by condoms, or HSV-1 by unprotected oral-genital contact. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=see_link\">",
"     \"Prevention of sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, individuals with HSV infection should abstain from sexual activity if lesions or prodromal symptoms are present. Furthermore, to reduce the risk of transmission, they should use condoms consistently even if asymptomatic, due to the potential for subclinical viral shedding. However, consistent condom use is difficult in monogamous HSV-2 serodiscordant couples. A study of condom use patterns among 1193 such couples demonstrated that the majority of persons either abstained from sexual activity or used condoms \"always\" during symptomatic periods; in contrast, condom use was low during asymptomatic periods [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CHRONIC SUPPRESSIVE THERAPY IN DISCORDANT COUPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic daily therapy may be considered for patients who have significant symptoms related to HSV",
"    <strong>",
"     -",
"    </strong>",
"    2 disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/8\">",
"     8",
"    </a>",
"    ]. Antiviral therapy may be administered as a daily continuous regimen or on an episodic basis based on symptoms. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=see_link\">",
"     \"Treatment of genital herpes simplex virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another reason to consider suppressive therapy for HSV recurrences is to reduce the risk of transmission to the uninfected partner, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Effect on transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppressive therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    is beneficial in decreasing transmission to an uninfected sexual partner. This was demonstrated in a large randomized placebo-controlled trial of 1484 immunocompetent, heterosexual, discordant couples [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/18\">",
"     18",
"    </a>",
"    ]. Clinically symptomatic partners with HSV-2 infection were randomly assigned to receive either 500 mg of valacyclovir once daily or placebo for eight months; the susceptible partner was evaluated monthly for clinical signs and symptoms of genital herpes. All couples were counseled regarding safer sex and condoms were offered at each visit.",
"   </p>",
"   <p>",
"    Suppressive therapy led to a significant reduction in overall acquisition of genital HSV-2 infection in the uninfected partner (1.9 versus 3.6 percent, hazard ratio 0.52, 95% CI 0.27-0.99).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     Valacyclovir",
"    </a>",
"    use was also associated with fewer days of viral shedding (2.9 versus 10.8 percent of days) and fewer recurrences of genital herpes (0.11 versus 0.40 per month) in the infected source partner. Therapy was extremely well-tolerated over the eight-month study period.",
"   </p>",
"   <p>",
"    In contrast, episodic therapy does not reduce the risk for transmission to the discordant partner [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical decision making",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to initiate suppressive therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    should weigh both the potential benefits of decreasing transmission to the uninfected partner and decreasing symptomatic disease in the infected partner. Conversations with the couple should also emphasize the additive role of condom use since all patients were offered this intervention as well. In addition, couples should be counseled that antiviral therapy reduces, but does not eliminate, viral shedding [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the study did not include persons with asymptomatic HSV-2 infection, daily suppressive therapy is likely to reduce the risk of HSV-2 transmission to their sexual partner as well. However, the infected partner, without clinically noticeable recurrences, will not benefit directly, and the efficacy of this intervention in asymptomatic HSV-2 infection is not known.",
"   </p>",
"   <p>",
"    Although antiviral agents other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    have not been studied for prevention of transmission, they are likely to provide similar benefits in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36344819\">",
"    <span class=\"h2\">",
"     Identification of HSV serostatus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sex partner of an HSV-seropositive patient should be counseled that he or she may have been infected in the past, even if he or she has had no history of genital herpes. Type-specific serologic testing of the asymptomatic partner is recommended when chronic suppressive therapy for HSV is being considered for the sole purpose of avoiding HSV transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppressive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    has been given to patients for up to eight years without adverse effects. Data for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    are available for up to one year, and these drugs are also well tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Laboratory monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory monitoring for toxicity is not required in otherwise healthy persons, even with prolonged administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment interruptions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment interruptions to assess the need for continued therapy are not necessary, if the drug is administered for protection of the partner. However, annual discussions of whether the patient wants to continue suppressive therapy are desirable, as the frequency of recurrences decreases over time in many patients. Furthermore, many patients also adjust psychologically to having a diagnosis of genital herpes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     STD SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with genital herpes are at risk for and should be screened for other sexually transmitted diseases. Educational efforts should also be made to decrease risky sexual behaviors at the time of diagnosis of genital herpes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CIRCUMCISION STATUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circumcision has been associated with a reduced risk of transmission of some infectious agents, such as HIV. While a meta-analysis of 26 studies showed no clear effect on HSV-2 infection, a clinical trial of circumcision in Uganda (that was aimed at decreasing HIV transmission) showed a 28 percent reduction in HSV-2 incidence among study participants in the circumcision arm [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=see_link\">",
"     \"Prevention of sexually transmitted infections\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TOPICAL MICROBICIDES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various topical agents are currently under investigation for the prevention of viral shedding or HSV-2 acquisition, including detergents, surfactants, inhibitors of pathogen-cell binding, acid buffering agents, antiviral agents, and barrier products [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/23\">",
"     23",
"    </a>",
"    ]. However, preliminary data from a 2009 clinical trial of microbicide use showed no effect on HSV-2 acquisition, despite some reduction in HIV acquisition [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=see_link\">",
"     \"Prevention of sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     VACCINE DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research has focused on the development of preventive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    therapeutic vaccines for HSV infection. However, vaccine development against HSV has not been as successful as efforts against another alpha-herpesvirus, varicella-zoster virus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/25\">",
"     25",
"    </a>",
"    ]. The correlate of protective immunity against HSV remains unknown, which is a major obstacle to HSV vaccine development [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Clinical trials of HSV vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;To date, there is no HSV vaccine that protects against infection with either HSV-1 or HSV-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/27\">",
"     27",
"    </a>",
"    ]. A summary of some of the major trials of HSV vaccines is listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Immunogenicity and protective efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several efficacy and immunogenicity trials of HSV-2 vaccines have been performed, with varying outcomes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two randomized, placebo-controlled trials of a vaccine containing two HSV-2 glycoproteins (gB2 and gD2) were performed in HSV-2-seronegative sexual partners of HSV-2-seropositive individuals and patients seen at STD clinics [",
"      <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/28\">",
"       28",
"      </a>",
"      ]. A total of 2012 vaccine recipients and 1135 placebo subjects were enrolled in the two trials combined. The rates of HSV-2 acquisition were the same in the vaccination and placebo recipients (ie, 4.2 and 4.6 per 100 patient-years, respectively).",
"     </li>",
"     <li>",
"      A similar HSV-2 glycoprotein D-subunit recombinant vaccine was evaluated in subjects whose regular partners had a history of genital herpes [",
"      <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/29\">",
"       29",
"      </a>",
"      ]. There was no overall benefit from vaccination. However, a subset analysis demonstrated significant vaccine efficacy (ie, 74 percent) only among those women who were seronegative for HSV-1 and HSV-2 at baseline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In light of these results, another large trial was designed to evaluate the efficacy of an HSV-2 glycoprotein D vaccine compared with a placebo vaccine (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=see_link\">",
"     hepatitis A vaccine",
"    </a>",
"    ) among 8323 women who were seronegative for HSV-1 and HSV-2 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/27\">",
"     27",
"    </a>",
"    ]. Overall, the HSV vaccine was not efficacious in preventing HSV-related infection or disease over the 20 months of follow-up. The vaccine did show modest efficacy against HSV-1 infection (35 percent; 95% CI 13-52) and HSV-1 associated genital disease (58 percent; 95% CI 12-80). Although the vaccine was immunogenic at month 7 after completion of the vaccine, neutralizing antibodies were undetectable by study month 16. The reasons for the disparate efficacy outcomes in the various trials are not clear, and a safe and effective HSV vaccine is not on the immediate horizon. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Therapeutic vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several therapeutic vaccine trials have been conducted to \"boost\" natural immunity in persons with prior HSV-2 infection in an effort to decrease recurrences.",
"   </p>",
"   <p>",
"    A trial of",
"    <span class=\"nowrap\">",
"     gD2/alum",
"    </span>",
"    vaccine showed that immunization of HSV-2 seropositive persons with a history of genital herpes reduced the number of recurrences (0.42 per month in vaccines versus 0.55 in placebo recipients). However, two other studies (one of a similar vaccine and another using a replication-defective HSV vaccine) did not demonstrate any clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;During pregnancy, the major concern regarding HSV infection relates to the morbidity and mortality associated with neonatal infection. Vertical transmission usually results from infant exposure to HSV in the birth canal at delivery, most often in a woman with a subclinical newly acquired genital HSV infection. The prevention of HSV infection in the pregnant woman is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33001?source=see_link\">",
"     \"Genital herpes simplex virus infection and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;RNA interference is an endogenous process by which messenger RNAs are inactivated leading to the arrest of RNA translation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/33\">",
"     33",
"    </a>",
"    ]. In cultured cells, short interfering RNAs (siRNAs) are effective in reducing gene expression by more than 90 percent and are nontoxic.",
"   </p>",
"   <p>",
"    Whether the use of this technology could be used in an HSV vaginal microbicide has been explored in a mouse model [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21751/abstract/34\">",
"     34",
"    </a>",
"    ]. Application of the interfering RNAs to vaginal epithelium prevented viral infection and shedding and protected mice against a lethal HSV-2 challenge. These findings highlight the potential utility of using siRNAs as vaginal microbicides, either to prevent HSV infection or to reduce the pathology of the virus in recurrent disease. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Topical microbicides'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention of genital herpes simplex virus type 2 (HSV-2) infections can avert significant morbidity associated with primary infection and the ongoing discomfort and psychological distress that may occur with recurrences. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Counseling at the time of diagnosis of HSV infection is important to educate the patient regarding the high probability of recurrence and the prevention of transmission to sexual partner(s). The diagnosis of genital HSV infection can be associated with significant psychological stress. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Counseling and education'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be counseled that viral shedding, which can occur during asymptomatic periods, can lead to transmission. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Disclosure of HSV status to sexual partners'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Consistent condom use has been associated with a decline in transmission of genital HSV infection. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Condom use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with symptomatic genital HSV-2 infection and an uninfected partner, we recommend chronic suppressive therapy to reduce clinical recurrences and viral transmission (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      (500 mg daily) is the best-studied regimen for this specific indication and offers the convenience of once-daily dosing; however,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      may be a reasonable alternative.",
"     </li>",
"     <li>",
"      In patients with symptomatic genital HSV infection, who have an uninfected partner, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      (500 mg daily) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with genital herpes are at risk for other sexually transmitted diseases and should be screened. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=see_link\">",
"       \"Prevention of sexually transmitted infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      No effective prophylactic or therapeutic vaccine currently exists, although vaccine development is ongoing. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Vaccine development'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/1\">",
"      Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007; 370:2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/2\">",
"      Reeves WC, Corey L, Adams HG, et al. Risk of recurrence after first episodes of genital herpes. Relation to HSV type and antibody response. N Engl J Med 1981; 305:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/3\">",
"      Benedetti JK, Zeh J, Corey L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann Intern Med 1999; 131:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/4\">",
"      Langenberg AG, Corey L, Ashley RL, et al. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 1999; 341:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/5\">",
"      Barton SE. Reducing the transmission of genital herpes. BMJ 2005; 330:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/6\">",
"      Gottlieb SL, Douglas JM Jr, Foster M, et al. Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling. J Infect Dis 2004; 190:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/7\">",
"      U.S. Preventive Services Task Force. Behavioral counseling to prevent sexually transmitted infections: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149:491.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/std/treatment/2010/default.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/9\">",
"      Wald A, Krantz E, Selke S, et al. Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition. J Infect Dis 2006; 194:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/10\">",
"      Hook EW, Leone P. Time to translate new knowledge into practice: a call for a national genital herpes control program. J Infect Dis 2006; 194:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/11\">",
"      Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/12\">",
"      Wald A, Ashley-Morrow R. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis 2002; 35:S173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/13\">",
"      Corey L. Challenges in genital herpes simplex virus management. J Infect Dis 2002; 186 Suppl 1:S29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/14\">",
"      Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001; 285:3100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/15\">",
"      Wald A, Langenberg AG, Krantz E, et al. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 2005; 143:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/16\">",
"      Hook EW 3rd. An ounce of prevention. Ann Intern Med 2005; 143:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/17\">",
"      Rana RK, Pimenta JM, Rosenberg DM, et al. Sexual behaviour and condom use among individuals with a history of symptomatic genital herpes. Sex Transm Infect 2006; 82:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/18\">",
"      Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/19\">",
"      Johnston C, Saracino M, Kuntz S, et al. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet 2012; 379:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/20\">",
"      Crosby RA, Head S, DiClemente RJ, et al. Do protective behaviors follow the experience of testing positive for herpes simplex type 2? Sex Transm Dis 2008; 35:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/21\">",
"      Weiss HA, Thomas SL, Munabi SK, Hayes RJ. Male circumcision and risk of syphilis, chancroid, and genital herpes: a systematic review and meta-analysis. Sex Transm Infect 2006; 82:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/22\">",
"      Tobian AA, Serwadda D, Quinn TC, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 2009; 360:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/23\">",
"      Corey L, Bodsworth N, Mindel A, et al. An update on short-course episodic and prevention therapies for herpes genitalis. Herpes 2007; 14 Suppl 1:5A.",
"     </a>",
"    </li>",
"    <li>",
"     Karim, SA, Coletti, A, Richardson, B, et al. Safety and Effectiveness of Vaginal Microbicides BufferGel and 0.5% PRO 2000/5 Gel for the Prevention of HIV Infection in Women: Results of the HPTN 035 Trial. The 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, February 8-11, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/25\">",
"      Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis 1998; 26:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/26\">",
"      Rouse BT, Kaistha SD. A tale of 2 alpha-herpesviruses: lessons for vaccinologists. Clin Infect Dis 2006; 42:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/27\">",
"      Belshe RB, Leone PA, Bernstein DI, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012; 366:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/28\">",
"      Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 1999; 282:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/29\">",
"      Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/30\">",
"      Straus SE, Corey L, Burke RL, et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994; 343:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/31\">",
"      Straus SE, Wald A, Kost RG, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 1997; 176:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/32\">",
"      de Bruyn G, Vargas-Cortez M, Warren T, et al. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 2006; 24:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/33\">",
"      Johnson DC. Silencing herpes simplex virus with a vaginal microbicide. N Engl J Med 2006; 354:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21751/abstract/34\">",
"      Palliser D, Chowdhury D, Wang QY, et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 2006; 439:89.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8344 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-33D61AF354-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_15_21751=[""].join("\n");
var outline_f21_15_21751=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COUNSELING AND EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Reducing risk of transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Determining partner susceptibility to infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Educational resources",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DISCLOSURE OF HSV STATUS TO SEXUAL PARTNERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Avoidance of sexual activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CONDOM USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CHRONIC SUPPRESSIVE THERAPY IN DISCORDANT COUPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Effect on transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical decision making",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36344819\">",
"      Identification of HSV serostatus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Laboratory monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment interruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      STD SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CIRCUMCISION STATUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TOPICAL MICROBICIDES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      VACCINE DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Clinical trials of HSV vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Immunogenicity and protective efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Therapeutic vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33001?source=related_link\">",
"      Genital herpes simplex virus infection and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/3/36916?source=related_link\">",
"      Patient information: Genital herpes (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=related_link\">",
"      Prevention of sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=related_link\">",
"      Treatment of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_15_21752="Incidence, risk factors, and pathology of ectopic pregnancy";
var content_f21_15_21752=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Incidence, risk factors, and pathology of ectopic pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/15/21752/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/15/21752/contributors\">",
"     Togas Tulandi, MD, MHCM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/15/21752/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/15/21752/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/15/21752/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/15/21752/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/15/21752/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectopic pregnancy occurs when the developing blastocyst becomes implanted at a site other than the endometrium of the uterine cavity. The most common extra-uterine location is the fallopian tube, which accounts for 98 percent of all ectopic gestations (",
"    <a class=\"graphic graphic_picture graphicRef55800 graphicRef62515 \" href=\"UTD.htm?13/15/13562\">",
"     picture 1A-B",
"    </a>",
"    ). Management of these pregnancies has changed dramatically over the years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/1\">",
"     1",
"    </a>",
"    ]. The guiding principle has become a conservative approach that attempts to save the tube, rather than salpingectomy. However, it is important to remember that hemorrhage from ectopic pregnancy is still the leading cause of pregnancy related maternal death in the first trimester and accounts for 4 to 10 percent of all pregnancy related deaths, despite improved diagnostic methods leading to earlier detection and treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence, risk factors, and pathology of ectopic pregnancy will be reviewed here. The clinical presentation, diagnosis, and treatment (medical and surgical) of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27417?source=see_link\">",
"     \"Methotrexate treatment of tubal and interstitial ectopic pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5976?source=see_link\">",
"     \"Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of ectopic pregnancy among women who go to an emergency department with first trimester bleeding, pain, or both ranges from six to 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/4\">",
"     4",
"    </a>",
"    ]. The overall incidence of ectopic pregnancy increased during the mid twentieth century, plateauing at approximately almost 20 per 1000 pregnancies in the early 1990s, the last time national data were reported by the Centers for Disease Control [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/2\">",
"     2",
"    </a>",
"    ]. This rising incidence is strongly associated with an increased incidence of pelvic inflammatory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The current incidence of ectopic pregnancy is difficult to estimate from available data (hospitalizations, insurance billing records) because inpatient hospital treatment of ectopic pregnancy has decreased and multiple health care visits for a single ectopic pregnancy have increased [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/6\">",
"     6",
"    </a>",
"    ]. Furthermore, since the incidence is expressed as the number of ectopic",
"    <span class=\"nowrap\">",
"     pregnancies/1000",
"    </span>",
"    pregnancies, the denominator is difficult to determine accurately since early pregnancy failures that do not result in delivery or hospitalization are often not counted.",
"   </p>",
"   <p>",
"    Ectopic pregnancy occurs with some seasonal variation and is most common in June and December [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/7\">",
"     7",
"    </a>",
"    ]. The reason is unclear; the authors postulated that reproduction is seasonal, depends on photoperiod and temperature, and varies with different latitudes. Therefore, depending on the location of the investigation, ectopic pregnancy may show different seasonal rhythmicities. An altered maturation of the follicle and oocyte may negatively influence reproductive outcome in the transition between two reproductive steady states of high and low overall fecundity.",
"   </p>",
"   <p>",
"    In the United States between 1980 and 2007, 876 deaths were attributed to ectopic pregnancy. The ectopic pregnancy maternal mortality ratio declined by 57 percent between the periods of 1980 to 1984 and 2003 to 2007, from 1.15 to 0.50 deaths per 100,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/8\">",
"     8",
"    </a>",
"    ]. The mortality ratio was 6.8 times higher for African Americans than whites and 3.5 times higher for women older than 35 years than those younger than 25 years during 2003 to 2007. Of the 76 deaths among women hospitalized with ectopic pregnancy between 1998 and 2007, 71 percent of the gestations were located in the fallopian tubes rather than other sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for ectopic pregnancy can be divided into those that confer high, moderate, or low risk (",
"    <a class=\"graphic graphic_table graphicRef82282 \" href=\"UTD.htm?10/38/10860\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/4,9,10\">",
"     4,9,10",
"    </a>",
"    ]. However, the characteristics that place a woman at risk for ectopic pregnancy are not completely independent of one another.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     High risk factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Previous ectopic pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have had conservative treatment for ectopic pregnancy are at high risk (15 percent overall) for recurrence. This risk is related to both the underlying tubal disorder that led to the initial ectopic pregnancy and to the choice of treatment procedure. As an example, a study of surgical and medical therapy of ectopic pregnancy reported the rates of recurrent ectopic pregnancy after single dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , salpingectomy, and linear salpingostomy were 8, 9.8, and 15.4 percent, respectively, among patients who attempted to conceive [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Tubal pathology and surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major cause of ectopic pregnancy is disruption of normal tubal anatomy from factors such as infection, surgery, congenital anomalies, or tumors. Anatomic distortion can be accompanied by functional impairment due to damaged ciliary activity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reconstructive surgery &mdash; The association between tubal reconstructive surgery and subsequent ectopic pregnancy depends upon the condition of the tube, the type of surgery, and the surgeon's expertise. The tubal surgery itself is not the main cause of ectopic pregnancy; rather, the underlying tubal damage resulting from prior pelvic inflammatory disease or a prior ectopic pregnancy is the major culprit. Although tubal surgery is a high risk factor for ectopic pregnancy, most women with tubal damage are unlikely to conceive with either an intrauterine or ectopic pregnancy in the absence of tubal reconstructive surgery.",
"     </li>",
"     <li>",
"      Sterilization &mdash; The estimated failure rate during the first year after tubal sterilization ranges from 0.1 to 0.8 percent; approximately one-third of these pregnancies are ectopic (",
"      <a class=\"graphic graphic_table graphicRef75321 \" href=\"UTD.htm?16/32/16907\">",
"       table 2",
"      </a>",
"      ). The risk of sterilization failure was illustrated by a long-term, multicenter, prospective cohort study that followed 10,685 women after tubal sterilization [",
"      <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/11\">",
"       11",
"      </a>",
"      ]. These women had 47 ectopic pregnancies with a 10 year cumulative rate of 7.3 per 1000 procedures. The major additional findings from this analysis were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The risk of ectopic pregnancy was higher in women sterilized before the age of 30",
"     </li>",
"     <li>",
"      Bipolar coagulation was more likely to result in ectopic pregnancy than postpartum partial salpingectomy (31.9 versus 1.2 ectopic pregnancies per 1000 procedures)",
"     </li>",
"     <li>",
"      The annual rate of ectopic pregnancy for all methods combined was similar in the first three years and in the fourth through tenth years after sterilization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The high risk of ectopic pregnancy after bipolar coagulation may be due to formation of a tuboperitoneal fistula at the coagulated segment of the tube that allows spermatozoa to escape and reach the oocyte.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     In-utero DES exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a history of in-utero diethylstilbestrol (DES) exposure have a ninefold-increased risk of ectopic pregnancy due to abnormal tubal morphology and, possibly, impaired fimbrial function [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3322?source=see_link\">",
"     \"Outcome and follow-up of diethylstilbestrol (DES) exposed individuals\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other risk factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Previous genital infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic infection (eg, nonspecific salpingitis, chlamydia, gonorrhea), especially recurrent infection, is a major cause of tubal pathology and, therefore, the increasing incidence of ectopic pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/9\">",
"     9",
"    </a>",
"    ]. As an example, a retrospective cohort study evaluated the risk of hospitalization for ectopic pregnancy in 11,000 Wisconsin women who had one or more chlamydial infections between 1985 and 1992 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/13\">",
"     13",
"    </a>",
"    ]. The odds ratios for ectopic pregnancy after two and after three or more episodes of chlamydial infection were 2.1 and 4.5, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11992?source=see_link\">",
"     \"Pathogenesis of and risk factors for pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pelvic infection may alter tubal function, in addition to causing tubal obstruction and pelvic adhesive disease. Some data suggest that a history of chlamydial infection results in the production of a protein (PROKR2) that makes a pregnancy more likely to implant in the tubes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H330799\">",
"    <span class=\"h3\">",
"     Intrauterine devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women using intrauterine contraceptive devices (IUD) have a lower incidence of ectopic pregnancy than non-contracepting women because the IUD works by preventing fertilization, as well as implantation. The rate of ectopic pregnancy in women using an IUD is one-tenth of the rate in women who are not using any type of contraceptive [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, IUC users are at higher risk of having an ectopic pregnancy if pregnancy occurs (1 in 2 pregnancies for the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    IUD and 1 in 16 pregnancies for the copper IUD versus 1 in 50 pregnancies among non-contraceptors) (",
"    <a class=\"graphic graphic_table graphicRef75321 \" href=\"UTD.htm?16/32/16907\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/16-19\">",
"     16-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Infertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of ectopic pregnancy is higher in the infertility population, although this could reflect the increased incidence of tubal abnormality in this group of women. Several reports have also suggested an association between fertility drugs and ectopic pregnancy, which may be related to altered tubal function secondary to hormonal fluctuation. As an example, one large multicenter study found that women taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate doubled their risk of ectopic pregnancy from 3 to 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/20\">",
"     20",
"    </a>",
"    ]. The incidence of ectopic pregnancy after treatment with gonadotropin appears to be slightly higher as well [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Multiple sexual partners",
"    </span>",
"    &nbsp;&mdash;&nbsp;A lifetime number of sexual partners exceeding one is associated with a moderate risk of ectopic pregnancy. This is related to the increased risk of pelvic inflammatory disease in woman with a history of multiple sexual partners. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11992?source=see_link\">",
"     \"Pathogenesis of and risk factors for pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking in the periconceptional period increases the risk of ectopic pregnancy in a dose-dependent manner, thus it can be either a low or moderate risk factor depending on the patient's habits [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/10,23\">",
"     10,23",
"    </a>",
"    ]. This may be the result of impaired immunity in smokers, thus predisposing them to pelvic inflammatory disease, or to impairment in tubal motility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     In vitro fertilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro fertilization (IVF) has been associated with an increased risk of both ectopic and heterotopic pregnancy (see",
"    <a class=\"local\" href=\"#H27\">",
"     'Heterotopic pregnancy'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. However, US registry data from 2002 showed an overall rate of ectopic pregnancy of 2.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/26\">",
"     26",
"    </a>",
"    ]. This rate is comparable to the ectopic pregnancy rate of 19 per 1000 pregnancies reported for the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cervical and interstitial pregnancies are other forms of ectopic pregnancy that are encountered more often following IVF (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Cervical pregnancy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H23\">",
"     'Interstitial or cornual pregnancy'",
"    </a>",
"    below). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Vaginal douching",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular vaginal douching is associated with an increased risk of both pelvic inflammatory disease and ectopic pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;A young age (ie, less than age 18) at the first sexual encounter slightly increases the risk of ectopic pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/28\">",
"     28",
"    </a>",
"    ]. There is also an increasing proportion of ectopic pregnancies among women in the older age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. A Norwegian study reported the overall rate of ectopic pregnancy in the population was 1.8 percent; however, women over the age of 35 years had a rate of 4.1 percent, which was eight times higher than that seen in younger age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/30\">",
"     30",
"    </a>",
"    ]. This high incidence in older women may be a reflection of cumulative risk factors over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Protective factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women using hormonal contraception or an IUD are at very low risk of conceiving either an intrauterine or ectopic pregnancy. However, if they conceive, the probability of an ectopic pregnancy is generally higher than in women not using contraception. The number of ectopic pregnancies as a proportion of all pregnancies occurring in contraceptive users is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef75321 \" href=\"UTD.htm?16/32/16907\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all ectopic pregnancies occur in the fallopian tube (98 percent). In one series of 1800 surgically treated cases, the distribution of sites was ampullary (70 percent), isthmic (12 percent), fimbrial (11.1 percent), ovarian (3.2 percent), interstitial (2.4 percent), and abdominal (1.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regardless of the location, the endometrium often responds to ovarian and placental production of pregnancy related hormones. The most common types of endometrium associated with ectopic pregnancy are decidual reaction (42 percent), secretory endometrium (22 percent), and proliferative endometrium (12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Tubal pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, 70 percent of tubal pregnancies occur in the ampullary portion of the fallopian tube, with the remainder about equally divided between the fimbrial and isthmus ends [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/31,33\">",
"     31,33",
"    </a>",
"    ]. A very small proportion occur in the interstitial portion (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Interstitial or cornual pregnancy'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Several factors may be involved in the pathogenesis of tubal pregnancies, but they are generally believed to be the result of (1) conditions that delay or prevent passage of the fertilized oocyte into the uterine cavity or (2) factors inherent in the embryo that result in premature implantation.",
"   </p>",
"   <p>",
"    Tubal conditions that can impair tubal transport include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic salpingitis &mdash; Tubal pathology, particularly chronic salpingitis, is observed in up to 90 percent of ectopic pregnancies. Chronic salpingitis is six times more common in tubes containing an ectopic pregnancy than in normal tubes [",
"      <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/34\">",
"       34",
"      </a>",
"      ]. The histologic features of chronic salpingitis are attenuation and blunting of the plicae and infiltration of the tubal wall by plasma cells and lymphocytes.",
"     </li>",
"     <li>",
"      Salpingitis isthmica nodosa &mdash; Salpingitis isthmica nodosa (SIN) is noted in approximately 10 percent of women with a tubal pregnancy. The gross appearance of SIN is bilateral nodularities in the isthmic portion of the tube. Histologically, the tubal mucosa penetrates into the myosalpinx, leading to hypertrophy of the surrounding muscular layers. The etiology of salpingitis isthmica nodosa is not known.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of factors (eg, lectin, integrin, matrix-degrading cumulus, prostaglandins, growth factors, cytokines, and modular proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/35\">",
"     35",
"    </a>",
"    ]) may cause premature implantation in the tube. The depth of implantation of the gestational sac varies according to the location of the ectopic pregnancy within the fallopian tube. A histopathologic study of 84 tubal pregnancies found that the gestational sac was inside the tubal lumen in one-half of ampullary pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/33\">",
"     33",
"    </a>",
"    ]. The muscularis of the tube was preserved in most of these cases. By comparison, the gestational sac was usually detected extraluminally or both inside and outside the lumen in isthmic pregnancies and the disruption of the tubal wall was more extensive. This suggests that the trophoblast penetrates the tubal wall relatively early in isthmic pregnancy.",
"   </p>",
"   <p>",
"    Embryos with cardiac activity have been identified by transvaginal ultrasound in approximately one-quarter of tubal pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/36\">",
"     36",
"    </a>",
"    ]. Fetal chromosomal and anatomic abnormalities have been found as well. However, chromosomal abnormality is probably not an important etiology of ectopic pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. As an example, in one study in which chorionic villi were karyotyped from 30 viable surgically excised ectopic gestations, the rate of karyotypic abnormality was not different from that of controls with intrauterine pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Cervical pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cervical pregnancy is a rare form of ectopic pregnancy in which the trophoblast implants in the cervical tissue of the endocervical canal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/51/11062?source=see_link\">",
"     \"Cervical pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Ovarian pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian pregnancy occurs in 1:7000 pregnancies and is becoming more common or approximately 0.5 to 3 percent of ectopic pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. In contrast to tubal pregnancy, a history of pelvic inflammatory disease or the use of an intrauterine contraceptive device does not increase the risk of ovarian pregnancy. Ovarian pregnancy appears to be a random event that is not associated with a history of infertility or recurrent extra-uterine pregnancy. Strict histopathological criteria are used to distinguish ovarian pregnancies from those originating in the fallopian tube [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Interstitial or cornual pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interstitial portion of the fallopian tube is the proximal segment that is embedded within the muscular wall of the uterus. A pregnancy implanted at this site is called an interstitial pregnancy (",
"    <a class=\"graphic graphic_figure graphicRef55921 \" href=\"UTD.htm?10/35/10804\">",
"     figure 1",
"    </a>",
"    ); the term cornual pregnancy is also widely used to describe a pregnancy at this location. Originally, the term cornual pregnancy referred only to pregnancies implanted in either the horn of a bicornuate uterus, a rudimentary horn of a unicornuate uterus, or in the lateral half of a septated or partially septated uterus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interstitial pregnancies may be misdiagnosed as intrauterine because they are partially implanted in the endometrium. A clue to correct diagnosis is its eccentric location and thin (less than 5 mm) myometrial mantle. Contrary to previous belief, rupture of interstitial pregnancy occurs relatively early in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34184?source=see_link&amp;anchor=H24#H24\">",
"     \"Ultrasonography of pregnancy of unknown location\", section on 'Interstitial pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These pregnancies are uncommon, comprising about 2 to 3 percent of all ectopic pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/45\">",
"     45",
"    </a>",
"    ]. The risk factors are similar to those for other tubal pregnancies, except for ipsilateral salpingectomy which is a risk factor that is specific to interstitial pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1820977\">",
"    <span class=\"h3\">",
"     Rudimentary uterine horn pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rudimentary horn pregnancy is not an ectopic pregnancy, but an intrauterine pregnancy that is located in the rudimentary uterine horn of a unicornuate uterus. The term cornual pregnancy was originally used to refer exclusive to either this location of a gestation or one located in the horn of a bicornuate uterus, as noted above. However, such pregnancies have a high risk of uterine rupture. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations and diagnosis of congenital anomalies of the uterus\", section on 'Obstetrical complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Angular pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angular pregnancy is an intrauterine pregnancy with a clinical course distinct from interstitial pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. The pregnancy is implanted medial to the uterotubal junction in the lateral angle of the uterine cavity, close to the proximal ostium of the fallopian tube. In contrast with an interstitial pregnancy, an angular pregnancy is located medial to the round ligament [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When viewed from the exterior of the uterus during laparoscopy or laparotomy, the uterine enlargement caused by an angular pregnancy displaces the round ligament superiorly and laterally, while remaining medial to the ligament itself. On the other hand, an interstitial pregnancy causes an enlargement of the uterus that is lateral to the round ligament.",
"   </p>",
"   <p>",
"    Angular pregnancy appears to be rare and there are few current reports regarding its diagnosis or management. In a classic review of a series of 39 angular pregnancies, the rate of spontaneous abortion was 39 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/43\">",
"     43",
"    </a>",
"    ]. Uterine rupture has rarely been reported with this type of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/43,46\">",
"     43,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Hysterotomy scar pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectopic pregnancy in a previous hysterotomy (cesarean) scar occurs in about 1 in 2000 pregnancies and 6 percent of ectopic pregnancies among women with a prior cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/47\">",
"     47",
"    </a>",
"    ]. It does not appear to be related to the number of cesarean deliveries. The pregnancy is located in the scar outside of the uterine cavity and surrounded by myometrium and connective tissue. Implantation in this location is believed to occur because the embryo migrates through a defect within the scar [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16457?source=see_link\">",
"     \"Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Heterotopic pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heterotopic pregnancy refers to the combination of an intrauterine pregnancy and a concurrent pregnancy at an ectopic location. The estimated incidence of heterotopic pregnancy is dependent upon the rates of ectopic pregnancy and dizygotic twinning. The incidence has been rising, mainly due to the increasing number of pregnancies derived from assisted reproductive technology (ART). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16457?source=see_link\">",
"     \"Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ectopic pregnancy is found in the fallopian tube in 90 percent of cases; other sites include the cornua (4 percent), ovary, cervix, and abdomen. A few cases have been diagnosed as late as 16 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Abdominal pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abdominal pregnancy may be primary, from direct implantation of the blastocyst on the peritoneal surface or abdominal viscera, or secondary, resulting from extrusion of an embryo from the tube [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/50\">",
"     50",
"    </a>",
"    ]. In a review of deliveries over a 20 year period at one institution, the incidence of abdominal pregnancy was approximately 1:5000 deliveries with nine early and six advanced abdominal gestations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21752/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16457?source=see_link\">",
"     \"Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/20/35138?source=see_link\">",
"       \"Patient information: Ectopic pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/43/38578?source=see_link\">",
"       \"Patient information: Ectopic (tubal) pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ectopic pregnancy occurs when the developing blastocyst implants at a site other than the endometrium of the uterine cavity. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hemorrhage from ectopic pregnancy is the leading cause of maternal mortality in the first trimester and accounts for 4 to 10 percent of all pregnancy-related deaths. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for ectopic pregnancy include: previous ectopic pregnancy, tubal pathology, and in-utero exposure to diethyl stilbestrol (",
"      <a class=\"graphic graphic_table graphicRef82282 \" href=\"UTD.htm?10/38/10860\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common location is the fallopian tube, which accounts for 98 percent of all ectopic gestations, but ectopic pregnancies also occur in cervical, interstitial, and cesarean scar locations, as well as in combination with intrauterine pregnancy (heterotopic pregnancy). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the fallopian tube, 70 percent of ectopic pregnancies occur in the ampullary portion, with the remainder about equally divided between the fimbrial and isthmus ends. A very small proportion occurs in the interstitial portion. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Tubal pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/1\">",
"      Yao M, Tulandi T. Current status of surgical and nonsurgical management of ectopic pregnancy. Fertil Steril 1997; 67:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Ectopic pregnancy--United States, 1990-1992. MMWR Morb Mortal Wkly Rep 1995; 44:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/3\">",
"      Fylstra DL. Tubal pregnancy: a review of current diagnosis and treatment. Obstet Gynecol Surv 1998; 53:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/4\">",
"      Murray H, Baakdah H, Bardell T, Tulandi T. Diagnosis and treatment of ectopic pregnancy. CMAJ 2005; 173:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/5\">",
"      Kamwendo F, Forslin L, Bodin L, Danielsson D. Epidemiology of ectopic pregnancy during a 28 year period and the role of pelvic inflammatory disease. Sex Transm Infect 2000; 76:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/6\">",
"      Zane SB, Kieke BA Jr, Kendrick JS, Bruce C. Surveillance in a time of changing health care practices: estimating ectopic pregnancy incidence in the United States. Matern Child Health J 2002; 6:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/7\">",
"      Cagnacci A, Landi S, Volpe A. Rhythmic variation in the rate of ectopic pregnancy throughout the year. Am J Obstet Gynecol 1999; 180:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/8\">",
"      Creanga AA, Shapiro-Mendoza CK, Bish CL, et al. Trends in ectopic pregnancy mortality in the United States: 1980-2007. Obstet Gynecol 2011; 117:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/9\">",
"      Ankum WM, Mol BW, Van der Veen F, Bossuyt PM. Risk factors for ectopic pregnancy: a meta-analysis. Fertil Steril 1996; 65:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/10\">",
"      Bouyer J, Coste J, Shojaei T, et al. Risk factors for ectopic pregnancy: a comprehensive analysis based on a large case-control, population-based study in France. Am J Epidemiol 2003; 157:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/11\">",
"      Peterson HB, Xia Z, Hughes JM, et al. The risk of ectopic pregnancy after tubal sterilization. U.S. Collaborative Review of Sterilization Working Group. N Engl J Med 1997; 336:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/12\">",
"      Goldberg JM, Falcone T. Effect of diethylstilbestrol on reproductive function. Fertil Steril 1999; 72:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/13\">",
"      Hillis SD, Owens LM, Marchbanks PA, et al. Recurrent chlamydial infections increase the risks of hospitalization for ectopic pregnancy and pelvic inflammatory disease. Am J Obstet Gynecol 1997; 176:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/14\">",
"      Shaw JL, Wills GS, Lee KF, et al. Chlamydia trachomatis infection increases fallopian tube PROKR2 via TLR2 and NF&kappa;B activation resulting in a microenvironment predisposed to ectopic pregnancy. Am J Pathol 2011; 178:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/15\">",
"      Sivin I. Dose- and age-dependent ectopic pregnancy risks with intrauterine contraception. Obstet Gynecol 1991; 78:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/16\">",
"      Backman T, Rauramo I, Huhtala S, Koskenvuo M. Pregnancy during the use of levonorgestrel intrauterine system. Am J Obstet Gynecol 2004; 190:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/17\">",
"      Mol BW, Ankum WM, Bossuyt PM, Van der Veen F. Contraception and the risk of ectopic pregnancy: a meta-analysis. Contraception 1995; 52:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/18\">",
"      Xiong X, Buekens P, Wollast E. IUD use and the risk of ectopic pregnancy: a meta-analysis of case-control studies. Contraception 1995; 52:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/19\">",
"      Furlong LA. Ectopic pregnancy risk when contraception fails. A review. J Reprod Med 2002; 47:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/20\">",
"      Cohen J, Mayaux MJ, Guihard-Moscato ML, Schwartz D. In-vitro fertilization and embryo transfer: a collaborative study of 1163 pregnancies on the incidence and risk factors of ectopic pregnancies. Hum Reprod 1986; 1:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/21\">",
"      Gemzell C, Guillome J, Wang CF. Ectopic pregnancy following treatment with human gonadotropins. Am J Obstet Gynecol 1982; 143:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/22\">",
"      McBain JC, Evans JH, Pepperell RJ, et al. An unexpectedly high rate of ectopic pregnancy following the induction of ovulation with human pituitary and chorionic gonadotrophin. Br J Obstet Gynaecol 1980; 87:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/23\">",
"      Saraiya M, Berg CJ, Kendrick JS, et al. Cigarette smoking as a risk factor for ectopic pregnancy. Am J Obstet Gynecol 1998; 178:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/24\">",
"      Strandell A, Thorburn J, Hamberger L. Risk factors for ectopic pregnancy in assisted reproduction. Fertil Steril 1999; 71:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/25\">",
"      Nazari A, Askari HA, Check JH, O'Shaughnessy A. Embryo transfer technique as a cause of ectopic pregnancy in in vitro fertilization. Fertil Steril 1993; 60:919.",
"     </a>",
"    </li>",
"    <li>",
"     www.cdc.gov/ART/ART02/download.htm (accessed November 1, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/27\">",
"      W&oslash;lner-Hanssen P, Eschenbach DA, Paavonen J, et al. Association between vaginal douching and acute pelvic inflammatory disease. JAMA 1990; 263:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/28\">",
"      Pisarska MD, Carson SA, Buster JE. Ectopic pregnancy. Lancet 1998; 351:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/29\">",
"      Nybo Andersen AM, Wohlfahrt J, Christens P, et al. Maternal age and fetal loss: population based register linkage study. BMJ 2000; 320:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/30\">",
"      Storeide O, Veholmen M, Eide M, et al. The incidence of ectopic pregnancy in Hordaland County, Norway 1976-1993. Acta Obstet Gynecol Scand 1997; 76:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/31\">",
"      Bouyer J, Coste J, Fernandez H, et al. Sites of ectopic pregnancy: a 10 year population-based study of 1800 cases. Hum Reprod 2002; 17:3224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/32\">",
"      Lopez HB, Micheelsen U, Berendtsen H, Kock K. Ectopic pregnancy and its associated endometrial changes. Gynecol Obstet Invest 1994; 38:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/33\">",
"      Senterman M, Jibodh R, Tulandi T. Histopathologic study of ampullary and isthmic tubal ectopic pregnancy. Am J Obstet Gynecol 1988; 159:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/34\">",
"      Kutluay L, Vicdan K, Turan C, et al. Tubal histopathology in ectopic pregnancies. Eur J Obstet Gynecol Reprod Biol 1994; 57:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/35\">",
"      Attar E. Endocrinology of ectopic pregnancy. Obstet Gynecol Clin North Am 2004; 31:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/36\">",
"      Timor-Tritsch IE, Yeh MN, Peisner DB, et al. The use of transvaginal ultrasonography in the diagnosis of ectopic pregnancy. Am J Obstet Gynecol 1989; 161:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/37\">",
"      Coste J, Fernandez H, Joy&eacute; N, et al. Role of chromosome abnormalities in ectopic pregnancy. Fertil Steril 2000; 74:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/38\">",
"      Goddijn M, van der Veen F, Schuring-Blom GH, et al. Cytogenetic characteristics of ectopic pregnancy. Hum Reprod 1996; 11:2769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/39\">",
"      Gaudoin MR, Coulter KL, Robins AM, et al. Is the incidence of ovarian ectopic pregnancy increasing? Eur J Obstet Gynecol Reprod Biol 1996; 70:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/40\">",
"      Raziel A, Golan A, Pansky M, et al. Ovarian pregnancy: a report of twenty cases in one institution. Am J Obstet Gynecol 1990; 163:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/41\">",
"      Spiegelberg, O. Zur casvistik des ovarials schwangerschaft. Arch Gynack 1878; 13:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/42\">",
"      Lau S, Tulandi T. Conservative medical and surgical management of interstitial ectopic pregnancy. Fertil Steril 1999; 72:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/43\">",
"      Jansen RP, Elliott PM. Angular intrauterine pregnancy. Obstet Gynecol 1981; 58:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/44\">",
"      Tulandi T, Al-Jaroudi D. Interstitial pregnancy: results generated from the Society of Reproductive Surgeons Registry. Obstet Gynecol 2004; 103:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/45\">",
"      Larra&iacute;n D, Marengo F, Bourdel N, et al. Proximal ectopic pregnancy: a descriptive general population-based study and results of different management options in 86 cases. Fertil Steril 2011; 95:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/46\">",
"      Ps B, Hk C. Angular ectopic pregnancy presenting as rupture of lateral wall of the uterus. J Hum Reprod Sci 2008; 1:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/47\">",
"      Rotas MA, Haberman S, Levgur M. Cesarean scar ectopic pregnancies: etiology, diagnosis, and management. Obstet Gynecol 2006; 107:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/48\">",
"      Ash A, Smith A, Maxwell D. Caesarean scar pregnancy. BJOG 2007; 114:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/49\">",
"      Hassiakos D, Bakas P, Pistofidis G, Creatsas G. Heterotopic pregnancy at 16 weeks of gestation after in-vitro fertilization and embryo transfer. Arch Gynecol Obstet 2002; 266:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/50\">",
"      Strafford JC, Ragan WD. Abdominal pregnancy. Review of current management. Obstet Gynecol 1977; 50:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21752/abstract/51\">",
"      Martin JN Jr, Sessums JK, Martin RW, et al. Abdominal pregnancy: current concepts of management. Obstet Gynecol 1988; 71:549.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5481 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-652B83C886-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_15_21752=[""].join("\n");
var outline_f21_15_21752=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      High risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Previous ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Tubal pathology and surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - In-utero DES exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Previous genital infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H330799\">",
"      - Intrauterine devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Infertility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Multiple sexual partners",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Smoking",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Vaginal douching",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Protective factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Tubal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Cervical pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Ovarian pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Interstitial or cornual pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1820977\">",
"      - Rudimentary uterine horn pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Angular pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Hysterotomy scar pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Heterotopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Abdominal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5481\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5481|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/35/10804\" title=\"figure 1\">",
"      Normal female anat detail",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5481|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/7/42102\" title=\"picture 1A\">",
"      Ectopic pregnancy 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/20/2374\" title=\"picture 1B\">",
"      Ectopic pregnancy 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5481|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/38/10860\" title=\"table 1\">",
"      Risk factors ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/32/16907\" title=\"table 2\">",
"      Ectopic risk by contraceptive",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16457?source=related_link\">",
"      Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/51/11062?source=related_link\">",
"      Cervical pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=related_link\">",
"      Clinical manifestations and diagnosis of congenital anomalies of the uterus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27417?source=related_link\">",
"      Methotrexate treatment of tubal and interstitial ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3322?source=related_link\">",
"      Outcome and follow-up of diethylstilbestrol (DES) exposed individuals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11992?source=related_link\">",
"      Pathogenesis of and risk factors for pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/43/38578?source=related_link\">",
"      Patient information: Ectopic (tubal) pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/20/35138?source=related_link\">",
"      Patient information: Ectopic pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5976?source=related_link\">",
"      Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34184?source=related_link\">",
"      Ultrasonography of pregnancy of unknown location",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_15_21753="Treatment of relapsed or refractory acute lymphoblastic leukemia in adults";
var content_f21_15_21753=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of relapsed or refractory acute lymphoblastic leukemia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/15/21753/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/15/21753/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/15/21753/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/15/21753/contributors\">",
"     Bob Lowenberg, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/15/21753/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/15/21753/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/15/21753/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 80 percent of adult patients with newly diagnosed acute lymphoblastic leukemia (ALL) will attain a complete remission (CR) with intensive induction chemotherapy. After further consolidation therapy and maintenance chemotherapy, less than half will have long-term leukemia-free survival; the majority of adults with ALL will ultimately relapse. In addition, up to 20 percent will have primary resistant disease.",
"   </p>",
"   <p>",
"    This topic review will review the treatment of relapsed or refractory ALL in adults. The following related subjects are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Induction therapy for ALL in adults. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=see_link\">",
"       \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Post-remission therapy for ALL. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/15/39161?source=see_link\">",
"       \"Post-remission therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of ALL in children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=see_link\">",
"       \"Overview of the treatment of acute lymphoblastic leukemia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Detection of minimal residual disease following treatment of ALL. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15880?source=see_link\">",
"       \"Detection of minimal residual disease in acute lymphoblastic leukemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31625?source=see_link\">",
"       \"Clinical use of minimal residual disease detection in acute lymphoblastic leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The clinical and pathologic features and diagnosis of ALL in adults. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26007?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION FOR RELAPSE OR RESISTANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Monitoring for relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;After initial therapy, patients are followed at routine intervals to monitor for treatment-related complications and relapsed disease. At these visits, patients are evaluated with a history, physical examination, and blood work. Bone marrow aspiration and biopsy is performed every three to six months for at least the next two years.",
"   </p>",
"   <p>",
"    The expectation is that a patient with ALL in continuous CR for seven to eight years is \"cured\" and no longer requires routine bone marrow examination. However, relapses of adult ALL as long as 21 years after diagnosis have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of unselected adult patients with ALL who survived more than three years, the relapse rate was 74 percent, with the latest relapse occurring eight years after diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In patients with ALL who received hematopoietic cell transplantation and were in CR at two years, the overall chance of being alive in CR at nine years was 82 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/3\">",
"       3",
"      </a>",
"      ]. The latest relapses in this group occurred at four to seven years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information on the subject of minimal residual disease in ALL is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15880?source=see_link\">",
"     \"Detection of minimal residual disease in acute lymphoblastic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31625?source=see_link\">",
"     \"Clinical use of minimal residual disease detection in acute lymphoblastic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Evaluation of suspected relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Essentially all patients with relapse after complete remission (CR) have ALL present in their bone marrow, although it may be patchy and remain occult. Up to one-third can have concurrent involvement of extramedullary sites such as the central nervous system, testes, skin, or pleura [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients suspected of having relapsed disease should be evaluated with a bone marrow aspiration and biopsy. This sample should be sent for pathologic review, immunophenotyping, cytochemistry, and cytogenetics. Marrow aspirate or peripheral blood blasts should also be sent for reverse transcriptase polymerase chain reaction (RT-PCR) analysis for BCR-ABL in order to rapidly identify Philadelphia chromosome positive ALL because more specific therapy is available for these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26007?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Areas suspected of harboring extramedullary disease, such as the central nervous system and testes, must also be evaluated even in asymptomatic patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Definitions of relapse and refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refractory (resistant) disease is defined as those patients who fail to obtain a CR with induction therapy, ie, failure to eradicate all detectable leukemia cells (less than 5 percent blasts) from the bone marrow and blood with subsequent restoration of normal hematopoiesis (greater than 25 percent marrow cellularity and normal peripheral blood counts).",
"   </p>",
"   <p>",
"    Relapsed disease describes the reappearance of leukemia cells in the bone marrow or peripheral blood after the attainment of a complete remission. As yet, the significance of the reappearance of ALL detected only by polymerase chain reaction (PCR) analysis is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pretreatment evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once relapsed disease is identified, further pretreatment evaluation should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human leukocyte antigen (HLA) typing should be performed for patients who are candidates for hematopoietic cell transplantation (HCT). This is extremely important since HCT is the most likely method for curing patients with relapsed ALL.",
"     </li>",
"     <li>",
"      Other laboratory studies include a complete blood count with differential, chemistries with liver and renal function and electrolytes, glucose, lactate dehydrogenase (LDH), calcium, phosphorus, uric acid, albumin and total protein, and serology for hepatitis B, herpes simplex virus (HSV) and cytomegalovirus (CMV) infection. Women of childbearing age should undergo a pregnancy test.",
"     </li>",
"     <li>",
"      A chest x-ray, an electrocardiogram (EKG) and a study of cardiac function (eg, ejection fraction measured by echocardiogram or MUGA) should be performed at baseline, especially for patients with a cardiac history, prior anthracycline exposure, or cardiovascular symptoms.",
"     </li>",
"     <li>",
"      Dental evaluation for possible infectious foci is warranted.",
"     </li>",
"     <li>",
"      Patients with neurologic signs or symptoms should undergo imaging studies to evaluate for meningeal disease, or central nervous system bleeding. Lumbar puncture is indicated in all patients to examine the cerebrospinal fluid (CSF) for leukemic involvement. Care must be taken to avoid contaminating the CSF specimen with peripheral blood if blasts are present. CSF should be sent for both cytology (examination of stained cytospin slides) and flow cytometry for detection of ALL blasts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     REMISSION INDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the majority of adults with ALL will ultimately relapse after initial complete remission (CR) and up to 25 percent will have primary resistant disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/5\">",
"     5",
"    </a>",
"    ]. Retreatment of such patients is generally unsuccessful, and most will die of their disease. However, allogeneic hematopoietic cell transplantation (HCT) after initial cytoreduction or in second CR offers a chance of cure in a small, highly selected group of patients. As such, induction of a second CR is the first step in the treatment of relapsed disease, while additional attempts to induce a first remission are a key factor in the treatment of primary refractory disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Salvage regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with primary refractory disease or those in first recurrence may have complete response rates to salvage chemotherapy as high as 30 to 50 percent, depending upon the intensity of their primary treatment regimen. The ideal salvage regimen is not known and these patients should be considered for enrollment in prospective trials. In general, a choice among therapies depends upon the timing of relapse:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the relapse occurs more than two years following initial treatment, a second remission may be attained using an induction regimen similar to that used in newly diagnosed ALL [",
"      <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=see_link\">",
"       \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with primary resistant disease or relapse while receiving induction, consolidation, or maintenance therapy, require reinduction with novel therapies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After attaining a second CR with a salvage regimen, patients should proceed as soon as possible to allogeneic HCT since second complete remissions are generally short lasting and HCT provides the best chance of cure in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/7\">",
"     7",
"    </a>",
"    ]. HCT can be performed using a related or unrelated donor, and using myeloablative or nonmyeloablative preparative regimens. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cytarabine-based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;First line salvage chemotherapy is often based on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (ara-C) in combination with other agents [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. As an example, 29 adults with recurrent or refractory ALL were treated with cytarabine (3.0",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    by three-hour IV infusion daily for five days) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV on day 3) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/11\">",
"     11",
"    </a>",
"    ]. Complete remission was attained in 11 (38 percent), with moderate but acceptable toxicity. There was one treatment-related death. Median duration of CR and overall survival of those attaining CR were short (three and eight months, respectively). In contrast, the combination of high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    with an identical dose and schedule of high-dose cytarabine was found to be insufficiently active (23 percent CR among 31 evaluable patients) by the Southwest Oncology Group to merit further study [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/8\">",
"     8",
"    </a>",
"    ]. The differences between these two small series are likely related to the extent of prior exposure to cytarabine and anthracyclines",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biological characteristics of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3068782\">",
"    <span class=\"h3\">",
"     Alkylating agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is anecdotal evidence for the use of an alkylating agent such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    for the treatment of relapsed ALL in adults. This regimen is based on experience in pediatric patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Nelarabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/45/21206?source=see_link\">",
"     Nelarabine",
"    </a>",
"    (Arranon), a prodrug converted in vivo to ara-GTP especially in T-cells, has shown efficacy as a single agent for the treatment of relapsed or resistant T-cell ALL in children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Complete remission rates of 20 to 35 percent have permitted some patients to go on to hematopoietic cell transplantation. Neurotoxicity, which can be severe, is dose-limiting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=see_link&amp;anchor=H49#H49\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\", section on 'Purine analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/45/21206?source=see_link\">",
"     Nelarabine",
"    </a>",
"    has been approved by the United States Food and Drug Administration for the treatment of patients with T-cell ALL (T-cell lymphoblastic lymphoma) that has not responded to, or has relapsed following treatment with at least two chemotherapy regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/17\">",
"     17",
"    </a>",
"    ]. Different doses and schedules are recommended for children and for adults. It has considerably less activity in B-lineage ALL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Clofarabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/5/33879?source=see_link\">",
"     Clofarabine",
"    </a>",
"    is a deoxyadenosine (nucleoside purine) analog approved by the United States FDA for the treatment of pediatric patients (ages 1 to 21 years) with relapsed or refractory ALL who have experienced treatment failure with two prior regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/18\">",
"     18",
"    </a>",
"    ]. The response rate in this setting is approximately 30 percent.",
"   </p>",
"   <p>",
"    There are limited data regarding the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/5/33879?source=see_link\">",
"     clofarabine",
"    </a>",
"    in adults with relapsed ALL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      trials of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/5/33879?source=see_link\">",
"       clofarabine",
"      </a>",
"      in ALL included 25 adult patients with ALL treated at a dose of 40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for five days [",
"      <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. Overall response rates in this population were approximately 17 percent.",
"     </li>",
"     <li>",
"      A similar combined rate of CR plus CR with insufficient hematological recovery of 17 percent was observed among 37 patients treated with the same dose and schedule of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/5/33879?source=see_link\">",
"       clofarabine",
"      </a>",
"      combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       gm/sq",
"      </span>",
"      m given daily for 5 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/21\">",
"       21",
"      </a>",
"      ]. Almost half of the patients were at least in second relapse or refractory. Whether cytarabine may contribute to the efficacy of clofarabine in a more uniform population of relapsed",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      refractory patients is not clear.",
"     </li>",
"     <li>",
"      A single center report of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/5/33879?source=see_link\">",
"       clofarabine",
"      </a>",
"      (52",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for five days) in three adults (age 19 to 49) with relapsed disease refractory to salvage therapy reported responses in all three patients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/22\">",
"       22",
"      </a>",
"      ]. One remains in CR one year after a second HCT. Another achieved a second CR, proceeded to HCT, but relapsed three months after HCT. The third had a partial response that was lost after a temporary discontinuation of clofarabine due to elevated transaminases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2914156\">",
"    <span class=\"h3\">",
"     Liposomal vincristine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     Vincristine",
"    </a>",
"    sulfate is available in both a conventional formulation and encapsulated within liposomes (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/2/8231?source=see_link\">",
"     liposomal vincristine",
"    </a>",
"    ). When compared with conventional vincristine, liposomal vincristine has a longer half-life [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/23\">",
"     23",
"    </a>",
"    ]. Liposomal vincristine received accelerated approval from the United States FDA for the treatment of adults with Philadelphia chromosome negative (Ph-) ALL in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/24\">",
"     24",
"    </a>",
"    ]. The rate of complete remission (CR) or complete remission with incomplete blood count recovery (CRi) in patients with second or greater relapse is approximately 20 percent. Rates are expected to be lower in patients with refractory ALL.",
"   </p>",
"   <p>",
"    A phase II, single arm trial evaluated single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/2/8231?source=see_link\">",
"     liposomal vincristine",
"    </a>",
"    in 65 adults with Ph- ALL in second or greater relapse who had received prior conventional formulation",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    and were not eligible for immediate transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/25\">",
"     25",
"    </a>",
"    ]. Intravenous liposomal vincristine (2.25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    infused over 60 minutes) was administered every seven days. Dose was based on actual body surface area and was not capped. A CR was attained in seven patients (11 percent) and a CRi was attained in six (9 percent). The median remission duration was 23 weeks (range 5 to 66 weeks) and the median overall survival was 4.6 months. Estimated survival rates at 6 and 12 months were 35 and 8 percent, respectively. The most common toxicities were constipation, nausea, pyrexia, fatigue, peripheral neuropathy, and cytopenias. Severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    toxicities included infections, neuropathy, neutropenia, anemia, and thrombocytopenia.",
"   </p>",
"   <p>",
"    A randomized trial comparing conventional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/2/8231?source=see_link\">",
"     liposomal vincristine",
"    </a>",
"    , both given in combination with standard multiagent chemotherapy, for newly diagnosed patients over age 60 with ALL is ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Special scenarios",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Philadelphia chromosome positive ALL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Philadelphia chromosome positive ALL is a distinct population of patients with ALL whose therapy includes the use of tyrosine kinase inhibitors. Standard induction therapy for this population includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    plus chemotherapy. This is typically followed by hematopoietic cell transplantation. Patients with imatinib resistance or intolerance to imatinib are candidates for the second-line tyrosine kinase inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h4\">",
"     Dasatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    (70 mg PO twice daily) was tested in an open-label phase II trial in 36 patients with Ph+ or",
"    <span class=\"nowrap\">",
"     BCR/ABL+",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    -resistant or -intolerant patients with ALL who were previously treated with standard induction or consolidation chemotherapy, as well as in imatinib-resistant or -intolerant patients with CML in lymphoid blast crisis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/26\">",
"     26",
"    </a>",
"    ]. Results of this trial at a minimum follow-up of eight months included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Major hematologic responses (ie, complete hematologic response or no evidence for leukemia) were noted in 42 percent at a median elapsed time of 1.8 months. The overall median duration of progression-free survival was 3.3 months, although 10 of the 15 patients who had achieved these responses had not progressed at the 8-month follow-up.",
"     </li>",
"     <li>",
"      The presence of",
"      <span class=\"nowrap\">",
"       BCR/ABL",
"      </span>",
"      mutations conferring",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      resistance did not preclude a response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      . Complete cytogenetic responses were attained in 58 percent.",
"     </li>",
"     <li>",
"      Only 2 of the 36 patients (6 percent) discontinued treatment as a result of toxicity. Febrile neutropenia and other cytopenias were manageable with dose reduction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The United States Food and Drug Administration (FDA) has approved",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    for use in the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    . Of importance, dasatinib does not have activity in the rare T315I Bcr-Abl mutation. The clinical value of such ABL kinase domain mutation studies has not been determined in this population. If a T315I mutation were detected, then tyrosine kinase inhibitor therapy is not likely to be effective, and investigational agents on a clinical trial should be considered. A randomized trial of dasatinib 140 mg once daily versus 70 mg twice a day in 84 patients with Ph+ or",
"    <span class=\"nowrap\">",
"     BCR/ABL+",
"    </span>",
"    ALL with resistance or intolerance to imatinib reported that the two dosing schedules had similar efficacy and safety [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Central nervous system involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twenty to 30 percent of patients with relapsed ALL will also have involvement of the central nervous system (CNS). CNS leukemia is defined by the presence of leukemic blasts in a centrifuged preparation of cerebrospinal fluid (CSF) that does not have evidence of blood contamination. Cranial irradiation plus intrathecal chemotherapy is the mainstay of treatment of CNS involvement. Typically, 2400 cGy of radiation is given to the entire cranium over 12 doses. In addition, at least six doses of intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    should be administered. There are very preliminary data available on the use of intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in sequence with conventional therapy for the treatment of refractory CNS ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26458?source=see_link\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=see_link&amp;anchor=H20#H20\">",
"     \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\", section on 'Central nervous system involvement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-half of adults who suffer a relapse of ALL will attain a second CR, although most will eventually die from leukemia. This dismal prognosis justifies the use of high-dose alternative treatments after relapse. In primary refractory or advanced relapsed ALL, allogeneic HCT is associated with three-year leukemia-free survival rates of 12 to 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]. This is clearly superior to chemotherapy alone, which achieves no cures at this stage of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Disease-related factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the International Bone Marrow Transplant Registry (IBMTR) indicate that the status of the disease is one of the most significant predictors for leukemia-free survival (LFS) following HLA-identical sibling transplants for ALL. The three-year actuarial probabilities of leukemia-free survival (LFS) for children and adults undergoing transplantation in first complete remission, second complete remission or higher, and for advanced (relapsed or refractory) ALL are 54 percent, 40 percent, and 20 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/34\">",
"     34",
"    </a>",
"    ]. Treatment-related mortality ranges from 25 to 35 percent and appears comparable for patients transplanted at all stages of the disease. Thus, the increased risk of failure with each subsequent remission is due to the parallel increase in the rate of relapse.",
"   </p>",
"   <p>",
"    The impression that allogeneic HCT is less effective during overt relapse than subsequent remission may not be valid, since this issue has never been analyzed on an intention-to-treat basis in clinical trials designed to address this question specifically. The potential benefit of tumor cytoreduction prior to HCT may be balanced or exceeded by increased morbidity from the reinduction chemotherapy. In one study of 37 consecutive adults with primary refractory ALL or in first relapse, only 65 percent of patients who reached CR, and only 51 percent of the total group, underwent the intended HCT because of complications from reinduction chemotherapy and early relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, only about one-half of patients will achieve a second CR whereas all will experience the toxicity of treatment.",
"   </p>",
"   <p>",
"    The greatest experience with myeloablative HCT for relapsed or refractory disease is provided by a retrospective analysis of 2255 patients with relapsed or refractory leukemia reported to the Center for International Blood and Marrow Transplant Research between 1995 and 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/32\">",
"     32",
"    </a>",
"    ]. This analysis included 583 patients with primary refractory ALL (25 percent), first untreated relapse (12 percent), first refractory relapse (43 percent), first relapse with unknown treatment status (2 percent), or second or additional relapse (19 percent). Overall, the survival rate at three years was 16 percent. Acute graft-versus-host disease (GVHD) was seen in 52 percent of patients with 27 percent experiencing severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    acute GVHD. Chronic GVHD was seen in approximately one-quarter of patients.",
"   </p>",
"   <p>",
"    A pretransplant scoring system was devised to predict the survival of patients not in CR who undergo myeloablative HCT based upon the assessment of four criteria (maximum score 6 points) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Timing of transplant: First refractory relapse = 1 point, Second or additional relapse = 2 points",
"     </li>",
"     <li>",
"      Donor CMV status: Positive = 1 point",
"     </li>",
"     <li>",
"      Percent bone marrow blasts: &gt;25 percent = 1 point",
"     </li>",
"     <li>",
"      Age: 10-39 years = 1 point; &ge;40 years = 2 points",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Total score predicted long-term survival when applied to 582 patients with relapsed or refractory ALL not in CR at the time of myeloablative HCT. Rates of three-year overall survival were 46, 22, and 10 percent for patients with 0 or 1, 2, and 3 points, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Allo-HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allo-HCT, when carried out in adults in second complete remission, results in long-term leukemia-free-survival (LFS) rates of 18 to 45 percent (",
"    <a class=\"graphic graphic_table graphicRef57938 \" href=\"UTD.htm?37/6/37995\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/29,30,33,36-41\">",
"     29,30,33,36-41",
"    </a>",
"    ]. The primary cause of failure is relapse. The IBMTR found that adults with high-risk or standard risk ALL transplanted in second complete remission had similar relapse rates (56 versus 49 percent, respectively), but the LFS rates at four years was significantly lower for high-risk patients (22 versus 36 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/39\">",
"     39",
"    </a>",
"    ]. This observation suggests that nonrelapse causes for death account for the poorer prognosis in the high-risk patients.",
"   </p>",
"   <p>",
"    The profile of prognostic factors for patients undergoing HCT in second CR is even more elusive than for patients in first CR. Almost all analyses addressing this issue have been performed on populations consisting of both adults and children, and the conclusions may not be directly applicable to the adults separately. Nevertheless, based upon indirect comparisons, HLA-identical allo-HCT appears superior to rescue with chemotherapy alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Auto-HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results of auto-HCT have been disappointing for adults with more advanced ALL. In one study, for example, there were no survivors among adults (greater than 18 years of age) transplanted in CR2 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/42\">",
"     42",
"    </a>",
"    ]. In two other series, relapse rates were unacceptably high in older patients and none of the patients over 28 years of age who were autografted in advanced disease survived [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As such, there appears to be little benefit from auto-HCT in adults with ALL in general. This is most likely due to the inability to collect leukemia-free stem cells from patients despite morphological CR. There is no advantage of auto-HCT over chemotherapy for consolidation of either high-risk or standard risk patients in first CR. For patients beyond first CR, the relapse rate is unacceptably high following auto-HCT, with or without purging, and the overall results are very poor.",
"   </p>",
"   <p>",
"    However, special situations may exist for those with Ph+ ALL and those with no detectable residual disease by highly-sensitive, multicolor, flow cytometry. The role of auto-HCT in patients with Ph+ ALL who are rendered molecularly negative prior to stem cell collection and then maintained on a Bcr-Abl inhibitor after transplantation remains under investigation. Long term disease-free survival has been observed in some of these patients. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of adults with relapsed or refractory ALL is generally poor. Median survival is less than one year, and less than one-quarter of patients survive three years. Long-term overall survival (OS) is dependent upon attaining a complete remission (CR) with subsequent allogeneic hematopoietic cell transplantation (HCT). Approximately 31 to 44 percent of patients will attain a CR with second line therapy, while 18 to 23 percent will attain a CR following third line therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/4,5,14,15,18,45-47\">",
"     4,5,14,15,18,45-47",
"    </a>",
"    ]. Less than half of patients will be candidates for HCT.",
"   </p>",
"   <p>",
"    Retrospective studies and observational series have identified certain patient and disease-related characteristics that appear to impact outcome. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of 609 adults with ALL who were treated on the",
"      <span class=\"nowrap\">",
"       MRC/ECOG",
"      </span>",
"      <span class=\"nowrap\">",
"       UKALL12/ECOG2993",
"      </span>",
"      study, the rates of five-year OS were 38 and 7 percent in those with newly diagnosed or relapsed ALL, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/5\">",
"       5",
"      </a>",
"      ]. Factors predicting a good outcome after second line therapy included:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Young age &mdash; Five-year OS rates were 12 versus 3 percent for those younger than 20 or older than 50 years, respectively.",
"     </li>",
"     <li>",
"      Long duration of first CR &mdash; Five-year OS rates were 11 versus 5 percent for those whose duration of first remission was more than or less than two years, respectively.",
"     </li>",
"     <li>",
"      In a highly selected group of patients with recurrent ALL who were able to receive HCT while in relapse, the estimated survival rate was 23 percent at five years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another retrospective analysis of 547 consecutive patients in first relapse following initial therapy within GMALL studies reported a median OS after relapse of 8.6 months with 24 percent survival at three years [",
"      <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/41\">",
"       41",
"      </a>",
"      ]. Factors associated with outcome following second line therapy included:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Age &mdash; Patients 25 years or younger were more likely to attain a CR (53 versus 37 percent). Survival at three years decreased with increasing age with estimated rates of 38, 28, and 12 percent in patients &le;25 years, 26 to 45 years, and &gt;45 years, respectively.",
"     </li>",
"     <li>",
"      Site of relapse &mdash; Estimated OS at three years was 23 percent following relapse in the bone marrow with or without involvement of additional sites (428 patients); 27 percent with isolated central nervous system involvement (18 patients); and 47 percent with other isolated extramedullary relapse (32 patients).",
"     </li>",
"     <li>",
"      Prior therapy &mdash; 378 patients relapsed during or after first-line chemotherapy with a median survival of 10 months and an estimated survival rate at three years of 28 percent. In comparison, 169 patients relapsed following HCT performed during first CR with a median survival of 5.8 months and an estimated survival rate at three years of 15 percent.",
"     </li>",
"     <li>",
"      Time to relapse &mdash; When compared with patients with a longer duration of first CR, patients whose disease relapsed &lt;18 months from initial therapy were less likely to attain a CR (36 versus 58 percent). &nbsp;",
"     </li>",
"     <li>",
"      Status of disease at HCT &mdash; 149 patients underwent HCT with an estimated three-year survival of 38 percent. In comparison, none of the patients who did not undergo HCT survived longer than one year. Survival rates were higher for those who underwent HCT in CR after first salvage (56 percent) than for those in CR after later salvage (39 percent) or for those not in CR at the time of HCT (20 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single institution retrospective analysis of 288 patients administered a second rescue therapy reported achievement of a complete response in 18 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/45\">",
"       45",
"      </a>",
"      ]. Median durations of remission and overall survival were seven and three months, respectively. Inferior survival rates were noted in patients with the following characteristics:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      First complete response less than 36 months",
"     </li>",
"     <li>",
"      Bone marrow blasts &gt;50 percent",
"     </li>",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &lt;50,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      Serum albumin level &lt;3",
"      <span class=\"nowrap\">",
"       g/L",
"      </span>",
"      (30",
"      <span class=\"nowrap\">",
"       g/liter)",
"       <br/>",
"       <br/>",
"       For",
"      </span>",
"      patients with zero or 1, 2, 3, or 4 of these factors, survival rates at one year were 33, 14, 8, and zero percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23720941\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Many agents are under active investigation. These include combinations of agents already used in ALL; agents used for other diseases; new antibodies (eg, anti-CD22 antibodies,",
"    <span class=\"nowrap\">",
"     CD19/CD3-bispecific",
"    </span>",
"    BiTE antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/48\">",
"     48",
"    </a>",
"    ]); and other novel agents. An individual&rsquo;s chance of responding to a particular regimen is influenced not only by prior exposure to chemotherapy, but also by other patient- and leukemia-associated factors. A preferred regimen would exclude agents at dose levels for salvage which the patient has been exposed to recently.",
"   </p>",
"   <p>",
"    Ongoing studies are investigating the use of chimeric antigen receptor T cells (CAR-T cells) directed at CD19 (NCT01044069) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. As an example, an intriguing report described five patients with relapsed B cell ALL who received autologous T cells modified with a lentiviral vector expressing chimeric antigen receptor with specificity for CD19, coupled with CD137 and CD3-zeta signalling domains after a preparatory regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?21/15/21753/abstract/49\">",
"     49",
"    </a>",
"    ]. All five patients demonstrated a molecular remission, which allowed them to become eligible for subsequent hematopoietic cell transplantation. Toxicity included significant cytokine elevations, some of which required treatment with steroid therapy. Further follow-up of these patients and larger trials are needed to determine the efficacy of this approach. A similar approach has been used for patients with other hematologic malignancies, including chronic lymphocytic leukemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\", section on 'Investigational therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/34/17955?source=see_link\">",
"       \"Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of adults with ALL will ultimately relapse. Optimally, the patient with resistant or relapsed disease should be entered onto a clinical trial.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients whose relapse occurs more than two years following initial treatment, we suggest reinduction therapy using an induction regimen similar to the one initially employed rather than using a novel agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Remission induction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with primary resistant disease and for those who relapse during induction, consolidation, or maintenance therapy, we suggest the use of a salvage therapy that incorporates an alkylating agent (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ), or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      and an anthracycline, or high-dose cytarabine, as employed in acute myeloid leukemia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link\">",
"       \"Induction therapy for acute myeloid leukemia in younger adults\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H7\">",
"       'Remission induction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend allogeneic hematopoietic cell transplantation in second complete or partial remission rather than the use of chemotherapy alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This is principally because complete responses obtained in patients with relapsed or resistant disease are often of short duration and allogeneic hematopoietic cell transplantation offers the possibility of cure. Matched unrelated donor HCT is an appropriate option for patients without a suitable related donor. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/1\">",
"      Navarro JL, de Blas Orlando J, R&iacute;os Herranz E, et al. Philadelphia positive acute lymphoblastic leukemia 16 years after the apparent cure of acute lymphoblastic leukemia. New leukemia or late relapse? Haematologica 1998; 83:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/2\">",
"      Brincker H, Christensen BE. Long-term survival and late relapses in acute leukaemia in adults. Br J Haematol 1990; 74:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/3\">",
"      Frassoni F, Labopin M, Gluckman E, et al. Are patients with acute leukaemia, alive and well 2 years post bone marrow transplantation cured? A European survey. Acute Leukaemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia 1994; 8:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/4\">",
"      Thomas DA, Kantarjian H, Smith TL, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer 1999; 86:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/5\">",
"      Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007; 109:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/6\">",
"      Woodruff RK, Lister TA, Paxton AM, et al. Combination chemotherapy for haematological relapse in adult acute lymphoblastic leukaemia (ALL). Am J Hematol 1978; 4:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/7\">",
"      Kantarjian HM, Thomas D, Ravandi F, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 2010; 116:5568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/8\">",
"      Rosen PJ, Rankin C, Head DR, et al. A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia. Leuk Res 2000; 24:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/9\">",
"      Giona F, Annino L, Rondelli R, et al. Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R-87 protocol. Br J Haematol 1997; 97:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/10\">",
"      Koller CA, Kantarjian HM, Thomas D, et al. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia 1997; 11:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/11\">",
"      Weiss MA, Aliff TB, Tallman MS, et al. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer 2002; 95:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/12\">",
"      Karbasian-Esfahani M, Wiernik PH, Novik Y, et al. Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia. Cancer 2004; 101:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/13\">",
"      Kurtzberg J, Ernst TJ, Keating MJ, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 2005; 23:3396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/14\">",
"      Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol 2005; 23:3376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/15\">",
"      DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 2007; 109:5136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/16\">",
"      G&ouml;kbuget N, Basara N, Baurmann H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood 2011; 118:3504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/17\">",
"      Cohen MH, Johnson JR, Massie T, et al. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin Cancer Res 2006; 12:5329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/18\">",
"      Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006; 24:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/19\">",
"      Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003; 102:2379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/20\">",
"      Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003; 21:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/21\">",
"      Advani AS, Gundacker HM, Sala-Torra O, et al. Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol 2010; 151:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/22\">",
"      McGregor BA, Brown AW, Osswald MB, Savona MR. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia. Am J Hematol 2009; 84:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/23\">",
"      Yan Z, Zhu ZL, Qian ZZ, et al. Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors. Acta Pharmacol Sin 2012; 33:852.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202497s000lbl.pdf (Accessed on August 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/25\">",
"      O'Brien S, Schiller G, Lister J, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol 2013; 31:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/26\">",
"      Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007; 110:2309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/27\">",
"      Lilly MB, Ottmann OG, Shah NP, et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol 2010; 85:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/28\">",
"      Jaime-P&eacute;rez JC, Rodr&iacute;guez-Romo LN, Gonz&aacute;lez-Llano O, et al. Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy. Br J Haematol 2009; 144:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/29\">",
"      Doney K, Fisher LD, Appelbaum FR, et al. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Bone Marrow Transplant 1991; 7:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/30\">",
"      Forman SJ, Schmidt GM, Nademanee AP, et al. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. J Clin Oncol 1991; 9:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/31\">",
"      Biggs JC, Horowitz MM, Gale RP, et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992; 80:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/32\">",
"      Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010; 28:3730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/33\">",
"      Oliansky DM, Larson RA, Weisdorf D, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review. Biol Blood Marrow Transplant 2012; 18:18.",
"     </a>",
"    </li>",
"    <li>",
"     Rowlings PA. 1996 IBMTR/ABMTR summary slides. ABMTR Newsletter, November 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/35\">",
"      Martino R, Bellido M, Brunet S, et al. Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia. Bone Marrow Transplant 1998; 21:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/36\">",
"      Barrett AJ, Horowitz MM, Gale RP, et al. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood 1989; 74:862.",
"     </a>",
"    </li>",
"    <li>",
"     Gratwohl A, Hermans J, Zwaan F, for the EBMT. Bone marrow transplantation for ALL in Europe. In: Acute Lymphoblastic Leukemia, Gale RP, Hoelzer D (Eds), Alan R Liss, New York 1990. p.271.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/38\">",
"      Wingard JR, Piantadosi S, Santos GW, et al. Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia. J Clin Oncol 1990; 8:820.",
"     </a>",
"    </li>",
"    <li>",
"     Blume KG, Schmidt GM, Chao NJ, et al. Bone marrow transplantation for acute lymphoblastic leukemia. In: Acute Lymphoblastic Leukemia, Gale RP, Hoelzer D (Eds), Alan R. Liss, New York 1990. p.279.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/40\">",
"      Terwey TH, Massenkeil G, Tamm I, et al. Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy. Bone Marrow Transplant 2008; 42:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/41\">",
"      G&ouml;kbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 2012; 120:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/42\">",
"      Weisdorf DJ, Billett AL, Hannan P, et al. Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood 1997; 90:2962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/43\">",
"      Soiffer RJ, Roy DC, Gonin R, et al. Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse. Bone Marrow Transplant 1993; 12:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/44\">",
"      Abdallah A, Egerer G, Goldschmidt H, et al. Continuous complete remission in adult patients with acute lymphocytic leukaemia at a median observation of 12 years after autologous bone marrow transplantation. Br J Haematol 2001; 112:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/45\">",
"      O'Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 2008; 113:3186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/46\">",
"      Tavernier E, Boiron JM, Huguet F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007; 21:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/47\">",
"      Oriol A, Vives S, Hern&aacute;ndez-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 2010; 95:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/48\">",
"      Topp MS, G&ouml;kbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012; 120:5185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/49\">",
"      Brentjens RJ, Davila ML, Riviere I, et al. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. Sci Transl Med 2013; 5:177ra38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/15/21753/abstract/50\">",
"      Grupp SA, Kalos M, Barrett D, et al. Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia. N Engl J Med 2013.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4518 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.65.66-4367187BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_15_21753=[""].join("\n");
var outline_f21_15_21753=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION FOR RELAPSE OR RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Monitoring for relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Evaluation of suspected relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Definitions of relapse and refractory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pretreatment evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      REMISSION INDUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Salvage regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cytarabine-based regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3068782\">",
"      - Alkylating agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Nelarabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Clofarabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2914156\">",
"      - Liposomal vincristine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Special scenarios",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Philadelphia chromosome positive ALL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Dasatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Central nervous system involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Disease-related factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Allo-HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Auto-HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23720941\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4518\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4518|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/6/37995\" title=\"table 1\">",
"      Allo SCT in CR2 ALL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26007?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31625?source=related_link\">",
"      Clinical use of minimal residual disease detection in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15880?source=related_link\">",
"      Detection of minimal residual disease in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=related_link\">",
"      Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=related_link\">",
"      Overview of the treatment of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/34/17955?source=related_link\">",
"      Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/15/39161?source=related_link\">",
"      Post-remission therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26458?source=related_link\">",
"      Treatment of leptomeningeal metastases (carcinomatous meningitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=related_link\">",
"      Treatment of relapsed or refractory chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_15_21754="Porokeratosis of Mibelli";
var content_f21_15_21754=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81011%7EDERM%2F62674%7EDERM%2F78667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81011%7EDERM%2F62674%7EDERM%2F78667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Porokeratosis of Mibelli",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A large plaque with a slightly atrophic center and a prominent peripheral keratotic ridge is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Porokeratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple porokeratosis of Mibelli lesions are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Porokeratosis of Mibelli",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A well-defined erythematous patch with a fine keratotic rim (cornoid lamella) is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_15_21754=[""].join("\n");
var outline_f21_15_21754=null;
var title_f21_15_21755="Dx criteria social phobia";
var content_f21_15_21755=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for social phobia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        A persistent fear of one or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. The individual fears that he or she will act in a way (or show anxiety symptoms) that will be humiliating or embarrassing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exposure to the feared social situation almost invariably provokes an immediate anxiety response, which may take the form of a Panic Attack. The person recognizes that the fear is unreasonable or excessive and the phobic situation is avoided or endured with intense anxiety.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The avoidance, anxious anticipation, or distress in the feared social or performance situation interferes significantly with the person's normal routine, occupational (academic) functioning, or social activities or relationships with others, or there is marked distress about having the phobia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Specifier:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Generalized (used if the fears include most social situations such as initiating or maintaining conversations, participating in small groups, dating, speaking to authority figures, attending parties.)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Diagnostic and Statistical Manual of Mental Disorders, 4th Ed, Primary Care Version (DSM-IV-PC). American Psychiatric Association, Washington, DC 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_15_21755=[""].join("\n");
var outline_f21_15_21755=null;
var title_f21_15_21756="Triatoma Spp in US";
var content_f21_15_21756=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F61997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F61997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    <em>",
"     Triatoma",
"    </em>",
"    species found in the United States",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       <em>",
"        Triatoma",
"       </em>",
"       species",
"      </td>",
"      <td class=\"subtitle1\">",
"       Probable range",
"      </td>",
"      <td class=\"subtitle1\">",
"       Allergic reactions reported?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <em>",
"        Triatoma rubida",
"       </em>",
"       *",
"      </td>",
"      <td>",
"       Arizona, California, New Mexico, Texas",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <em>",
"        Triatoma protracta",
"       </em>",
"       *",
"      </td>",
"      <td>",
"       Arizona, California, Colorado, Nevada, New Mexico, Texas, Utah",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <em>",
"        Triatoma recurva",
"       </em>",
"       *",
"      </td>",
"      <td>",
"       Arizona",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <em>",
"        Triatoma gerstaeckeri",
"       </em>",
"       *",
"      </td>",
"      <td>",
"       New Mexico, Texas",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <em>",
"        Triatoma lecticularia",
"       </em>",
"       *",
"      </td>",
"      <td>",
"       Arizona, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland, Missouri, New Mexico, North Carolina, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <em>",
"        Triatoma sanguisuga",
"       </em>",
"       *",
"      </td>",
"      <td>",
"       Alabama, Arizona, Arkansas, Florida, Georgia, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Virginia",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <em>",
"        Triatoma incrassata",
"       </em>",
"      </td>",
"      <td>",
"       Arizona",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <em>",
"        Triatoma indictiva",
"       </em>",
"      </td>",
"      <td>",
"       Arizona, New Mexico, Texas",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <em>",
"        Triatoma neotomae",
"       </em>",
"      </td>",
"      <td>",
"       Arizona, California, New Mexico, Texas",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <em>",
"        Triatoma rubrofasciata",
"       </em>",
"      </td>",
"      <td>",
"       Florida",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Most common species.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moffitt, JE, Venarske, D, Goddard, J, et al. Allergic reactions to Triatoma bites. Ann Allergy Asthma Immunol 2003; 91:122. Copyright &copy;2003 American College of Allergy, Asthma, and Immunology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_15_21756=[""].join("\n");
var outline_f21_15_21756=null;
var title_f21_15_21757="Features of chronic GVHD";
var content_f21_15_21757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F63007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F63007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic and disctinctive clinical manifestations of chronic graft-versus-host disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Organ or site",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnostic (sufficient to establish the diagnosis of chronic GVHD)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Distinctive (seen in chronic GVHD, but insufficient alone to establish a diagnosis of chronic GVHD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Poikiloderma",
"         </li>",
"         <li>",
"          Lichen planus-like features",
"         </li>",
"         <li>",
"          Sclerotic features",
"         </li>",
"         <li>",
"          Morphea-like features",
"         </li>",
"         <li>",
"          Lichen sclerosus-like features",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Depigmentation",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nails",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Dystrophy",
"         </li>",
"         <li>",
"          Longitudinal ridging, splitting, or brittle features",
"         </li>",
"         <li>",
"          Onycholysis",
"         </li>",
"         <li>",
"          Pterygium unguis",
"         </li>",
"         <li>",
"          Nail loss (usually symmetric; affects most nails)*",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scalp and body hair",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          New onset of scarring or nonscarring scalp alopecia (after recovery from chemoradiotherapy)",
"         </li>",
"         <li>",
"          Scaling, papulosquamous lesions",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mouth",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Lichen-type features",
"         </li>",
"         <li>",
"          Hyperkeratotic plaques",
"         </li>",
"         <li>",
"          Restriction of mouth opening from sclerosis",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Xerostomia",
"         </li>",
"         <li>",
"          Mucocele",
"         </li>",
"         <li>",
"          Mucosal atrophy",
"         </li>",
"         <li>",
"          Pseudomembranes*",
"         </li>",
"         <li>",
"          Ulcers*",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eyes",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          New onset dry, gritty, or painful eyes",
"          <sup>",
"           &Delta;",
"          </sup>",
"         </li>",
"         <li>",
"          Cicatricial conjunctivitis",
"         </li>",
"         <li>",
"          Keratoconjunctivitis sicca",
"          <sup>",
"           &Delta;",
"          </sup>",
"         </li>",
"         <li>",
"          Confluent areas of punctate keratopathy",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genitalia",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Lichen planus-like features",
"         </li>",
"         <li>",
"          Vaginal scarring or stenosis",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Erosions*",
"         </li>",
"         <li>",
"          Fissures*",
"         </li>",
"         <li>",
"          Ulcers*",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GI tract",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Esophageal web",
"         </li>",
"         <li>",
"          Strictures or stenosis in the upper to mid third of the esophagus*",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Bronchiolitis obliterans diagnosed with lung biopsy",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Bronchiolitis obliterans diagnosed with PFTs and radiology",
"          <sup>",
"           &Delta;",
"          </sup>",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Muscles, fascia, joints",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Fasciitis",
"         </li>",
"         <li>",
"          Joint stiffness or contractures secondary to sclerosis",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Myositis or polymyositis",
"          <sup>",
"           &Delta;",
"          </sup>",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagnosis of chronic GVHD requires the presence of at least one diagnostic clinical sign of chronic GVHD or the presence of at least one distinctive manifestation confirmed by pertinent biopsy or other relevant tests in the same or another organ. Furthermore, other possible diagnoses for clinical symptoms must be excluded. No time limit is set for the diagnosis of chronic GVHD.",
"    <div class=\"footnotes\">",
"     GVHD: graft-versus-host disease; PFTs: pulmonary function tests.",
"     <br/>",
"     * In all cases, infection, drug effects, malignancy, or other causes must be excluded.",
"     <br/>",
"     &Delta; Diagnosis of chronic GVHD requires biopsy or radiology confirmation (or Schirmer test for eyes).",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Filipovitch AH, Weisdorf D, Pavletic S, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: 1. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 2005; 11:945. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_15_21757=[""].join("\n");
var outline_f21_15_21757=null;
var title_f21_15_21758="Contents: Psychiatric disorders";
var content_f21_15_21758=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?23/51/24382\">",
"       Adult Primary Care and Internal Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Psychiatric disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Psychiatric disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Attention deficit hyperactivity disorder",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/63/32761\">",
"           Adult attention deficit hyperactivity disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/7/20599\">",
"           Pharmacotherapy for adult ADHD",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Delirium",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/10/39081\">",
"           Diagnosis of delirium and confusional states",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/33/28185\">",
"           Prevention and treatment of delirium and confusional states",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Eating disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/38/7781\">",
"           Eating disorders in pregnant women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/2/23593\">",
"           Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/63/44023\">",
"           Eating disorders: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Emergencies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/8/10377\">",
"           Suicidal ideation and behavior in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Grief and bereavement",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/29/31190\">",
"           Grief and bereavement",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/4/3145\">",
"           Delusional parasitosis: Epidemiology, clinical presentation, assessment and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/3/29751\">",
"           Overview of psychotherapies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/14/22760\">",
"           Pathologic gambling",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/52/22343\">",
"           Psychological stress and infertility",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/34/1575\">",
"           Treatment of delusional parasitosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Mood disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/41/21145\">",
"           Medical consultation for electroconvulsive therapy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Personality disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/19/10553\">",
"           Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/1/42009\">",
"           Borderline personality disorder: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/55/40824\">",
"           Personality disorders",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pregnancy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/11/20666\">",
"           Postpartum blues and depression",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Psychotic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/58/28583\">",
"           Overview of psychosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/47/34552\">",
"           Schizophrenia: Clinical manifestations, course, assessment, and diagnosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Somatoform disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/21/7512\">",
"           Factitious disorder and Munchausen syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/38/27242\">",
"           Overview of idiopathic environmental intolerance (multiple chemical sensitivity)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/23/10617\">",
"           Primary care management of medically unexplained symptoms",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Substance use disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/42/36521\">",
"           Dual diagnosis: Severe mental illness and substance use disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/27/5562\">",
"           Impaired healthcare provider",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/10/1191\">",
"           Opioid detoxification during treatment for addiction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/51/3897\">",
"           Opioid intoxication in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/5/28758\">",
"           Opioid withdrawal in the emergency setting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/61/38874\">",
"           Overview of the risks and benefits of alcohol consumption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/55/41847\">",
"           Psychosocial treatment of alcohol abuse and dependence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/58/5033\">",
"           Substance use disorders: Principles for recognition and assessment in general medical care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/52/29514\">",
"           Treatment of opioid abuse and dependence",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-1B4DFA78CF-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f21_15_21758=[""].join("\n");
var outline_f21_15_21758=null;
var title_f21_15_21759="Calculator: Estimated Date of Delivery (EDD) (Patient information)";
var content_f21_15_21759=[" <div id=\"disclaimer\">",
"  The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"  <a href=\"/home/terms-use\" target=\"_blank\">",
"   UpToDate Terms of Use",
"  </a>",
"  &copy;2013 UpToDate, Inc.",
" </div>",
" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"EstimatedDateDeliveryPatient_form\" name=\"EstimatedDateDeliveryPatient_form\" onkeydown=\"clrResults();\" onkeyup=\"EstimatedDateDeliveryPatient_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Estimated Date of Delivery (EDD) (Patient information)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Current Date",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\" nowrap=\"nowrap\">",
"             &nbsp;&nbsp;",
"             <select class=\"medCalcFontSelect\" name=\"current_month\" onchange=\"EstimatedDateDeliveryPatient_fx();\">",
"              <option value=\"0\">",
"               Jan",
"              </option>",
"              <option value=\"1\">",
"               Feb",
"              </option>",
"              <option value=\"2\">",
"               Mar",
"              </option>",
"              <option value=\"3\">",
"               Apr",
"              </option>",
"              <option value=\"4\">",
"               May",
"              </option>",
"              <option value=\"5\">",
"               Jun",
"              </option>",
"              <option value=\"6\">",
"               Jul",
"              </option>",
"              <option value=\"7\">",
"               Aug",
"              </option>",
"              <option value=\"8\">",
"               Sep",
"              </option>",
"              <option value=\"9\">",
"               Oct",
"              </option>",
"              <option value=\"10\">",
"               Nov",
"              </option>",
"              <option value=\"11\">",
"               Dec",
"              </option>",
"              <option selected=\"selected\" value=\"-1\">",
"               MM",
"              </option>",
"             </select>",
"             <select class=\"medCalcFontSelect\" name=\"current_date\" onchange=\"EstimatedDateDeliveryPatient_fx();\">",
"              <option value=\"1\">",
"               1",
"              </option>",
"              <option value=\"2\">",
"               2",
"              </option>",
"              <option value=\"3\">",
"               3",
"              </option>",
"              <option value=\"4\">",
"               4",
"              </option>",
"              <option value=\"5\">",
"               5",
"              </option>",
"              <option value=\"6\">",
"               6",
"              </option>",
"              <option value=\"7\">",
"               7",
"              </option>",
"              <option value=\"8\">",
"               8",
"              </option>",
"              <option value=\"9\">",
"               9",
"              </option>",
"              <option value=\"10\">",
"               10",
"              </option>",
"              <option value=\"11\">",
"               11",
"              </option>",
"              <option value=\"12\">",
"               12",
"              </option>",
"              <option value=\"13\">",
"               13",
"              </option>",
"              <option value=\"14\">",
"               14",
"              </option>",
"              <option value=\"15\">",
"               15",
"              </option>",
"              <option value=\"16\">",
"               16",
"              </option>",
"              <option value=\"17\">",
"               17",
"              </option>",
"              <option value=\"18\">",
"               18",
"              </option>",
"              <option value=\"19\">",
"               19",
"              </option>",
"              <option value=\"20\">",
"               20",
"              </option>",
"              <option value=\"21\">",
"               21",
"              </option>",
"              <option value=\"22\">",
"               22",
"              </option>",
"              <option value=\"23\">",
"               23",
"              </option>",
"              <option value=\"24\">",
"               24",
"              </option>",
"              <option value=\"25\">",
"               25",
"              </option>",
"              <option value=\"26\">",
"               26",
"              </option>",
"              <option value=\"27\">",
"               27",
"              </option>",
"              <option value=\"28\">",
"               28",
"              </option>",
"              <option value=\"29\">",
"               29",
"              </option>",
"              <option value=\"30\">",
"               30",
"              </option>",
"              <option value=\"31\">",
"               31",
"              </option>",
"              <option selected=\"selected\" value=\"-1\">",
"               DD",
"              </option>",
"             </select>",
"             <select class=\"medCalcFontSelect\" name=\"current_year\" onchange=\"EstimatedDateDeliveryPatient_fx();\">",
"              <option value=\"2009\">",
"               2009",
"              </option>",
"              <option value=\"2010\">",
"               2010",
"              </option>",
"              <option value=\"2011\">",
"               2011",
"              </option>",
"              <option value=\"2012\">",
"               2012",
"              </option>",
"              <option value=\"2013\">",
"               2013",
"              </option>",
"              <option value=\"2014\">",
"               2014",
"              </option>",
"              <option value=\"2015\">",
"               2015",
"              </option>",
"              <option value=\"2016\">",
"               2016",
"              </option>",
"              <option value=\"2017\">",
"               2017",
"              </option>",
"              <option value=\"2018\">",
"               2018",
"              </option>",
"              <option value=\"2019\">",
"               2019",
"              </option>",
"              <option value=\"2020\">",
"               2020",
"              </option>",
"              <option value=\"2021\">",
"               2021",
"              </option>",
"              <option value=\"2022\">",
"               2022",
"              </option>",
"              <option value=\"2023\">",
"               2023",
"              </option>",
"              <option value=\"2024\">",
"               2024",
"              </option>",
"              <option value=\"2025\">",
"               2025",
"              </option>",
"              <option value=\"2026\">",
"               2026",
"              </option>",
"              <option value=\"2027\">",
"               2027",
"              </option>",
"              <option value=\"2028\">",
"               2028",
"              </option>",
"              <option value=\"2029\">",
"               2029",
"              </option>",
"              <option value=\"2030\">",
"               2030",
"              </option>",
"              <option selected=\"selected\" value=\"-1\">",
"               YYYY",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              First Day of Last Period",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\" nowrap=\"nowrap\">",
"             &nbsp;&nbsp;",
"             <select class=\"medCalcFontSelect\" name=\"lmp_month\" onchange=\"EstimatedDateDeliveryPatient_fx();\">",
"              <option value=\"0\">",
"               Jan",
"              </option>",
"              <option value=\"1\">",
"               Feb",
"              </option>",
"              <option value=\"2\">",
"               Mar",
"              </option>",
"              <option value=\"3\">",
"               Apr",
"              </option>",
"              <option value=\"4\">",
"               May",
"              </option>",
"              <option value=\"5\">",
"               Jun",
"              </option>",
"              <option value=\"6\">",
"               Jul",
"              </option>",
"              <option value=\"7\">",
"               Aug",
"              </option>",
"              <option value=\"8\">",
"               Sep",
"              </option>",
"              <option value=\"9\">",
"               Oct",
"              </option>",
"              <option value=\"10\">",
"               Nov",
"              </option>",
"              <option value=\"11\">",
"               Dec",
"              </option>",
"              <option selected=\"selected\" value=\"-1\">",
"               MM",
"              </option>",
"             </select>",
"             <select class=\"medCalcFontSelect\" name=\"lmp_date\" onchange=\"EstimatedDateDeliveryPatient_fx();\">",
"              <option value=\"1\">",
"               1",
"              </option>",
"              <option value=\"2\">",
"               2",
"              </option>",
"              <option value=\"3\">",
"               3",
"              </option>",
"              <option value=\"4\">",
"               4",
"              </option>",
"              <option value=\"5\">",
"               5",
"              </option>",
"              <option value=\"6\">",
"               6",
"              </option>",
"              <option value=\"7\">",
"               7",
"              </option>",
"              <option value=\"8\">",
"               8",
"              </option>",
"              <option value=\"9\">",
"               9",
"              </option>",
"              <option value=\"10\">",
"               10",
"              </option>",
"              <option value=\"11\">",
"               11",
"              </option>",
"              <option value=\"12\">",
"               12",
"              </option>",
"              <option value=\"13\">",
"               13",
"              </option>",
"              <option value=\"14\">",
"               14",
"              </option>",
"              <option value=\"15\">",
"               15",
"              </option>",
"              <option value=\"16\">",
"               16",
"              </option>",
"              <option value=\"17\">",
"               17",
"              </option>",
"              <option value=\"18\">",
"               18",
"              </option>",
"              <option value=\"19\">",
"               19",
"              </option>",
"              <option value=\"20\">",
"               20",
"              </option>",
"              <option value=\"21\">",
"               21",
"              </option>",
"              <option value=\"22\">",
"               22",
"              </option>",
"              <option value=\"23\">",
"               23",
"              </option>",
"              <option value=\"24\">",
"               24",
"              </option>",
"              <option value=\"25\">",
"               25",
"              </option>",
"              <option value=\"26\">",
"               26",
"              </option>",
"              <option value=\"27\">",
"               27",
"              </option>",
"              <option value=\"28\">",
"               28",
"              </option>",
"              <option value=\"29\">",
"               29",
"              </option>",
"              <option value=\"30\">",
"               30",
"              </option>",
"              <option value=\"31\">",
"               31",
"              </option>",
"              <option selected=\"selected\" value=\"-1\">",
"               DD",
"              </option>",
"             </select>",
"             <select class=\"medCalcFontSelect\" name=\"lmp_year\" onchange=\"EstimatedDateDeliveryPatient_fx();\">",
"              <option value=\"2009\">",
"               2009",
"              </option>",
"              <option value=\"2010\">",
"               2010",
"              </option>",
"              <option value=\"2011\">",
"               2011",
"              </option>",
"              <option value=\"2012\">",
"               2012",
"              </option>",
"              <option value=\"2013\">",
"               2013",
"              </option>",
"              <option value=\"2014\">",
"               2014",
"              </option>",
"              <option value=\"2015\">",
"               2015",
"              </option>",
"              <option value=\"2016\">",
"               2016",
"              </option>",
"              <option value=\"2017\">",
"               2017",
"              </option>",
"              <option value=\"2018\">",
"               2018",
"              </option>",
"              <option value=\"2019\">",
"               2019",
"              </option>",
"              <option value=\"2020\">",
"               2020",
"              </option>",
"              <option value=\"2021\">",
"               2021",
"              </option>",
"              <option value=\"2022\">",
"               2022",
"              </option>",
"              <option value=\"2023\">",
"               2023",
"              </option>",
"              <option value=\"2024\">",
"               2024",
"              </option>",
"              <option value=\"2025\">",
"               2025",
"              </option>",
"              <option value=\"2026\">",
"               2026",
"              </option>",
"              <option value=\"2027\">",
"               2027",
"              </option>",
"              <option value=\"2028\">",
"               2028",
"              </option>",
"              <option value=\"2029\">",
"               2029",
"              </option>",
"              <option value=\"2030\">",
"               2030",
"              </option>",
"              <option selected=\"selected\" value=\"-1\">",
"               YYYY",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Results:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Estimated Due Date",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input maxlength=\"16\" name=\"edd_lmp_result\" onfocus=\"blur();\" size=\"16\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Estimated Gestational Age",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input maxlength=\"16\" name=\"current_gest_lmp\" onfocus=\"blur();\" size=\"16\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       This calculator helps you estimate your date of delivery based on the timing of your last menstrual period.",
"      </li>",
"      <li>",
"       <b>",
"        Gestational Age",
"       </b>",
"       estimates how long the baby has been developing since conception. Your healthcare provider uses the gestational age in weeks (rather than months) to plan your prenatal care. Most pregnancies last approximately 40 weeks from the first day of the last menstrual period.",
"      </li>",
"     </ul>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
"with(document.EstimatedDateDeliveryPatient_form){",
"todaydatetime = new Date;",
"todaymonth = todaydatetime.getMonth();",
"todaydate = todaydatetime.getDate();",
"todayfullyear = todaydatetime.getFullYear();",
"",
"}",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_15_21759=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function EstimatedDateDeliveryPatient_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.EstimatedDateDeliveryPatient_form){",
"",
"",
"doCalc = true;",
"dp = 0;",
"monthname = new Array('Jan', 'Feb', 'Mar', 'Apr', 'May', 'Jun', 'Jul', 'Aug', 'Sep', 'Oct', 'Nov', 'Dec');",
"current_time = new Date;",
"lmp_time = new Date;",
"edd_lmp = new Date;",
"var current_month_value = parseFloat(current_month.options[current_month.selectedIndex].value);",
"var current_date_value = parseFloat(current_date.options[current_date.selectedIndex].value);",
"var current_year_value = parseFloat(current_year.options[current_year.selectedIndex].value);",
"if ((current_month_value == 1) && (current_date_value > 28)){",
"if ((current_year_value % 4) == 0){ current_date_value = 29; current_date.selectedIndex = 28; }",
"else{ current_date_value = 28; current_date.selectedIndex = 27; };",
"}",
"if (((current_month_value == 3) || (current_month_value == 5) || (current_month_value == 8) || (current_month_value == 10)) && (current_date_value > 30)){ current_date_value = 30; current_date.selectedIndex = 29; };",
"current_time.setFullYear(current_year_value);",
"current_time.setMonth(current_month_value, current_date_value);",
"current_time.setHours(0);",
"var lmp_month_value = parseFloat(lmp_month.options[lmp_month.selectedIndex].value);",
"var lmp_date_value = parseFloat(lmp_date.options[lmp_date.selectedIndex].value);",
"var lmp_year_value = parseFloat(lmp_year.options[lmp_year.selectedIndex].value);",
"if ((lmp_month_value == 1) && (lmp_date_value > 28)){",
"if ((lmp_year_value % 4) == 0){ lmp_date_value = 29; lmp_date.selectedIndex = 28; }",
"else{ lmp_date_value = 28; lmp_date.selectedIndex = 27; };",
"}",
"if (((lmp_month_value == 3) || (lmp_month_value == 5) || (lmp_month_value == 8) || (lmp_month_value == 10)) && (lmp_date_value > 30)){ lmp_date_value = 30; lmp_date.selectedIndex = 29; };",
"lmp_time.setFullYear(lmp_year_value);",
"lmp_time.setMonth(lmp_month_value, lmp_date_value);",
"lmp_time.setHours(0);",
"edd_lmp.setTime(lmp_time.getTime() + 24192000000);",
"lmpmillis = current_time.getTime() - lmp_time.getTime();",
"lmpweeks = fixDP(lmpmillis / 604800000, 1);",
"lmpweeksfloor = Math.floor(lmpweeks);",
"lmpdays =  Math.round(7 * (lmpweeks - lmpweeksfloor));",
"daystxt = ' days';",
"if (lmpdays == 1) daystxt = ' day';",
"if ((lmp_year_value >= 0) && (lmp_month_value >= 0) && (lmp_date_value >= 0)){",
"edd_lmp_result.value = monthname[edd_lmp.getMonth()] + ' ' + edd_lmp.getDate() + ', ' + edd_lmp.getFullYear();",
"current_gest_lmp.value = lmpweeksfloor + ' weeks' + ' ' + lmpdays + daystxt; }",
"else{ edd_lmp_result.value = ''; current_gest_lmp.value = ''; }",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.EstimatedDateDeliveryPatient_form){",
"",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.EstimatedDateDeliveryPatient_form){",
"",
"edd_lmp_result.value = '';",
"current_gest_lmp.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f21_15_21759=null;
